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Abstract 
 
Zinc is an essential micronutrient that is required for the normal growth and 
development of all organisms. Hence uptake and transport play a vital role in 
maintaining zinc homeostasis. Two membrane-bound protein families, 
SLC30 (ZnT) and SLC39 (Zip) are involved in the transportation of cellular 
zinc.  
This study contributes to the knowledge of zinc homeostasis involving 
members of the ZnT family, in particular ZnT5 and ZnT6, and their role in the 
molecular basis of an inherited disorder of zinc metabolism in humans, and 
their function in cultured neuronal cells. 
Two cases of zinc deficiency in neonates were investigated. Zinc levels in the 
milk of both mothers were reduced by at least 75% compared to normal. A 
reduction in alkaline phosphatase activity in maternal lymphoblasts was 
consistent with a loss of zinc transport activity. Significant reduction of mRNA 
expression and protein levels of human zinc transporters, SLC30A5 (ZnT5) 
and SLC30A6 (ZnT6), in maternal tissue were observed, suggesting a causal 
link to the zinc deficiency disorder. Lymphoblasts and fibroblasts isolated 
from both mothers showed altered DNA methylation in ZnT5 at epi-labile 
CpG sites, and novel splice variants along with full-length expression in 
ZnT6. Altered DNA methylation, likely accounts for reduced ZnT5 mRNA 
expression and low protein levels in lymphoblasts. Reduced ZnT6 mRNA 
expression and protein levels in lymphoblasts may be secondary to reduced 
ZnT5 expression, given that ZnT5 and ZnT6 function as a heterodimer with 
 xxii 
 
regards to zinc transport. These results suggest that these two cases of zinc 
deficiency in neonates caused by a mammary gland disorder are due to 
defects in the human zinc transporters ZnT5 and ZnT6. 
The co-dependency of ZnT5 and ZnT6 on each other was investigated in 
neuronal cells by using overexpressed and knockdown constructs of these 
genes. ZnT5 expression levels of mRNA and protein in cells with 
overexpression and knockdown constructs of the ZnT6 gene was not altered, 
but on the other hand ZnT6 mRNA and protein levels in cells with 
overexpression and knockdown constructs of the ZnT5 gene were altered by 
the changes in ZnT5. This indicates the possibility of these two transporters 
to work together in neuronal cells. 
The omega-3 fatty acid, DHA is crucial for neurological function. Low dietary 
intake of DHA has been linked to Alzheimer’s disease and DHA deficiency 
causes neuronal cell death. Previous studies show that DHA affects zinc 
transport and zinc transporter levels in neuronal cells. The aim of the current 
study was to explore the molecular basis of the link between the omega-3 
fatty acid DHA and zinc metabolism through the ZnT5 and ZnT6 transporters. 
M17 neuronal cells exposed to DHA showed a significant reduction in 
intracellular zinc levels and increased zinc efflux, compared to untreated 
cells. DHA treatment induced neurite outgrowth in cultured cells. Both QRT-
PCR and western blot analysis showed high expression of ZnT5 and ZnT6 
transporters at the transcription and translation levels. A link between DHA, 
zinc and activation of ZnT5 and ZnT6 transporters was established where 
RARE’s (retinoic acid responsive elements) were located in the promoter 
regions of the ZnT5 and ZnT6 genes, for ligand activated transcription factors 
 xxiii 
 
which could switch on gene expression. In conclusion, the ZnT5 and ZnT6 
transporters may be regulated by DHA through a pathway involving changes 
in zinc fluxes. 
Using bioinformatics tools and soft-wares, all members of ZnT family were 
analysed for their structure and the phylogenetic relationships between them. 
Some of the members are very diverse from others. A total of 10 members of 
ZnT family were characterized into four main subfamilies, according to the 
similarity amongst different members based on their coding and promoter 
regions. Hormonally influenced transcription binding sites present in 
promoter region of the genes have been reported and considered in relation 
to regulation of the transcription and translation of the genes. Three 
dimensional structural models were generated and analysed by comparison 
to Yiip where X-ray structure crystallography has previously been reported  
The results presented in this thesis provide novel data about the role of ZnT5 
and ZnT6 in an inherited disorder of zinc deficiency in premature babies and 
in brain cells where a relationship between zinc fluxes, zinc transporter 
expression and DHA exposure was found.  
  
 
 
 
 
 
 
CHAPTER 1 
 
Introduction
 2 
 
1.1 History of zinc 
Zinc is an essential trace element that is required for growth and 
development of all organisms. Zinc has been known to humans for 
centuries. It was used as an alloy with copper, called brass since the 5th 
Millennium BC. At the beginning of the sixteenth century metallic zinc was 
isolated (Sieveking et al., 1970). Later on, it was found that zinc is 
essential for the function of the living organisms when growth of bread 
mould Aspergillus niger was found dependant on this mineral (Raulin et al., 
1869) similarly studies on higher plants, rodents and humans confirmed 
the indispensability of zinc for growth and development of all forms of the 
life (Maze, 1914; Todd et al., 1934; Prasad et al., 1963).  
1.2 Chemistry of zinc 
Zinc is a small, stable metal ion with d-shell filled with 2 s electrons. The 
natural redox state for zinc is Zn (II) and it does not undergo oxidation or 
reduction processes (Vallee and Falchuk, 1993). Other chemical features 
that enable zinc to have a fundamental role in many biological processes 
include its amphoteric character, which allows it to participate in both 
hydrate and hydroxide metal complexes. Zinc’s Lewis acid properties and 
its multiple coordination geometries, enable it to co-ordinate 2 to 8 ligands 
with 4, 5 and 6 most frequently found in catalytic sites (Williams, 1984; 
Auld, 2001). Considering all the features of  zinc in addition to the relatively 
rapid exchange of the ligands from its complexes (Vallee and Auld, 1993), 
it is not surprising that zinc participates in almost all cellular processes 
from cell division, development and differentiation to apoptosis (Beyersman 
 3 
 
and Haase, 2001). Zinc, along with other elements including copper, iron, 
selenium, is classified as an essential trace element as it is required in 
milligram amounts in the diet and its absence results in severe malfunction 
leading even to death if prolonged deficiency occurs.  
1.3 Zinc homeostasis 
Inside cells, approximately half of the zinc is located in the cytoplasm and 
cytosolic organelles. An additional 30 to 40% is found in the nucleus while 
a small proportion is associated with cell membranes (Vallee and Falchuk 
,1993). The majority of the intracellular zinc is bound by proteins and only 
very small proportion could be classified as free zinc. An estimation of the 
free intracellular zinc concentration depends on selection of the 
quantitative technique used and ranges from 24 pM using 65Zn 
measurements (Simons, 1991) to 2 nM when the fluorescent probe Mag-
Fura-2 was used (Sensi et al., 1997). 
The human body contains up to 2 g of zinc with the greatest proportion 
present in muscle and bones (80%-90%) followed by skin, liver, retina, 
prostate and other tissues (Jackson, 1989). The zinc content of most of 
tissue remains constant even with the intake change as high as 10-fold. 
This is mainly achieved through the homeostatic action of gastrointestinal 
system regulating the zinc absorption and excretion in accordance to 
requirements (Johnson et al., 1993). 
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1.3.1 Zinc absorption 
Dietary zinc is absorbed in small intestine, mainly in the distal duodenum 
and proximal jejunum where it enters the enterocytes and is transferred 
across the basolateral membrane to portal circulation (Lee et al., 1989). 
Studies measuring the fractional absorption of the zinc using stable isotope 
tracers show that increased dietary zinc intake causes a decline in the 
efficiency of zinc absorption (Jackson et al., 1984) while with reduced 
intake fractional absorption dramatically increases (Wada et al., 1985; 
Taylor et al., 1991; Lee et al., 1993). While the zinc content of the diet may 
vary considerably, the intracellular zinc concentration remains relatively 
constant, for example approximately 200 PM in eukaryotic cells (Palmiter 
and Findley, 1995). The absorption of zinc can also be affected by different 
ligands present in the lumen of the gut that gets secreted by body or are 
produced by consumed food. Some animal amino acids like cysteine, 
histidine, tryptophan (Wapnir and Stiel, 1986) and low molecular weight 
ligands like piconilic acid (Evans, 1983), citrate (Lonnerdal et al., 1980) 
facilitates zinc absorption. Similarly other dietary nutrients like phytates, 
reduce the zinc absorption by forming indigestible complexes with zinc 
(O’Dell and savage, 1960). Other metals like calcium, cadmium, copper 
and iron in high concentration can also reduce the absorption of zinc as 
they will be competing against zinc for metabolic sites (Breskin et al., 1983; 
Hill and matrone, 1970; Oberleas et al., 1966; Van Campen., 1969). 
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1.3.2 Zinc distribution 
Absorbed zinc is transported into the blood. Although most of the blood 
zinc (75-80%) is firmly bound to carbonic anyhydrase in erythrocytes, the 
primary source of zinc accessible to the cells is found in the plasma and 
represents less than 1% of whole body zinc (Vallee and Gibson, 1949). 
The majority of plasma zinc (60-70%) is loosely bound to albumin and 
tightly to D2-macroglobulin (~30%). The rest is associated with E–globulin, 
free amino acids present in ionic form (Prasad and Oberleas, 1970). 
Radiolabelled zinc (65Zn) studies have indicated that virtually all absorbed 
zinc is transported through the body by albumin (Smith and Cousin, 1980). 
Plasma zinc concentrations are relatively constant despite the fact that all 
absorbed zinc enters the circulation. Plasma zinc homeostasis is achieved 
by maintaining a rapid plasma zinc turnover (~150 times a day) (King et al., 
2000). Plasma zinc concentrations only fall with short-term extremely low 
zinc intakes, prolonged mild deficiency or marginal intake during increase 
zinc demand: pregnancy, lactation and infancy (reviewed in Krebs, 2000). 
1.3.3 Zinc transport  
Zinc transporters mediate cellular zinc uptake, efflux and intracellular 
distribution. Two major families of zinc transporters exist: Cation Diffusion 
Facilitators (CDF) also known as the SLC30 family and Zrt Irt-like Proteins 
(ZIP), known as the SLC39 family. The detailed function and 
characterisation of these two families is described in section 1.11. 
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1.3.4 Zinc storage 
Zinc is transported from small intestine to the liver from where it is 
redistributed to the other tissues. The muscle, skin, hair, bones and testis 
hold relatively high concentrations of zinc but in severe zinc deficiency the 
decline in tissue zinc was only noticed in plasma, liver, testis and bones 
(reviewed in Jackson et al., 1982). During such prolonged deficiencies, 
firstly the plasma zinc decreases giving signal to selected tissues to 
conserve zinc (King et al., 2000). The decline in bone zinc happens most 
likely due to decrease zinc uptake rather than enhanced release (Zhou et 
al., 1993). 
1.3.5 Zinc excretion 
The gut is the major organ in the regulation of zinc excretion from the body. 
Fecal zinc consists of the unabsorbed exogenous fraction and a significant 
fraction of endogenous excreted zinc, originating from pancreatic 
secretion, bile and intestinal zinc release and sloughing of mucosal cells 
(Krebs, 2000). Zinc is also excreted from the body through the urine but 
these losses are low compared to gastrointestinal losses and do not 
fluctuate readily with zinc uptake. Only very low levels of dietary zinc 
intakes can rapidly reduce urinary excretion (Johnson et al., 1993). 
Additional small amounts of zinc can be lost from the body with sweat, 
menstrual blood and shedding of skin, hair and nails (reviewed in 
Underwood, 1981). 
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1.4 Biological/physiological roles of zinc 
Zinc is an essential trace element required for the structural stability of a 
variety of proteins involved in transcription and protein trafficking, as well 
as for the catalytic activity of metalloenzymes and serves as a cofactor in a 
variety of biochemical reactions. Furthermore, many studies have been 
undertaken to understand the role of zinc in various vital cell processes 
such as in the function of nucleic acids, cell signalling, membrane stability 
and cell death.  
1.4.1 Zinc and nucleic acids 
A direct role for zinc in DNA transcription became evident when some 
classes of RNA polymerases were discovered to be zinc-dependant, for 
example six subunits of yeast RNA polymerase II contain zinc-finger 
domains (Cramer at al., 2000). Additionally, four structural proteins (L24, 
L37, L37a and L44) of the large ribosomal subunit are also zinc-binding 
molecules (Ban et al., 2000). The DNA binding domain of glucocorticoid 
and estrogen receptors that enhance the expression of some genes in 
response to specific hormones for example cortisol or estrogen contains 
two atoms of zinc (Freedman et al., 1988). 
Zinc deficiency reduces the activity of deoxythymidine kinase, an enzyme 
responsible for the phosphorylation of deoxythymidine, a crucial step for 
DNA synthesis (Chesters et al., 1990). Deoxythymidine kinase is not a 
metalloenzyme but its expression is regulated by zinc-dependent factor 
binding in the promoter region (Chesters et al., 1995). Also, most likely zinc 
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affects the chromatin structure and function through the binding to histone 
deacetylases, which regulate transcription of DNA (Finnin et al., 1999). 
In 1984 Ginsberg et al. discovered presence of zinc in TFIIIA transcription 
factor from Xenopus laevis. One years latter conserved, repetitive motif of 
TFIIIA containing Cys and His ligands were called zinc-finger domain (Miller 
et al., 1985). The motif found in TFIIIA is classified as classical zinc-finger 
and contains multiple Cys2His2 sequence separated by the TGEKP linker – 
presumably DNA binding site (Laity et al., 2000). The example of classical 
Cys2His2 zinc-finger transcription factor can be metal response element-
binding transcription factor MTF-1 (Bittel et al., 1998). Zinc enzymes and 
proteins are used in most of the cellular processes from controlling of DNA 
and RNA stability through transcription processes, cell signaling, membrane 
stability and free radicals scavenging to cell apoptosis (for more details see 
Section 1.4.2,1.4.3, 1.4.5). 
1.4.2 Zinc and Membranes 
Zinc deficiency affects erythrocytes and platelets plasma membranes. Zinc 
depletion in rat red blood cells significantly decreased the plasma 
membrane zinc content without an observable reduction in the total cellular 
Zn content. Upon zinc repletion, the membrane zinc level was quickly 
restored (Taylor et al., 1988). An increase in the osmotic fragility of 
erythrocytes was another feature observed in Zn-deficient rats, and this 
could be reversed by zinc supplementation (O’Dell et al., 1987). 
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The deleterious effects of zinc deficiency on membrane can be explained, 
to some extent, by the repressed activity of enzymes for example the 
calcium pump, Ca-ATPase (Johanning et al., 1990). Zinc may alter 
membrane metabolism through alteration of membrane lipid metabolism. 
Nutritional zinc deficiency affects synthesis of cholesterol, phospholipids, 
fatty acids and lipoproteins (Cunnane, 1988). The mechanism of these 
processes is not clear but Zelenski et al. (1999) has demonstrated the role 
of a zinc metalloenzyme Site-2 protease in the control of cholesterol 
biosynthesis. In this way zinc maintains the integrity and balance of the 
membrane lipids. 
1.4.3 Zinc and Cell signalling 
Zinc plays important role in cell signalling from signal molecule production 
and recognition through second messenger metabolism to protein 
phosphorylation. Zinc itself can act as signalling ion in neurons, by 
attenuating the activity of NMDA glutamate receptors or by increasing the 
activity of GABA receptors (Westbrook and Mayer, 1987). In hepatocytes, 
an increase in the extracellular zinc concentration increases the 
intracellular concentration of calcium, through release of calcium from 
cellular stores (McNulty and Taylor, 1999) leading to the activation of 
calcium-dependent protein kinases. Intracellular glucocorticocoid and 
estrogen receptor bind their substrate through the zinc domains. Zinc 
deficiency decreases production of hepatic insulin-like growth factor-I (IGF-
I) (Roth and Kirchgessner, 1994) but also increases the expression of IGF-
I binding protein-3, which competes with IGF-I receptor in IGF-I coupling 
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(MacDonald et al., 1998). In a zinc sufficient state, the receptor activation 
by IGF-I causes a cascade of phosphorylation and leads to cellular 
response for example the induction of cell division (MacDonald, 2000). 
Zinc levels influence second messenger metabolism through regulating the 
activity of cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP). Francis et al. (1994) have found two zinc-binding 
motifs in the catalytic region of cyclic nucleotide phosphodiesterase V, 
which regulate its activity and hence the degradation of cAMP and cGMP. 
Other members of cGMP and cAMP- families were shown to be inhibited 
by zinc concentrations higher than 1 uM while in some cases low zinc 
concentration was able to activate the enzyme (Percival et al., 1997; 
Kovala et al., 1997; He et al., 2000). These observations suggest that zinc 
may have a direct physiological role in regulating the activity of cyclic 
nucleotides. 
A direct role of zinc in protein phosphorylation is suggested from studies on 
the regulation of protein kinase C. This enzyme contains two independent 
zinc-binding domains, each able to link 2 atoms of zinc in the region of the 
lipid-binding region (Quest et al., 1992; Hommel et al., 1994). The zinc 
chelator 1,10-phenanthroline was able to inhibit activity of PKC, pointing to 
a role of chelatable zinc pools in regulation of the enzyme (Forbes et al., 
1991). 
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1.4.4 Zinc and immune system 
Zinc is crucial for immune responses, affecting proliferation of T and B-
lymphocytes, baseline and antibody dependent activity of killer 
lymphocytes and phagocytotic and bacterial capacities of neutrophils. Zinc 
deficiency induces impaired haemostasis as a result of defective platelet 
aggregation and a decrease in T cell number (Tapiero and Tew, 2003). In 
mast cells cytokine production gets altered as a result of reduced lytic 
activity of natural killer T cells (NKT) due to zinc deficiency (Muzzioli et al., 
2009; Mochegiani et al., 2003). Zinc supplementation enhanced innate 
immunity against enterotoxigenic E. coli infection in children due to 
increased C3 complement along with increased phagocytosis and T cell 
functionality (Sheikh et al., 2010).  
1.4.5 Zinc and oxidative stress 
Zinc deficiency enhances the production of free radicals that can lead to 
peroxidation of lipids (Burke and Fenton, 1985) and protein oxidation 
(DiSilvestro and Blostein-Fujii, 1997), hence can result in the susceptibility 
of the organism to oxidative tissue injury. Zinc also increases the 
production of metallothioneins that act as free radical scavengers (Maret, 
1994). Zinc plays a protective role in preventing oxidation of δ-
aminolevulinate dehydrogenase sulphydryl groups from oxidation (Gibbs et 
al., 1985). 
In all living organisms, cells require adequate levels of antioxidants as a 
defence mechanism to avoid any harmful effect of an excessive production 
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of reactive oxygen species (ROS), also known as free radicals. During the 
inflammatory processes, the activation of phagocytes or the action of 
bacterial products with specific receptors are capable of promoting the 
assembly of NADPH oxidase, which catalyses the production of high 
amounts of the superoxide anion radical. Neutrophils and macrophages 
get recognized under these particular circumstances to produce 
superoxide free radicals that are essential for defence against invading 
microbes (Puertollano et al., 2011).  
1.4.5 Zinc and apoptosis 
Apoptosis is programmed cell death involved in several biological events 
due to harmful substances or induced by organism due to physiological or 
environmental changes. Zinc is described as an inhibitor of apoptosis, 
where as its depletion induces death in many cell lines (Seve et al., 2002). 
Low cellular zinc concentrations can enhance apoptosis in different cell 
types eg fibroblasts, glioma, hepatocytes, T cell precursors and testicular 
cells. Zinc acts as an inhibitor of caspase-3, caspase-8, and caspase-9 
which are cysteine proteases and have basic role in apoptosis (Thornberry 
and Lazebnik, 1998; Truong-Tran et al., 2001). The movement of 
intracellular zinc is maintained by several zinc transporters to have a 
balance between life and programmed cell death (Seve et al., 2002). Zinc 
deficiency can also induce apoptosis by altering signal transduction growth 
factors controlled by receptor tyrosine kinases (Clegg et al., 2005). 
However zinc can have a negative effect in cases when excessive 
accumulation in synaptic spaces mediates apoptotic cell death in the 
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developing rodent brain (Capasso et al., 2005; Cho et al., 2010). A 
comparison of the effects of zinc deficiency and zinc intoxication (excess 
zinc) have been illustrated in figure 1.1 (Plum et al., 2010). 
1.5 Zinc Deficiency  
The main symptoms of zinc deficiency are anorexia, loss of appetite, smell 
and taste failure, severe skin lesions, impaired immune response, 
diarrhoea, hypogonadism and neurological disorders. 
Zinc is such an important element in human health that even a small 
deficiency can lead to disaster. The history of recognizing the significance 
of zinc in the human body is remarkably short considering the importance 
of zinc in biology. In 1961, the first case of zinc deficiency was reported in 
a man from Iran, outlining the symptoms of zinc deficiency with severe 
anemia, growth retardation, hypogonadism, rough skin and mental lethargy 
(Prasad et al., 1961). The anemia was successfully treated with iron 
supplementation but the other symptoms only disappeared upon oral zinc 
therapy (Prasad et al., 1963a, Prasad, 1966). Later in Egypt, patients 
demonstrating similar symptoms were also studied. Their body zinc levels 
were low relative to normal, classifying them as zinc deficient (Prasad et 
al., 1963b). Similarly, many other studies recognised that zinc deficiency 
was a widespread problem in the world. 

  
Figure 1.1 Comparison of the effects of zinc intoxication 
versus deficiency.  
Intoxication by excessive exposure to, or intake of zinc (left hand side) and 
deprivation of zinc by malnutrition or medical conditions (right hand side) and 
their effect on different organ systems.  
Effects that affect several organs or could not be attributed to a certain organ 
system are classified as systemic symptoms.
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Plum et al., 2010 
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In pregnant women, zinc deficiency may lead to fetal brain cells decrease 
and may affect their development. Zinc deficiency in children can impact 
normal growth and intellectual development. In adult males, zinc deficiency 
may lead to prostatic hyperplasia, affecting the reproductive function and 
fertility. Malnutrition and high phytate diet are the most common causes of 
zinc deficiency not only in developing countries but also in some groups 
from industralised countries including vegans, vegetarians and low 
socioeconomic groups (Freeland-Graves et al., 1980; Ramakrishnan, 
2002). National food balance datasheets were used to estimate that 
approximately half of world’s population is at risk of zinc deficiency 
(Wuehler et al., 2005). 
A significant issue is the lack of a quick and reliable method to determine 
body zinc status. Most of the time plasma zinc concentrations are used to 
estimate zinc status, however it may not be affected in mild zinc deficiency 
and even more plasma zinc levels are altered by infections or stress. 
Plasma zinc concentrations can remain unchanged in case of severe zinc 
deficiency because zinc can be released from tissues (reviewed in Aggett 
and Comerford, 1995; Krebs and Hambidge, 2001). The zinc concentration 
in red blood cells is not readily changed even in severe deficiency. The 
response of leukocytes to zinc changes is more rapid but assay is very 
laborious. Measurement of zinc in hair and nails can be misleading, as the 
zinc concentrations may remain normal in severe deficiency due to growth 
arrest of these tissues. Several others commonly used methods also 
present some problems. Possibly the best approach to diagnosis of zinc 
deficiency is to measure zinc levels in several body compartments and to 
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correlate it to the extent of which zinc supplementation ameliorates the 
symptoms of the deficiency (reviewed in Thompson, 1991; Agget,t 1991; 
Aggett and Comerford, 1995; Prasad, 1985; Krebs and Hambidge, 2001).  
1.6 Neonatal requirement of zinc 
Lactation is one of the physiological stages of life when demand for zinc 
rapidly increases to compensate for the secretion into the milk in lactating 
women. It was demonstrated that the fractional zinc absorption during 
lactation increases nearly 2 fold while endogenous fecal loses may remain 
unchanged (Fung et al., 1997). Zinc levels in human milk change with 
progression of lactation from the highest in colostrums (~8.12 Pg/ml), 
reduced to 50% (~4.56 Pg/ml) in first week of lactation and then through 
gradually decline to ~ 20% in next 12 months to a level of ~0.9 Pg/ml 
(Casey et al., 1985; Krebs et al., 1995; Krebs, 1998; Dorea, 2012). 
Compared to cow’s milk, the zinc concentration in human milk is on 
average two times lower but its bioavailability for infants is very high. The 
fractional zinc absorption in infants reaches 55% from human milk (Krebs 
et al., 1996). 
The zinc requirements of the infant up to 6 months of age are usually met 
by an exclusive breast-milk diet despite the decline in breast milk zinc 
concentration, which is not compensated by the increase in volume of milk 
consumed. It is mainly due to infant’s very efficient fractional absorption of 
highly available zinc from the milk and conservation of endogenous losses 
(Krebs and Hambidge, 1986). After 6 months, the breast milk diet needs 
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be complemented with additional food, especially meat, to provide 
adequate zinc status in infants (Krebs and Westcott, 2002). 
1.7 Zinc supplementation  
The minimum zinc requirements for humans with satisfactory growth and 
health vary a lot due to different factors like type of diet consumed, stress 
and climatic conditions. The recommended daily intake ranges between 3-
5 mg/day for infants, 7-10 mg/day for children up to 10 years of age and 
12-15 mg/day for older children and adults (Aggett and Comerford, 1995; 
Tapiero and Tew, 2003; MacDonald, 2000), and the tolerable upper intake 
level of zinc recommended is 25mg/day by Scientific Committee for Food 
(SCF, 2003). The major source of the everyday zinc supply in humans is 
dietary. The richest sources of dietary zinc include seafood, specifically 
oysters, red meat, dairy products and nuts (Underwood, 1981). Many types 
of food are relatively rich in zinc for example cereals, corn and vegetables 
however intake of the zinc from the diet containing these foods may not be 
adequate. The reason for this is the presence of phytate (inositol 
hexaphosphate) in these foods, which have an inhibitory effect on zinc 
absorption. The phosphate groups in phytate bind zinc, creating insoluble 
complexes, which are not absorbed by gastrointestinal system through the 
lack of phytases (Lonnerdal, 2000).  
The efficiency of zinc supply is dependent on the dose and length of the 
treatment. High doses of zinc supplementation and prolonged use can result 
in zinc accumulation that can further impact the immune system 
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(Mocchegiani et al., 2001). Consumption of 12 mg Zn/day is considered a 
physiological dose of zinc for a short period (1 month) and restores immune 
efficiency in Down’s syndrome individuals (Licastro et al., 1993). Zinc 
treatment has been successful in curing patients with acrodermatitis 
enteropathica and Wilson’s disease. At the same time, there are cases of 
acute and chronic zinc poisoning due to excess zinc which is toxic (Pagani et 
al., 2007), therefore a suitable range between 0.1 and 0.5 mM cellular level 
of zinc must be controlled within a cell (Eide, 2006). 
1.8 Zinc and diseases  
Zinc is one of the most important trace elements present in human body with 
numerous functions therefore it is not surprising that zinc deficiency can have 
devastating effect on human health and hence can lead to a variety of 
diseases. 
1.8.1 Zinc and cancer 
Zinc plays an important role in prevention of cancer by providing host 
defence against prognosis and the treatment of several malignancies 
(Dhawan and Chadha, 2010). The involvement of zinc in cancer development 
was shown by abnormal levels of zinc in different types of cancer (John et al., 
2010). Reduced zinc serum levels have been demonstrated in patients with 
different malignancies, for example breast cancer (Schlag et al., 1978), 
gallbladder (Gupta et al., 2005) and lung (Issell et al., 2006).  
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1.8.2 Zinc and Alzheimer’s disease 
Zinc metabolism is altered in Alzheimer’s disease (AD) and other 
neurodegenerative diseases (Aschner, 1996; Wang et al., 2010). In AD 
patients brain β-amyloid (Aβ) plaques are formed and post-mortem studies of 
AD brains showed accumulation of zinc in those A-Beta plaques (Dong et al., 
2003; Friedlich et al., 2004; Stoltenberg et al., 2005). Zinc is the only 
physiologically available metal that can precipitate Aβ because Ab peptide 
has zinc-binding sites. The abnormal increase of zinc in the brains of AD 
patients demonstrated that zinc binding to Aβ plays a role in the formation of 
amyloid plaques (Faller, 2009). Similarly zinc chelating agents like clioquinol 
(CQ) and DP-109, that are known to modulate brain zinc levels can inhibit the 
formation of amyloid plaques (Cherny et al., 2001; Bush, 2000, 2002; Lee et 
al., 2004a). The disruption of zinc homeostasis is a potential therapeutic 
strategy for AD (Wang et al., 2010).  
1.8.3 Zinc, diabetes and cardiovascular disease 
Worldwide cardiovascular disease (CVD) is the leading cause of deaths. With 
advance age, plasma zinc levels drop and show a strong association with 
increasing CVD cardiovascular disease (Little et al., 2010). The trace 
element zinc is also known to play an important role in pancreatic islets 
where it acts as a specific structural component of the insulin molecule and 
helps in insulin secretion (Ynsa et al., 2009). It is also involved in synthesis 
and signaling of insulin, glucagon secretion (Bosco et al., 2010). Shokrzadeh 
 20 
 
et al (2009) showed a high excretion of zinc in the group with diabetes 
mellitus and congestive heart failure. 
1.8.4 Zinc and Wilson disease 
Wilson disease is an inherited autosomal recessive disorder that results due 
to copper imbalance and results in defect in ATP7B gene and neurological 
disturbance. The zinc supplementation in Wilson’s disease enhances the 
intestinal and hepatic metalothioneins (MTs) synthesis that protects the 
hepatic system from high copper levels (Stefanidou and Maravelias, 2004). 
The intensive zinc treatment does not cure Wilson patient’s, but it does 
improve some clinical symptoms of these patients. Even though zinc 
treatment has some side effects, none of them are severe and hence zinc 
acetate is recommended for long-term management of patients with Wilson’s 
disease (Huster, 2010; Shimizu et al., 2010). 
Zinc deficiencies are also associated with number of other diseases for 
example: renal disease, sickle cell anemia, alcoholism, AIDS, burns, and 
others (Keen and Gershwin, 1990; Mocchegiani and Fabris, 1995; Fraker et 
al., 2000; Mocchegiani et al., 2000).  
1.9 Inherited disorders of zinc deficiency 
1.9.1 Acrodermatitis enteropathica 
Acrodermatitis enteropathica (AE) is rare, recessively inherited disorder, 
described and named by Danbolt and Closs (1942). The symptoms of this 
condition are similar to those of zinc deficiency and include skin lesions, 
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diarrhea, alopecia and neuropsychological disturbances. Symptoms appear 
after weaning, suggesting a protective function of human milk (Danbold and 
Closs, 1942). Expressed breast milk and an ionophore, diiodoquine were 
firstly used to control effects of the disease but in 1974 Moynahan found that 
zinc therapy rapidly corrected the symptoms. Low plasma zinc levels, low 
alkaline phosphatase activity and a rapid response to zinc treatment were 
shown to be good indicators for the presence of this disorder (Danks, 1985). 
Atherton et al. (1979) demonstrated a defect of mucosal zinc uptake in the 
small intestine of patients with acrodermatitis enteropathica, confirming a zinc 
deficiency disorder. Kinetic assays in cultured fibroblasts from patients with 
acrodermatitis enteropathica show decreased rate of cellular zinc 
accumulation (Grider et al., 1998; Grider and Young, 1996). The region 
suspected to carry the gene responsible for this disorder was recently 
mapped to chromosome region 8q24.3 (Wang et al., 2001). Intensive search 
of this region has identified a novel gene encoding a zinc transporting 
molecule termed ZIP4, which harboured a selection of point mutations and 
deletions in patients with acrodermatitis enteropathica (Wang et al., 2002; 
Kury et al., 2002; Kury et al., 2001; Nakano et al., 2003).  
1.9.2 Mammary gland disorder of zinc secretion 
A disorder leading to zinc deficiency has been found in some premature 
babies. This condition, unlike acrodermatitis enteropathica, manifests itself in 
infants during breast-feeding. Plasma zinc levels and alkaline phosphatase 
activity are reduced in zinc deficient infants but are normal in the mothers. 
The zinc uptake from the small intestinal mucosa of affected babies is normal 
or even increased (Aggett et al., 1980). The zinc levels in the breast milk zinc 
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from the mothers of the zinc deficient infants are significantly lower than in 
control mothers of premature and term babies (Zimmerman et al., 1982). Oral 
zinc supplements induce a complete remission of symptoms when given to 
infants but have no effect on zinc levels in milk when provided to mothers 
(Weymouth et al., 1982). These results strongly suggest a role for mammary 
gland in regulation of zinc secretion into the milk and defect of such transport 
in this disorder. The zinc requirements for premature infants are higher than 
the term infants, as they are rapidly growing and their zinc storage is 
inadequate. Also their capacity to absorb zinc may be impaired, making them 
especially prone to develop acrodermatitis. Interestingly, some cases of term 
babies suffering from this condition have also been reported (Kuramoto et al., 
1991; Glover and Atherton, 1988). Although this constellation of alimentary 
zinc deficiency has been described as early as 1979 but still most of the 
cases were initially misdiagnosed and received inappropriate topical and oral 
therapy. 
The ‘Lethal milk’ (lm) mouse is a murine model of the human premature 
babies zinc deficiency as the pups nursed on lm/lm dams develop symptoms 
characteristic for nutritional zinc deficiency and die before weaning (Piletz 
and Ganschow, 1978a; Piletz and Ganschow, 1978b).  
1.10 Zinc and lipids interactions in the brain 
Zinc regulates neuronal cell proliferation, survival and differentiation. It play 
a vital role in neural development, learning and memory (Frederickson et al., 
2005). Disturbances in lipid metabolism were reported in zinc deficient 
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patients and zinc-deficient pregnant rats had impaired transport of poly 
unsaturated fatty acids (PUFA) to the foetus (Cunnane, 1988). These reports 
showed the association between zinc and lipids specifically poly unsaturated 
fatty acids. 
1.10.1 DHA  
DHA (Docosahexaenoic Acid) is a long-chain fatty acid that belongs to the 
Omega-3 fatty acid family. Omega-3 are essential fatty acids that cannot be 
synthesised by the human body and adequate amounts are required for 
normal function of body. There are 3 main forms of Omega-3, Alpha-linolenic 
acid (ALA), Eicosapentanoic acid (EPA) and DHA. DHA is the most complex 
form of Omega-3 and is difficult to include in our diet as only few foods 
contain a significant amount. 
The retina has the highest concentration of DHA in the human body. DHA is 
considered as an essential component of breast milk where newborn babies 
utilise it for brain, nerve and eye tissue development. The minimum intake of 
DHA is set to be 500 mg (Burr et al., 1989; Krishnamurti et al., 2002). 
1.10.2 DHA and Brain 
In human brains, fat content is greater than 50% by mass and DHA 
represents 30% of brain mass. Epidemiological studies have shown an 
inverse association between prognosis of Alzheimer Disease (AD) and 
omega-3 dietary intake. Decreased blood levels of omega-3 fatty acids have 
been associated with several neurodegenerative conditions eg. AD, 
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schizophrenia and depression (Fenton et al., 2000; Young and Conquer, 
2005). A population based study in Netherlands demonstrated that 
consumption of fish was inversely related to dementia and AD (Kalmijn et al., 
1997). In another human study progression of AD, total intake of DHA was 
associated with reduced risk of AD (Morris at al., 2003). Overall communities 
with regular consumption of fish have shown reduced prevalence of 
neurodegenerative disease and cognitive decline in elderly men (van Glender 
et al., 2007; He et al., 2004). Low levels of plasma DHA have been reported 
with dementia and AD patients (Tully et al., 2003). Patients having highest 
quartile of blood DHA concentration showed lower risk of developing 
dementia as compared to patients having lowest three quartile of blood DHA 
concentration with the mean value upto nine years (Schaefer et al., 2006).  
1.10.3 Link between DHA and zinc 
Alterations in both zinc and DHA homeostasis are associated with 
neurodegenerative disorders (Lukiw et al., 2005; Cuajungco and Lees, 1997). 
Rats fed an omega-3 DHA deficient diet showed altered zinc homeostasis 
and demonstrated a strong link between DHA and zinc (Jayasooriya et al., 
2005). Abnormalities in brain zinc metabolism can trigger β-amyloid 
formation (Bush et al., 1994). Zinc is one of the metals found in high levels in 
brains from human AD patients and transgenic Tg2576 mice (APP mice), 
which are prone to develop amyloid plaques (Suh et al., 2000). In studies of 
AD brains, zinc chelation caused the precipitation of Aβ suggesting the 
association of zinc with AD (Cherny et al., 1999). Similarly ZnT3 knockout 
mice (APP mice) showed reduced amyloid plaques (lee et al., 2002). In 
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current study, ZnT5 and ZnT6 have shown association with DHA in presence 
of zinc in neuronal cells (Discussed in chapter 5). 
1.11 Cellular zinc transport  
As any other metal or ion, zinc gets distributed in different cells by specific 
transporters called zinc transporters. Different organisms have different 
mechanism of transportation. Bacterial transport system has been well 
studied and documented in literature, and provide the basic platform for 
understanding transportation mechanisms in many other organisms. The 
following sections discuss transportation of zinc in both prokaryotes and 
eukaryotes. 
1.11.1 Bacterial zinc transporters 
Zinc is an essential trace element for bacteria as for any other organism. 
More is known about bacteria than any other organism. Many different zinc 
transporters have been discovered in various types of bacteria and 
interestingly, almost every transport system is controlled by its own regulator 
(Hantke, 2001). Transportation in bacteria has provided excellent approach 
to investigate zinc transport function in eukaryotes. Three families for zinc 
efflux and two families for zinc uptake have been reported in bacteria. 
1.11.1.1 Cellular zinc import systems 
The high affinity zinc uptake process in bacteria is mediated by the ABC 
(ATP Binding Cassette) transporter family. The first described 
representatives of this family were E. coli Znu (zinc uptake) proteins. The 
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znuA gene encodes protein localized to the periplasmic compartment while 
ZnuB is part of cytoplasmic membrane and znuC gene encodes an ATPase 
component, positioned in the cytoplasm. Together the whole znuABC 
complex can transport Zn2+, Mn2+ and possibly Fe2+ (Patzer and Hantke, 
1998; Hantke, 2001). This complex comes into action when bacteria grow in 
environments characterized by very low zinc availability (Yatsunyk et al., 
2008). Another example of a transporter belonging to ABC family is the Pzp1 
protein of Hemophilus influenzae. The growth of pzp1 mutant was inhibited, 
indicating an important function of transporter in the life of organism (Lu et 
al., 1997). Recent study showed involvement of another zinc uptake protein 
ZinT (formerly known as YodA), which originally identified as cadmium stress 
stimulated protein in E. coli (Puskarova et al., 2002; Ho et al., 2008). Zin T is 
involved in periplasmic zinc binding under zinc limiting conditions (Kershaw 
et al., 2007; Graham et al., 2009). Another study demonstrated the direct 
interaction of ZinT with ZnuA for zinc uptake (Petrarca et al., 2010). 
Another zinc transporter ZupT was found in bacteria, where metal uptake 
was carried out under conditions of moderate zinc availability by the low-
affinity zinc uptake. ZupT (ygiE), represents the first bacterial member of the 
ZIP family that mediates zinc uptake. Either ZupT (ygie) or znuABC is 
necessary for growth under zinc-limited conditions (Gabbianelli et al., 2011; 
Hantke, 2005). Pit transporter has also been proposed to influx zinc in 
exchange for inorganic phosphate (Beard et al., 2000). YciABC membrane 
protein in B. subtilis has been identified as possible low-affinity zinc 
transporter (Gaballa and Helmann, 2002).  
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1.11.1.2 Cellular zinc export systems 
Several members of the Cation Diffusion Facilitators (CDF) family have been 
identified in bacteria and most of them play a role in export not only of Zn2+ 
but also of Co2+ and Cd2+. The zinc transporter CzcD from Ralstonia 
metallidurans is a representative of this family, which has been found to 
protect this organism against the high concentration of zinc present in 
decantation tanks of a zinc factory where it was found (Anton et al., 1999). 
zitB (formerly ybgR) encodes an additional zinc transporter that belongs to 
the CDF family of proteins. Three bacterial CDF homologs, YiiP and ZitB 
from E. coli and CzcD from Ralstonia have been characterized functionally 
and are related to their mammalian counterparts (Lu and Fu, 2007). 
The best characterised members of Resistance, Nodulation, Division (RND) 
heavy metal efflux family are mainly from Cupriavidus (previously called 
Ralstonia and Alcaligenes) in the form of three transporters CzcA, CzcB and 
CzcC organised in sophisticated complex (Valencia et al., 2013). CzcA is 
zinc-proton exchanger localized to the cytoplasmic membrane whereas CzcC 
is found in outer membrane. Both of them are connected together through 
CzcB, which resides in the periplasm. The whole complex forms channel, 
allowing extrusion of toxic metals from the cytoplasm to the extracellular 
space (Rensing et al., 1997). The RND types of exporters are only identified 
in a few gram-negative bacteria (Hantke, 2001).  
P-type ATPases are large family of cation transporting, ATP-dependant 
proteins found in prokaryotes as well as in eukaryotes, which can transport 
variety of ions: Cu+, Ag+, Zn2+, Cd2+ and Pb2+. The E. coli ZntA cytoplasmic 
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membrane protein is an example of such transporter, which confers 
resistance to Cd2+ and Zn2+.  
All three types of zinc efflux transporters can protect bacteria from high, toxic 
concentrations of zinc. 
1.11.2 Eukaryotic zinc transport  
In eukaryotes the ATP-dependant zinc transporters have not been identified 
to date. However members belonging to two metal transporter families have 
been implicated in transmembrane transport of zinc but the detailed 
mechanisms of their active zinc transport have yet to be elucidated. The Zrt, 
Irt-like Proteins (ZIP) family is involved in transporting extracellular zinc into 
cell or stored intracellular zinc into the cytoplasm. Many members of this 
family has been identified in eukaryotes. The members of cation diffusion 
facilitator (CDF) play a similar role in eukaryotes as it was described for 
bacteria in the efflux of zinc out of the cell. Additionally they can also 
sequester zinc into intracellular organelles. 
1.11.2.1 Zrt, Irt-like Proteins (ZIP) or SLC39 family 
The name of the family comes from the first identified members, iron 
transporter from plant Arabidopsis thaliana (Irt1) and yeast Saccharomyces 
cerevisiae the zinc transporter Zrt1 (Eide et al., 1996; Zhao and Eide, 1996a). 
Over 80 genes have recently been included in this family, originating from 
such distantly related organisms as for example, yeast and humans (Gaither 
and Eide, 2001). Most of ZIP proteins have been predicted to contain eight 
transmembrane domains and long, cytoplasmic, histidine-rich loop between 
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domains III and IV, which may facilitate zinc binding. Transmembrane 
domains IV and V of all ZIP members contain conserved histidine residues 
(Figure 1.2). They may help to bind and move zinc ion throughout the 
transmembrane channel (Eng et al., 1998; Guerinot, 2000). The region 
possibly accountable for recognition of the zinc is the loop between 
transmembrane domains II and III (Gaither and Eide, 2001). However, the 
mechanism of the zinc transport by ZIPs is not fully understood. Proposed 
mechanisms include exchange of zinc with another ion or diffusion of zinc 
through the plasma membrane due to concentration gradient (Eide, 2000).  
1.11.2.2 Cation Diffusion Facilitators (CDF) or SLC30 family 
The many members of the CDF family encode putative zinc efflux genes. The 
recent analysis of database sequences has revealed the presence of 104 
CDF members originating from all phylogenetic levels (Gaither and Eide, 
2001). The predicted CDF gene products are proteins with six 
transmembrane domains, except for the yeast Msc2 and the mammalian 
ZnT-5 transporters (Li and Kaplan, 2001; Kambe et al., 2002). Their carboxy 
and amino termini are localised to the cytoplasmic side of the cell membrane. 
A histidine-rich intracellular loop, a potential zinc-binding region, is found 
between transmembranes IV and V in all representatives of this family 
(McMahon and Cousins, 1998). A second potential zinc binding region with 
multiple histidines is found in the C-terminus (Figure 1.3). 
  
Figure 1.2 Predicted structure of the members of ZIP family 
Transmembrane domains are shown in purple and conserved histidine 
residues are highlighted in green. 
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Figure 1.3 Predicted structure of the members of ZnT family 
Transmembrane domains are shown in yellow and conserved histidine 
residues are highlighted in green. 
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The most conserved domains among CDF family are highly amphipathic 
transmembrane domains: I, II and V but their function has not yet been 
elucidated (Gaither and Eide, 2001). 
1.11.3 Zinc transport in Saccharomyces cerevisiae  
Even though it is single-celled, the yeast has all the characteristic traits of 
eukaryotic cells, including organelles and DNA confined to a nucleus. Yeast 
chromosomes are not circular, which is a characteristic feature of 
prokaryotes. Several yeasts, in particular S. cerevisiae, have been widely 
used in genetics and cell biology, largely because it is a simple eukaryotic 
cell, serving as a model for all eukaryotes, including humans. S. cerevisiae is 
generally regarded as the most well understood eukaryotic organism 
(Guldener et al., 2005). Studies on zinc transporters and their regulators in 
the yeast Saccharomyces cerevisiae have facilitated our general 
understanding of zinc transport.  
1.11.3.1 Cellular zinc uptake 
The first two uptake zinc transporters to be identified in yeast were the ZRT1 
and ZRT2 gene products. The ZRT1 and ZRT2 genes share (44%) amino 
acid sequence identity and a high similarity (67%) and both belong to the ZIP 
family (Eide, 2003). The ZRT1 is a high affinity zinc transporter, which is 
active in cells cultured in the presence of a low concentration of zinc. The 
zrt1 yeast mutant grew poorly on zinc-deficient medium, demonstrating a 
disruption to the high affinity zinc uptake system but not to the low affinity 
one (Zhao and Eide, 1996a). This second system was found to be controlled 
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by the transporter ZRT2, a low affinity zinc transporter that is active in zinc 
replete cells (Zhao and Eide, 1996b). Interestingly, the zrt1 zrt2 mutant was 
found to be viable but required a high concentration of zinc to grow (Zhao 
and Eide, 1996b). This finding suggests the existence of an additional uptake 
system, which recently was attributed to iron, copper and zinc transporter 
FET4 (Waters and Eide, 2002). FET4 is yeast specific and homology does 
not match to any other eukaryotic member, although it can be related to 
bacterial protein COG5478. 
Another member of the ZIP family, ZRT3 was isolated from yeast and found 
to be induced under the zinc limiting conditions. It is closely related to zinc 
uptake transporter ZupT from E. coli (Grass et al., 2002). Out of remaining 
ZIP proteins, only Atx2p has been characterized that resides in in the Golgi 
complex. It’s involvement in zinc homeostasis has not been investigated yet 
but might function in the transport of manganese from the lumen to the 
cytoplasm (Lin and Culotta, 1996). Phosphate transporter Pho84 has also 
been suggested to participate in uptake as ZnPO4 (Jensen et al., 2003). The 
last ZIP protein in yeast, Yi1023cp is not fully characterized but is closely 
related to human ZIP4 protein (lyons et al., 2004).  
1.11.3.2 Cellular zinc efflux  
An excess of the metal could be toxic for the organism, therefore a 
detoxification mechanism is present to efflux extra zinc out of the cell or by 
compartmentalization. In an abundance of intracellular zinc, Zrc1 and Cot1 
facilitate the sequestration of zinc into the vacuoles. Both proteins are closely 
related (60% identity) and demonstrate the conserved features characteristic 
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for CDF family (Eide, 1998). The ZRC1 gene was identified in search for 
genes conferring resistance to zinc. Overexpression of ZRC1 allows cells to 
withstand high zinc concentrations while the zrc1 mutant shows increased 
zinc sensitivity (Kobayashi et al., 1996). The COT1 gene was isolated by a 
similar method as a cadmium resistance gene (Conklin et al., 1992). Later its 
suppression of zinc toxicity was also demonstrated (Conklin et al., 1994). 
Zrc1 and Cot1 were found to localise to the membrane of vacuole, further 
supporting their role in zinc detoxification (Li and Kaplan, 1998; MacDiarmid 
et al., 2002). The mechanism of zinc transport into the vacuole by Zrc1 and 
Cot1 is based on Zn2+/H+ exchange (MacDiarmid et al., 2002). 
Another member of CDF family, Msc2 was discovered during the study on 
chromatid recombination (Thompson and Stahl, 1999), is believed to 
transport zinc into the lumen of the endoplasmic reticulum. The predicated 
protein structure of Msc1 indicates 12 transmembrane domains with two 
histidine-rich regions that is unusual for the CDF family but six of the C-
terminal domains show highly conserved region with other members of the 
family (Gaither and Eide, 2001). Msc2 interacts with fourth CDF protein 
Zrg17. These two proteins function as a complex to transport zinc into the 
secretory pathway (Ellis, 2005).  
1.11.4 Mammalian zinc transporters 
Zinc metabolism came into existence by identification and characterization of 
zinc transporters. Zinc transport proteins were identified in 1997/98. All of 
these proteins have transmembrane domains and are encoded by two solute 
linked carrier gene families ZnT (SLC30) and Zip (SLC39). In human cells 
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total of 10 ZnT’s and 15 Zip’s have been reported. These two families play 
opposite roles in cellular zinc homeostasis. ZnT transporters tends to reduce 
intracellular availability of zinc by promoting zinc efflux from cells or 
sequestering into intracellular vesicles whereas Zip transporters increase 
intracellular zinc availability by promoting extra cellular zinc uptake or by 
releasing vesicular zinc into the cytoplasm. Both the ZnT and Zip transporter 
families perform tissue specific expression and different response to dietary 
zinc deficiency or to physiologic stimuli via hormones and cytokines. 
Metallothionein is also included for its primary role in binding the intracellular 
free zinc and redistributing it to zinc-dependant molecules. 
1.11.4.1 ZIP family 
The first members of ZIP family, ZIP1, ZIP2 and ZIP3 genes were isolated 
from Arabidopsis thaliana when they restored the growth of zinc uptake yeast 
mutant (zrt1 zrt2) on zinc-limited medium. The ZIP4 gene was identified by 
plant database search however it did not rescue the growth of yeast mutant. 
All mammalian ZIP sequences, isolated later, have been named after plant 
transporters: ZIP1 to ZIP15. The study on yeast and plant ZIP family has 
facilitated the characterization of the human genes. 
ZIP1 
The human Zip1 gene, hZip1 was identified in expressed sequence tag 
(EST) database by homology to Arabidopsis thaliana ZIP1 gene (Grotz et al., 
1998; Lioumi et al., 1999). It is expressed in human prostate cells, where it 
was found to be upregulated in response to testosterone and prolactin and 
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down-regulation in response to high zinc (Costello et al., 1999). In another 
study, hZIP1 was isolated from prostate cDNA library and designated ZIRTL 
(Zinc-Iron Regulated Transporter-Like) Gaiter and Eide (2001). In human 
erythroleukemia (K562) cells overexpression of ZIRTL increased zinc uptake 
activity and antisense oligonucleotide inhibition of hZIP1 expression reduced 
zinc uptake. Similar results were obtained in prostate cell line (Franklin et al., 
2003). hZIP1 protein is associated with organelles in cells cultured in zinc 
adequate medium but goes to the cell surface when zinc is limited (Wang et 
al., 2004), where a di-leucine sorting signal of ZIP1 is required for the 
endocytosis of protein (Huang and Krischke, 2007). In mice, ZIP1 was not 
regulated by dietary zinc. 
ZIP2 
The human ZIP2 gene was identified by sequence homology to A. thaliana 
ZIP2. Human erythroleukemia K562 cells transfected with hZIP2 construct 
accumulated more 65Zn than control cells suggesting that hZIP2 was involved 
in zinc uptake. hZIP2 mRNA is not detected in many human tissue and cell 
lines, which may be related to the low levels of expression of this transporter 
or its limited tissue distribution.  
The ZIP2 protein was localised to the plasma membrane in K562 cells 
(Gaither and Eide, 2000) and treatment of the cells with the zinc chelator 
TPEN gave a 27-fold up-regulation. In response to zinc supplementation, the 
expression of hZIP2 was only slightly down regulated (~1.5-fold) (Cousins et 
al., 2003). These results confirm the potential role of hZIP2 in zinc uptake. In 
mice, the gene is expressed in skin, liver, ovary and visceral yolk sac and did 
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not respond to dietary zinc deficiency (Dufner-Beattie et al., 2003). This gene 
may be regulated in a cell-specific manner or post-translational mechanisms 
are involved in its regulation.  
ZIP3 
The human ZIP3 gene has been identified by sequence homology to fungal 
and plant ZIPs (Gaither and Eide, 2000) however no experimental data has 
been reported. The mouse ZIP3 gene was identified from mouse ESTs. The 
predicted mZIP3 protein shows 78% identity to human ZIP3. The expression 
of mZIP3 gene in HEK293 cells resulted in increased zinc uptake. This 
uptake was inhibited by Cu2+, Cd2+, Mn2+, Mg2+ and Ni2+ suggesting that 
mZIP3 may be capable of transporting broad range of metals. The mRNA 
expression of mZIP3 was limited to few tissues with highest level in testis. 
Similarly to the mZIP1 and mZIP2 the transcriptional expression of mZIP3 in 
small intestine and visceral yolk sac was not responsive to mouse nutritional 
zinc deficiency (Dufner-Beattie et al., 2003). 
ZIP4 
The human ZIP4 gene was first identified by sequence homology to the other 
ZIP members. The hZIP4 mRNA expression was detected in the kidney, 
colon, duodenum, jejunum, and most of the intestinal tract. Two alternative 
forms of the protein exist, short form of 622 amino acids and the long form of 
647 amino acids. The hZIP4 gene spans 4.7kb and has 12 exons. 
Using immunohistochemisny, hZIP4 was shown to localize to the luminal 
plasma membrane of the enterocyte (Kury et al., 2002). ZIP4 transcriptional 
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up-regulation was observed during restricted zinc levels induced by the 
transcription factor Kruppel-like factor 4 (KLF4) (Weaver et al., 2007). 
Mutations in both of the hZIP4 alleles and heterozygous deletions result in 
the zinc deficiency disorder, acrodermatitis enteropathica (Kury et al., 2002). 
When treated with zinc, a quick recovery of patients with acrodematitis 
enteropathica was observed, suggesting that hZIP4 may not be the only 
functional zinc uptake protein (Wang et al., 2002). As zinc is necessary for 
many different processes in the body, it may be required to transport zinc to 
different cells and intracellular sites, through a variety of zinc transporters. 
ZIP5 
ZIP5 proteins share 30% homology with ZIP4 and mouse and human ZIP5 
are very similar in sequence with 84% identity (Wang et al., 2004). It shows 
high expression in liver, kidney, pancreas, small intestine and colon. Unlike 
ZIP4, ZIP5 is present in the basolateral surface of these cell types under zinc 
replete conditions but gets internalized during dietary zinc deficiency (Dufner-
Beattie et al, 2004). During zinc deficiency, ZIP5 mRNA remains associated 
with polysomes while the protein is internalized and degraded in enterocytes, 
acinar cells and endoderm cells (Weaver et al., 2007). 
ZIP6 
ZIP6 (LIV-1) was identified in MCF-7 and ZR-75 breast cancer cells for the 
first time and their expression was stimulated by estrogen treatment 
(Manning et al., 1988). It is considered as the founder of LZT (LIV-1 
subfamily of ZIP zinc transporters) Tissues like placenta, mammary gland 
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and prostrate, which are sensitive to hormones, showed high expression for 
ZIP6 gene (Taylor and Nicholas, 2003). These are present in the plasma 
membrane of these cells and act as an importer of zinc. These also have 
been associated with the prognosis of breast cancer and ZIP6 is considered 
as a reliable marker for estrogen receptor positive cancers (Scheider et al., 
2006; Tozlu et al., 2006). In dendritic cells under decreased intracellular zinc 
conditions, after exposure to lipopolysaccharide (LPS) ZIP6 expression goes 
down. A cell-permeable zinc chelator, TPEN, mimicked the effects of LPS, 
whereas zinc supplementation or overexpression of the gene encoding ZIP6, 
a zinc transporter whose expression was reduced by LPS, inhibited LPS-
induced upregulation of major histocompatibility complex (MHC) class II and 
costimulatory molecules (Kitamura et al., 2006).  
ZIP7 
ZIP7 was found originally by homology to mouse KE4 gene and the human 
HKE4 gene was mapped to the centromeric side of the HLA class II region of 
chromosome 6 (Ando et al., 1996). Protein expression of ZIP7 is repressed 
under high zinc conditions, whereas there were no effects of zinc on ZIP7 
gene expression and intracellular localization, neither did zinc deficiency 
affect the intracellular distribution of ZIP7 in mammalian cells suggesting that 
ZIP7 is a functional zinc transporter that acts by transporting zinc from the 
Golgi apparatus to the cytoplasm of the cell (Huang et al., 2005; Taylor et al., 
2007). This transporter shows association with the prognosis of breast 
cancer as studies on MCF-7 and tamoxifen-resistant (TamR) MCF-7 
demonstrated that ZIP7 is required for increasing intracellular zinc levels that 
 40 
 
can lead to activation of epithelial growth factor receptor/IGF-I receptor/Src 
signaling as well as growth and invasion (Taylor et al., 2008). 
ZIP8 
Refining the mouse chromosomal location of cadmium lead to the 
identification of mouse ZIP8 as the transporter responsible for cadmium 
induced toxicity in the testis (Dalton et al., 2000; Dalton et al., 2005). ZIP8 
was expressed in lung, kidney, testis, liver, brain, small intestine and the 
membrane fraction of mature red blood cells (RBCs) (Wang et al., 2007; Ryu 
et al., 2008). The localization of this transporter during zinc deficient 
conditions is plasma membrane but during adequate zinc conditions it gets 
internalized (Wang et al., 2007), in contrast, in mature RBCs after zinc 
dietary deficiency no changes were observed in the localization (Ryu et al., 
2008). In primary human lung epithelia and BEAS-2B cell cultures, ZIP8 
expression is stimulated by TNF-α. TNF-α induces the expression of a 
glycosylated protein that gets translocated to the plasma membrane and 
mitochondria. Increased Zip8 expression resulted in an increase in 
intracellular zinc content and coincided with cell survival in the presence of 
TNF-α. This study suggested that upregulation of Zip8 is sufficient to protect 
lung epithelia against TNF-α-induced cytotoxicity (Besecker et al., 2008). 
ZIP9 
National Institute of Health Mammalian Gene collection Program identified 
human and mouse ZIP9 by sequencing a cDNA clone containing a complete 
ORF for gene (Strausberg et al., 2002). Sequence homology confirms this as 
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a member to ZIP family but this is the only member in subfamily I (Taylor et 
al., 2007). 
ZIP10 
The expression of ZIP10 gets suppressed by induction of MTF-1 unlike ZNT1 
zinc transporter (Wimmer et al., 2005). rZIP10 localises in plasma membrane 
and high expression was observed with zinc supplementation, which is in 
contrast to mouse and zebra fish where its expression goes down with zinc 
supply (Pawan et al., 2007). mRNA expression of this transporter in breast 
cancer samples suggested the association of ZIP10 with metastasis of breast 
cancer to the lymph nodes (Kagara et al., 2007). 
ZIP11 
It is member of gufA subfamily of ZIP transporters and is named after the 
Myxococcus xanthus gene, which has unknown function (Yu et al., 2013). 
ZIP12 
ZIP12 was found on the basis of screening of a schizophrenia susceptibility 
locus on chromosome 10p for proteins that may be involved in zinc transport. 
An association was demonstrated by missense homozygous mutation in 
ZIP12 and frequency of schizophrenia development in a small group of 
patients (Bly, 2006). 
ZIP13 
ZIP13 is a member of the LIV-I subfamily of ZIP zinc transporters (Taylor et 
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al., 2007). Mice deficient in Zip13 showed changes in bone, teeth and 
connective tissue of the clinical spectrum of human Ehlers-Danlos syndrome 
(EDS). The ZIP13 knockout mice show defects in the maturation of 
osteoblasts, chondrocytes, odontoblasts, and fibroblasts. This study revealed 
that a crucial role of ZIP13 in connective tissue development is due to its 
involvement in the BMP/TGF-beta signaling pathways (Fukada et al., 2008). 
ZIP14 
This member belongs to LZT subfamily and its function has been associated 
with inflammation. Zip14 expression was shown up-regulated through IL-6, 
and suggested that it plays a major role in the mechanism responsible for 
hypozincemia that accompanies the acute-phase response to inflammation 
and infection (Liuzzi et al., 2005). Two different mRNA transcripts have been 
identified so far ZIP14A and ZIP14B (Liuzzi and Cousins, 2004; Girijashanker 
et al., 2008). Both ZIPA and ZIPB are localized to the apical surface of cells 
(Tominaga et al., 2005; Liuzzi et al., 2005). An alternative transcript variant of 
SLC39A14, caused by pre-mRNA splicing (SLC39A14-exon4B), has also 
been suggested as a biomarker for colorectal cancer (CRC) (Sveen et al., 
2012). 
1.11.4.2 ZNT family 
Members of mammalian CDF family are denoted ZnT (zinc Transporters) 
and were first described in rodents (Palmiter and Findley, 1995) but now 
human othologues have been identified (Huang and Gitsher, 1997; Palmiter 
et al., 1996a). The exact mechanism by which the ZnT proteins transport zinc 
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is unclear. A total of 10 mammalian members are known for this family. Their 
detailed structural features like transmembrane domains (TMD), total length, 
number of exons, N and C terminal regions are explained in chapter six. 
ZnT1  
ZnT-1 was the first described zinc transporter in mammalian cells and shows 
similarity to the yeast metal efflux genes ZRC1 and COT1. It was discovered 
in complementation studies by transforming a rat kidney cDNA library into 
zinc sensitive strain of baby hamster kidney (BHK) cells and selecting cells 
surviving in high concentration of zinc (Palmiter and Findley, 1995). The ZnT-
1 gene product is a small protein, comprising of 507 amino acids, which is 
ubiquitously expressed (Palmiter and Findley, 1995). The ZnT1 mRNA 
expression is zinc responsive (McMahon and Cousins, 1998) through MTF-1 
(metal-responsive element-binding transcription factor-1), which binds to its 
metal responsive element (MRE) in the promoter region (Langmade et al., 
2000). A recent study demonstrated that a tumor suppressor PTEN 
(phosphatase and tensin homologue deleted on chromosome 10) modulates 
the MTF-1 mediated expression of ZnT1 and metallothionein (Lin et al., 
2012). ZnT1 interacts with other proteins. For example, it decreases cell 
surface expression of functional L-type calcium channels (LLCCs) by 
interacting to β-subunit of LTCC (Levy et al., 2009) or downregulates the 
transcription factors stimulated by MTF1, c-jun and Elk by forming 
heterocomplexes with EVER proteins (Lazarczyk et al., 2008). It is also 
known to modulate Raf-1 activity via direct interaction (Jirakulaporn and 
muslin, 2004). 
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The ZnT1 protein is mainly localised to the plasma membrane (Palmiter and 
Findley, 1995) but its subcellular localization shows diversification. It is 
present in basolateral membrane in enterocytes but at the apical membrane 
in pancreatic acinar cells (Cousins et al., 2006; Cousins and McMohan, 
2000; Liuzzi and Cousins, 2004). Another study also revealed its presence in 
the endoplasmic reticulum (ER) by forming complexes with EVER proteins in 
human keratinocytes where it gives rise to rare autosomal recessive disorder 
epidermodysplasia verruciformis (Lazarczyk et al., 2008). It’s mRNA and 
protein expression has been studied for liver, intestine and brain (McMohan 
and Cousins, 1998; Liuzzi et al., 2001) 
ZnT2 
Another member of the CDF family sharing all their features is the ZnT2 gene 
product. Rat ZnT2 was isolated using a similar strategy as for ZnT1. The 
remaining BHK zinc resistant clones, which did not contain ZnT-1 cDNA were 
sequenced and one of the newly identified clone was termed ZnT2 as it 
shared sequence similarity to ZnT1 (Palmiter et al., 1996a). Mouse intestine, 
testis and kidney tested positively for ZnT2 mRNA expression (Palmiter et 
al., 1996b). At the cellular level, the protein product of this gene was detected 
in cytoplasmic vesicles characterised by their high zinc content as detected 
by the Zinquin probe (Palmiter et al., 1996a). Zinc-sensitive BHK mutant cells 
transformed with ZnT2 construct were resistant to high zinc concentrations, 
but the total cell zinc content was increased, implying that this gene product 
has a function in delivering access of zinc to secretory vesicles (Palmiter et 
al., 1996a). ZnT2 expression has been observed in small intestine, kidney, 
 45 
 
placenta and liver (McMohan and Cousins, 1998). ZnT2 expression gets 
upregulated by prolactin a lactogenic hormone in mammary cells via 
JAK2/STAT5 signalling pathway (Qian et al., 2009). STAT5 and 
glucocorticoid receptor interaction regulates ZnT2 expression in pancreatic 
acinar cells (Guo et al., 2010). 
The subcellular localization for ZnT2 is very diverse. It has been localized in 
secretory vesicles of mammary gland, pancreas and prostrate (Kelleher et 
al., 2011). It has been observed in endosomal/lysosomal acidic 
compartments (Falcon-Perez and Dell’Angelica, 2007; Palmiter et al., 
1996a). Mitochondrial localization of ZnT2 via its association with the inner 
membrane has also been reported (Seo et al., 2011). SNPs (Single 
Nucleotide Polymorphism) in ZnT2, changes the subcellular localization that 
can affect cellular zinc metabolism (Seo and Kelleher, 2010). ZnT2 gene is 
associated with 75% reduction of zinc levels in milk that resulted in transient 
zinc deficiency and dermatitis in infants (Chowanadisai et al., 2006).  
ZnT3 
The third CDF zinc transporter gene, ZnT3 was cloned from a mouse brain 
cDNA library using a rat ZnT2 cDNA probe. The gene product is highly 
similar to ZnT2 (52% identity). It contains six transmembrane domains but 
the histidine-rich fragment is shorter than in other ZnT family members. The 
mRNA expression of ZnT3 was reported to be restricted to testis and brain 
(Palmiter et al., 1996b) with strong expression in synapses of glutamatic 
neurons in the hippocampus and neocortex, suggesting a role for it in 
packaging zinc into synaptic vesicle (Sensi et al., 2009; Wenzel et al., 1997). 
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Synaptic vesicular zinc is depleted in Znt3-knockout mice (Cole et al., 1999). 
As zinc released into the synaptic cleft is an important modulator of neuronal 
activity (Sensi et al., 2009), ZnT3 plays an important role in presynaptic 
Erk1/2 signalling during hippocampus dependent learning (Sindreu et al., 
2011). 
Mice with mutant of AP-3 (mocha mouse) showed loss of ZnT3 or disturbed 
localization hence indicates that synaptic localization of ZnT3 is controlled by 
AP-3 (Kantheti et al., 1998). Estrogen decreases the expression of ZnT3 by 
down regulating the expression of δ-subunit adaptor protein complex (AP-3 
δ) that determines the level of ZnT3 (Lee et al., 2004). Knockouts of ZnT3 
showed age dependent learning disabilities and memory loss (Adlared et al., 
2010; Martel et al., 2011). Other than its role in brain, it has been reported to 
regulate insulin production in pancreatic β cells, where ZnT3-knoclout mice 
showed mildly impaired glucose metabolism after streptozotocin treatment 
(Smidt et al., 2009) and retinal cells (Smidt and Rungby, 2012).  
ZnT4 
The ZnT4 gene was found during an attempt to scan for the gene underlying 
the ‘pallid’ mouse mutant (Huang and Gitschier, 1997). The ZnT4 protein, in 
addition to all features characteristic for whole family, exhibited the presence 
of a ‘leucine zipper’ motif in the N-terminal region, which may facilitate 
protein-protein binding (Murgia et al., 1999). Ubiquitous expression of the 
ZnT4 gene product was detected in rat tissue and cells with strongest signals 
from the mammary gland, brain and testis. The ability of ZnT4 to transport 
zinc was confirmed by complementation of a zinc-sensitive (' zrc1) yeast 
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mutant. The most interesting discovery was revealed following the 
sequencing of ZnT-4 gene in the ‘lethal milk’ mouse. A nonsense mutation at 
arginine codon 297 resulted in premature protein termination, producing a 
nonfunctional protein (Huang and Gitschier, 1997). This finding suggested 
the possibility that ZnT-4 was responsible for secreting zinc into the milk in 
the mouse and hence may underline a zinc-deficiency disorder found in 
premature babies. In 2003, however, Michalczyk et al., found no mutations or 
changes in ZnT4, indicating that this gene did not cause the neonatal zinc 
deficiency disorder. 
Immunocytochemistry of a c-myc tagged protein revealed localisation of 
ZnT4 to cytoplasmic vesicles mainly in close relation to the perinuclear 
region (Murgia et al., 1999).Overall the localization has been seen in 
intracellular vesicles, the trans-Golgi network as well as endosomal 
compartments (Falcon-Perez and Dell’Angelica, 2007; Ho et al., 2004; 
Palmiter and Huang, 2004). It also has been reported to be present in the 
plasma membrane in some cells (Henshall et al., 2003; Overbeck et al., 
2008). Altered expression of ZnT4 has been reported in AD brain (Smith et 
al., 2006), although no evidence to describe the underlying mechanism is 
known. 
ZnT5 
Almost simultaneously two independent groups reported the identification of 
another member of CDF family designated ZnT-5 or ZTL1 (ZnT-Like 
Transporter). The ZnT-5 gene was isolated from the mouse EST sequences 
while searched with ZRC1 gene. The mouse gene was estimated to code for 
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761 amino acids whereas human ZnT-5 with high homology to mZnT-5 
(94%) consists of 765 amino acids. The predicted protein structure of both 
mouse and human ZnT-5 transporters has showed 15 transmenbrane 
domains with 6 C-terminal domains characteristic of CDF transporter family 
(Kambe et al., 2002). The part of ZTL1 gene was isolated from EST 
databases during the homology search with ZnT1 and then ZTL1 sequence 
was extended using 5’RACE system. This 523 amino acids protein (172-666 
amino acids identical to hZnT-5) has 12 predicted membrane-spanning 
domains.  
In promoter region of hZTL1 five metal response elements (MRE) were 
identified, suggesting the regulation by MTF-1 (Cragg et al., 2002). Both 
hZnT-5 and hZTL1 transcripts are widely expressed but hZnT-5 was the 
most abundant in pancreatic E cells (Kambe et al., 2002; Cragg et al., 2002). 
The electron microscopy revealed the association of hZnT-5 protein with 
zinc-rich secretary granules that accumulate insulin in E cells suggesting a 
role of this transporter in delivering zinc for formation of insulin crystals. In 
the HeLa cells transfected with inducible hZnT-5, this gene product was 
detected in Golgi apparatus. The 65Zn uptake into the isolated hZnT-5-
induced Golgi vesicles was higher than in uninduced vesicles. This transport 
was dependant on time, temperature and concentration and was saturable 
(Kambe et al., 2002). 
The myc-tagged hZTL1 was localized to apical side of the CaCo-2 cells. The 
endogenous expression of hZTL1 was induced in Caco-2 cells grown in high 
zinc concentrations.Increased 65Zn uptake was recorded in Xenopus laevis 
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oocytes when injected with hZTL1 cRNA demonstrating saturable and pH 
dependant features (Cragg et al., 2002). The ZnT-5-null mice showed poor 
growth, muscle weakness and developed osteopenia due to impairment of 
osteoblast maturation. More than half of hZTL1 knockout male mice died 
from sinus bradycardia indicating that this protein is required for regulation of 
cardiac conduction system (Inoue et al., 2002). 
ZnT5 protein expression goes down in human ileal mucosa with high dietary 
zinc intake (Cragg et al., 2005). Similarly exposure of high zinc to (human 
epithelial colorectal) Caco-2 cells resulted in inhibition of ZnT5 transcription 
and translation even though the the mRNA stability is increased by high 
doses of zinc (Jackson et al., 2007). The expression of ZnT5 is 
transcriptionally up regulated by unfolded protein response (UPR) inducer, 
which is mediated by the transcription factor XBPI through the conserved 
UPR element (5’-TGACGTGG-3’) in its promoter region (Ishihara et al., 
2006). ZnT5 expression is increased by LPS or interlukein-6 in the liver 
(Lichten and Cousins, 2009; Liuzzi et al., 2005). ER (endoplasmic reticulum) 
bound transcription binding factor, CREBH is activated in response to 
proinflammatory cytokines and LPS and binds to UPR sequence (Zhang et 
al., 2006). ZnT5 form heterodimer complexes with ZnT6 and participate in 
TNAP (Tissue Non-specific Alkaline Phosphatase) activation in early 
secretory pathway (explained in detail in chapter 5). Endogenous ZnT5 is 
concentrated in cytoplasmic vesicles, such as COPII-coated vesicles in HeLa 
cells (Suzuki et al., 2005a) and is associated with insulin granules membrane 
in pancreatic β cells (Kambee et al., 2002).It also plays important role in 
cellular events, for example it is essential for nuclear factor-kB activation 
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through the FcεRI-indused (Fc epsilon receptor I) translocation of the protein 
kinase C (PKC) to plasma membrane in mast cells (Nishida et al., 2009). 
ZnT6 
The mouse ZnT6 transporter was discovered using the mouse ZnT-4 
sequence to search EST databases. The amino acid sequence of mouse 
ZnT-4 demonstrates similarities to rat ZnT2, mouse ZnT3 and ZnT4 (32%, 
33% and 33% identities, respectively). The predicted protein structure of this 
gene resembles the other members of ZnT family except it lacks histidines in 
the second intracellular loop, presenting serine residues instead (Huang et 
al., 2002). Site-directed mutagenesis demonstrated that these serines were 
crucial for zinc binding function (Palmiter and Huang, 2004). An abundant 
mRNA expression of mZnT-6 was detected in brain, liver and small intestine 
whereas protein expression was demonstrated in brain, small intestine and 
kidney but not in liver, suggesting tissue-specific translational or 
posttranslational regulation. Expression of mZnT6 suppressed the growth of 
yeast 'zrt1, 'zrt3 and 'msc2 mutant, defective in accumulation of 
cytoplasmic zinc, when grown in media with normal zinc levels but zinc 
supplementation rescued yeast growth. 
In cultured rat NRK and human MCF-7 cells, the protein product of ZnT6 was 
localized predominantly to the TGN however it was redistributed from TGN to 
vesicular cytoplasmic compartment in response to zinc treatment. The 
cellular role of ZnT-6 was suggested be either delivering zinc into zinc-
dependant enzymes in TGN or export of the excess of zinc through vesicular 
transport (Huang et al. 2002). High expression of ZnT6 has been observed in 
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hippocampus gyrus of the human brain in AD and Pick disease (Ryu et al., 
2008). 
ZnT7 
The mouse ZnT7 transporter was discovered using the mouse ZnT1 
sequence to search EST databases (Kirschke and Huang, 2003). The 
closest homoloque of the mZnT-7 gene was the C-terminal part of the 
mZnT5 gene (47% identity). The predicted protein structure of ZnT7 
resembles other members of ZnT family with exception of the presence of a 
second intracellular loop very rich in histidine residues. The mRNA 
expression of mZnT7 gene was detected in most tissues tested but was most 
abundant in the liver, spleen and small intestine. The mZnT7 protein was 
detected in the small intestine and lungs at different sizes of 85, 65 and 43 
kDa possibly due to some modifications, possibly phosphorylation or 
glycosylation. Mouse ZnT7 protein was not expressed in brain, liver, kidney 
and heart despite the presence of mRNA in these tissues, suggesting 
translational or posttranslational regulation. 
Perinuclear localization of mZnT7 protein was detected in small intestinal 
epithelial cells and in lung fibroblasts where it co-localised with Golgi 
apparatus markers. An additional punctuate vesicular cytoplasmic pattern 
was found that was distinct from the punctuate staining of ZnT4 or ZnT6. 
Accumulation of zinc in the Golgi apparatus was identified with Zinquin probe 
in CHO cells expressing mZnT7 which had been exposed to increased 
concentrations of zinc. Therefore it is possible that ZnT7 transporter delivers 
zinc into the Golgi apparatus (Kirschke and Huang, 2003). ZnT7 is 
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predominantly localized in the cis-face or the forming face of the Golgi 
apparatus (Chi et al., 2006). ZnT7 forms homo-dimers to activate TNAP in 
early secretory pathway (Suzuki et al., 2005a). Disruption of ZnT7 in DT40 
cells resulted in 20% decrease in TNAP suggesting partial dependence of 
TNAP activity on ZnT7. ZnT7-knockout mice resulted in zinc deficient 
phenotype that did not respond to dietary zinc supplementation and had 
decreased body fat composition (Huang et al., 2007). ZnT7 has been shown 
to up regulate insulin gene expression via Mtf1 (Huang et al., 2010). This 
study suggests that ZnT7 plays a crucial role in maintaining cellular zinc 
homeostasis and might be involved in the regulation of body composition. 
ZnT8 
ZnT8 was first time identified in the insulin granules of pancreatic beta cells 
and shown to facilitate the accumulation of zinc from the cytoplasm into 
intracellular vesicles (Chimienti et al., 2004). It was also expressed in other 
tissues including glucagon secreting pancreatic α cells (Wijesekara et al., 
2010). The islet-specific expression of ZnT8 is regulated by the β cell 
enriched transcription factor Pdx-1 through an intronic enhancer (Pound et 
al., 2011; Tamaki et al., 2009). ZnT8 protein was expressed in fetal 
pancreatic cells and showed down regulation in the islets of diabetic mice by 
using mouse diabetic models (Tamaki et al., 2009). It also plays an essential 
role in zinc accumulation in the insulin granules, where insulin binds to zinc 
to form zinc-insulin crystals. 
Insulin granules in Znt8-knockout mice are immature with pale insulin “pro-
granules” (Lemaire et al., 2009; Wijesekara et al., 2010). Overexpression of 
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ZnT8 in insulinoma cells enhances glucose-stimulated insulin secretion 
(Chimienti et al., 2006). The non-synonymous SNP of ZnT8 (rs13266634) 
that introduced the substitution (arginine to tryptophan) at amino acid 325 at 
the C-terminal region is associated with increased susceptibility for type 2 
diabetes (Sladek et al., 2007). Recent study suggests that ZnT8 contributes 
to the risk of developing type 2 diabetes through β-cell- and non-β-cell-
specific effects (Hardy et al., 2012). 
ZnT9 
ZnT9 gene was originally isolated from human embryonic lung cells (Sim and 
Chow, 1999). The total length consisting 569 amino acids protein has a 
putative cation efflux motif, a DNA excision repair motif and a nuclear 
receptor interaction sequence. It is considered to be associated with cytocol 
and nuclear fractions and not to the membranes even though has predicted 
six trans-membrane domains (Sim and Chow, 1999). ZnT9 also shares 
homology with cation efflux domain (pfam01545), renamed as GAC63, as it 
acts as a component of the p160 coactivator signal transduction pathway 
(Chen et al., 2005). ZnT9 seems to be expressed ubiquitously and its mRNA 
expression is not affected either by high dose of zinc or by zinc depletion in 
peripheral blood lymphocytes (Overbeck et al., 2008). To date, no studies 
have assessed the function of this protein. 
ZnT10 
ZnT10 was discovered using sequence homology with ZnT1 (Seve et al., 
2004). EST (expressed sequence tag) analysis revealed the fetal restricted 
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expression profile to the fetal brain and liver for ZnT10. Recently ZnT10 has 
been reported to localize in the early/recycling endosomes in vascular 
smooth muscle cells (Patrushev et al., 2012). ZnT10 along with ZnT3 
regulates cellular senescence induced by angiotensin II in the vesicular 
smooth muscle cells by reducing cytosolic zinc concentrations (Patrushev et 
al., 2012). It plays key role in the regulation of manganese homeostasis, 
although the mechanism is not yet discovered and reported to be involved in 
parkinson’s by causing hypermanganesemia (Quadri et al., 2012; Tuschl et 
al., 2012).  
1.11.4.3 NRAMP (Natural Resistance-Associated Macrophage 
Proteins) or SLC11 family 
The DCT1/DMT1/Nramp2 gene is proton-coupled divalent metal transporter 
playing a crucial role in intestinal iron uptake but also capable of Mn2+, Cu2+, 
Zn2+ and PB2+ transport (Gunshin et al., 1997; Nevo and Nelson, 2006). 
Mammalian members of the SLC11 family are thought to have 12 
transmembrane domains (TMDs) (Czachorowski et al., 2009) with a 
conserved hydrophobic core of 10 TMDs (Cellier at al., 1996; Cellier at al., 
1995), with no similarity to either ZIP of CDF families. Iron deficiency induces 
the mRNA and protein expression of DCT1/DMT1/Nramp2 (Yeh et al., 2000). 
The DCT1/DMT1/Nramp2 protein is localized to apical membrane of 
duodenal enterocytes (Canonne-Hergaux et al., 1999) however in a variety of 
other tissues it shows endosomal and lysosomal vesicular localization (Roth 
et al., 2000; Tabuchi et al., 2000). The mammalian SLC11 family is 
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comprised of two members; SLC11A1 and SLC11A2. The specific role of this 
transporter in zinc homeostasis has not been studied yet. 
1.12 Project aims 
Zinc is an essential trace element required by all organisms for normal 
functioning, as it plays critical roles as a structural component of proteins and 
a co-factor in catalysis of many enzymes. Even though many transporters 
have been identified in bacteria, yeast and rodent cells, the biological 
assimilation and transport of zinc into cells is still not well understood. The 
functions of many of the ZnT/SLC30A (putative zinc exporters) and 
ZIP/SLC39A transporters are yet to be elucidated. This thesis describes an 
investigation into the molecular basis of an inherited disorder of zinc 
deficiency in milk that identified defects in ZnT5 and ZnT6 zinc transporters. 
Following this, further investigation to characterise the role of ZnT5 and ZnT6 
was carried out in neuronal cells as these two transporters are known to be 
linked with brain zinc homeostasis. The link between the omega-3 fatty acid 
DHA and zinc fluxes was investigated as both have been proven to play a 
crucial role in normal functioning of human brains. To better understand the 
relationship of ZnT5 and ZnT6 with rest of the family members, 
bioinformatics tools were used. 
The main aims of this project are: 
1. To analyse the role of ZnT family members in inherited disorder of premature 
babies with zinc deficiency causing impaired zinc secretion into milk. 
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2. To investigate the dependency between hZnT5 and hZnT6 in M17 
neuronal cells. 
3. To establish the effect of the lipid, DHA, on zinc transporter expression in 
M17 cells. 
4. To characterize in-silico associations between different members of the 
ZnT family. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER 2 
Materials and Methods  
 58 
 
2.1 Case history summaries 
Infant number I was born premature at 36 weeks and was breast-fed for 
three months, without fortified milk. A red necrolytic rash developed at two 
months of age (Figure 3.1a, b). Zinc deficiency was confirmed at three 
months post-partum by tests showing zinc blood levels of 4.5 μmoles/l; 0.29 
μg/ml (reference range 10.3–18.1 μmoles/l; 0.67-1.18 μg/ml). Breast milk zinc 
from the mother of infant I (Mother 1) was 0.29 μg/ml, which was less than 
one quarter that of the normal zinc level (1.35 μg/ml) at the corresponding 
stage of lactation. Treatment with zinc (50 mg/day) to infant resulted in a 
dramatic improvement in the rash within three days. Infant number II was 
born premature at 37 weeks gestation and developed dermatitis affecting the 
face and perioral skin, with scalp scale and similar symptoms as that of infant 
number I. The maternal milk zinc level (Mother 2) at seven months was 0.2 
μg/ml, which was considerably less than the normal zinc level (0.85 μg/ml). 
On commencing treatment with zinc (50 mg/day), the rash cleared in three 
days and hair started to grow fully (Michalczyk et al. 2003). It is interesting 
that both mothers who produced zinc-deficient milk had no clinical symptoms 
of zinc deficiency themselves.  
2.2 Sample collection and cell culture 
Ethical approval for the collection of blood and skin biopsies was obtained 
from Deakin University Melbourne, Australia (EC32-2000) and the Royal 
Children’s Hospital Parkville, Australia (ERC 2025B). Fibroblast and 
lymphoblast cell lines from patients (Mother 1 and Mother 2) and respective 
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controls (two lymphoblast and two fibroblasts) from healthy mothers were 
established as previously described (Michalczyk et al. 2003). Immortalised 
fibroblasts from zinc deficient disorder mothers and two separate controls 
from healthy people were cultured in BME supplemented with 10% FBS 
(Bovogen; Melbourne, Australia). Lymphoblasts were grown as suspended 
cultures in RPMI 1640 culture media (Thermo Fisher Scientific; Melbourne, 
Australia) supplemented with 20% FBS. Normal resting breast tissue was 
obtained from breast biopsies performed for diagnosis of breast disease. The 
tissue was immediately frozen at -80ºC until use. The human epithelial breast 
cell line PMC42-LA, a variant of PMC42 cell line, originally derived from a 
pleural effusion (Whitehead et al., 1983), was cultured in RPMI 1640 
supplemented with 10% FBS (Bovogen; Melbourne, Australia) at 37ºC in 5% 
CO2.  PMC42-LA and fibroblasts were passaged when confluent using 0.05% 
trypsin-EDTA solution in PBS (Sigma-Aldrich; Sydney, Australia). 
Lymphoblasts were pelleted when the culture reached high density by 
centrifugation and distributed to new flasks.  
Two different neuoblastoma cell lines M17 and SY5Y were cultured in 
Nunclon 75 cm2 culture flasks in OPTI-MEM (Thermo Fisher Scientific; 
Melbourne, Australia) and RPMI respectively supplemented with 10% FBS. 
Cells were grown to confluency in 75 cm2 culture flasks before subculturing 
into new flasks for experiments. After four to five days when cells reached up 
to 70% confluency, five out of ten flasks were treated with different 
concentrations of DHA (Sigma-Aldrich; MO, USA) (0, 5, 10, 15, 20 μg/ml) for 
48 hours. Another five flasks received additional treatment of 5 μM of ZnCl2 
along with different concentrations of DHA (0, 5, 10, 15, 20 μg/ml) for 48 
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hours. Cell culture media with specific amount of DHA and Zn were 
incubated overnight in warm room at 37ºC on a medium speed shaker before 
used for cell treatments. 0μg/ml DHA and 5 μM of ZnCl2 was considered as 
control sample. To check the effect of vitamin E (Sigma-Aldrich, Sydney, 
Australia) on DHA, cells were treated with and without vitamin E (0 μg/ml and 
20 μg/ml) and DHA (0 μg/ml and 20 μg/ml). The cells were passaged when 
confluent using 0.025% trypsin-EDTA solution in phosphate buffered saline 
(PBS) (Sigma-Aldrich, Sydney, Australia). Cells were pelleted by 
centrifugation, rinsed three times with PBS and immediately frozen at -80qC 
for further analysis. 
To induce cellular differentiation, M17 cells were grown on porous Transwell 
filters (BD Falcon; Sydney, Australia) coated with thin layer of diluted (1in 5 
dilution) extracellular matrix gel from Engelbreth Holm-Swarm mouse 
sarcoma (Sigma-Aldrich; Sydney, Australia) (EHS matrix). Cells were treated 
with 1μg/ml of Retinoic acid (RA) Sigma-Aldrich, Sydney, Australia) for 14 
days. Media was changed every second day with fresh RA. Cells were 
treated with 1 μM of mitotic inhibitor (5-fluoro-2’-deoxyuridine, 1-β-D-ribo 
furano syluracil) (Sigma-Aldrich; Sydney, Australia) for four days. 
Differentiated M17 cells were treated with different concentrations of Zn and 
DHA as explained above for 48 hours. Cultures were viewed with an 
Olympus CK2 inverted phase-contrast microscope. 
Cells were grown in 75 cm2 culture flasks (Nunc; NY, USA) and collected for 
western blot, Quantitative Real Time PCR, DNA sequence analysis, alkaline 
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phosphatase assay and methylation studies from all different cell lines 
mentioned above.  
2.3 Plasmid preparation and cell transfection  
A previously developed hZnT5 and hZnT6 overexpressing cDNA in pA-puro 
vector (Suzuki T et al., 2005a) were used to transfect M17 neuroblastoma 
cells using polyethylenimine solution (Shin et al., 2005). Sequence identity 
was confirmed with sequencing of the inserts using specific primers for puro 
vector (Table 2.1). Specifically, 20 μg of plasmid DNA was diluted in 150 mM 
NaCl to a concentration of 10 μg/ml. Polyethylenimine (Lecocq et al., 2000) 
pH 5.0 was added to DNA/NaCl solution to a final concentration of 0.813 
mg/ml. The mixture was vortexed for 10sec and incubated for 30 minutes at 
room temperature. The mixture was diluted in 15ml RPMI with 10% FBS and 
added to a 75cm2 culture flask containing 75% confluent M17 cells for 
overnight. Transfected cells were selected using 2.5 μg/ml puromycin 
(Invitrogen Life Technologies, Melbourne, Australia) in OPTI-MEM 10% FBS 
medium over four weeks. Fresh medium with antibiotics was added every 
three days. 
2.4 siRNA Construction and Transfection 
A pSilencer TM 4.1-CMV hygro Kit (Ambion, Australia) was used to create 
hZnT5, hZnT6 and control siRNAs (short interfering RNA) according to the 
manufacturer protocol. The sequence identity of the siRNA inserted region 
for hZnT5 and hZnT6 knocked-down constructs were confirmed by sequence 
analysis using CMV-4.1(F) and CMV-4.1(R) primers (Table 2.1). Three 
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different siRNA constructs were prepared for knock downs of ZnT5 and ZnT6 
genes. The sequences of oligonucleotides are shown in Table 2.1.  
After comparing the efficacy of each knocked-out construct, the best one was 
chosen to continue the experiments.M17 cells were grown to 70% confluency 
in OPTI-MEM 10% FBS medium. 20 μg of plasmid DNA containing siRNA for 
ZnT5, ZnT6 and control were gently mixed with 3.75 ml of serum free OPTI-
MEM media and 6 μl of Reagent Plus (Lipofectamin transfection kit, 
Invitrogen Life Technologies, Melbourne, Australia). After 5 mins of 
incubation 15 μl of lipofectamin was added to the solution followed by a 
gentle mix and incubation at room temperature for 30 minutes. The mixture 
was added to 15 ml OPTI-MEM 10% FBS medium and transferred to a 
75cm2 culture flask containing 70% confluent M17 cells. After overnight 
incubation at 37ºC, cells were washed with normal media. Transfected cells 
were selected using 400 μg/ml hygromycin B (Roche; Roche Diagnostics, 
Germany) in OPTI-MEM 10% FBS medium over eight weeks. Fresh medium 
with antibiotics was added every three days. 
Cells with ZnT6 knocked down showed a great reduction in mRNA using all 
three different siRNA but for ZnT5 transfections the best results were gained 
by using one siRNA with forward and reverse sequence (ZnT5 S-3(F); ZnT5 
S-3(R) (Table 2.1). The maximum number of passages for cells to retain the 
disruption was three to four. Once siRNA was stably transfected and 
checked by quantitative real-time PCR (qRT-PCR) and western blot analysis, 
double knockdowns with two genes disrupted (ZnT5 + ZnT6 together) was 
attempted.  
  
Table 2.1 Primer Table for overexpression and knock-down 
constructs
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Forward primer (5’-3’) Reverse primer (5’-3’) 
ZnT5 S-1(F) 
GATCCGAATAGTACAGCAGGTTACTTCAAGA
GAGTAACCTGCTGTACTATTCTTA 
ZnT5 S-1(R) 
AGCTTAAGAATAGTACAGCAGGTTACTCTCTT
GAAGTAACCTGCTGTACTATTCG 
ZnT5 S-2(F) 
GATCCGGATTAATATCATACCGAGTTCAAGA
GACTCGGTATGATATTAATCCTTA 
ZnT5 S-2(R) 
AGCTTAAGGATTAATATCATACCGAGTCTCTT
GAACTCGGTATGATATTAATCCG 
ZnT5 S-3(F) 
GATCCCACGTCCTGTCTGGAGGAGTTCAAGA
GACTCCTCCAGACAGGACGTGTTA 
ZnT5 S-3(R) 
AGCTTAACACGTCCTGTCTGGAGGAGTCTCT
TGAACTCCTCCAGACAGGACGTGG 
ZnT6 S-1(F) 
GATCCGGCTTTAAATAGGCTTCCTTTCAAGA
GAAGGAAGCCTATTTAAAGCCTTA 
ZnT6 S-1(R) 
AGCTTAAGGCTTTAAATAGGCTTCCTTCTCTT
GAAAGGAAGCCTATTTAAAGCCG 
ZnT6 S-2(F) 
GATCCGACCATGATAGACTCTAACTTCAAGA
GAGTTAGAGTCTATCATGGTCTTA 
ZnT6 S-2(R) 
AGCTTAAGACCATGATAGACTCTAACTCTCTT
GAAGTTAGAGTCTATCATGGTCG 
ZnT6 S-3(F) 
GATCCCTCCAGCTAAACCTAGTAGTTCAAGA
GACTACTAGGTTTAGCTGGAGTTA 
ZnT6 S-3(R) 
AGCTTAACTCCAGCTAAACCTAGTAGTCTCTT
GAACTACTAGGTTTAGCTGGAGG 
CMV-4.1 (CMV-4.1 vector) (F) 
AGGCGATTAAGTTGGGTA 
CMV-4.1 (CMV-4.1 vector) (R) 
CGGTAGGCGTGTACGGTG 
Actin (pA-puro vector) (F) 
GCAGCCAATCAGAGCGG 
SV40pA (pA-puro vector) (R) 
GAAATTTGTGATGCTATTGC 
F primer (pA-puro vector) 
TCGGCTTCTGGCGTGTGACCGGCGGCTCTA 
R primer (pA-puro vector) 
TTTCCACACCCTAACTGACACACATTCCAC 
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To attain double knock-downs, single gene disrupted (ZnT5 or ZnT6) M17 
cells were tried to transfect with another siRNA, using the same method. 
2.5 Quantitative Real Time PCR (qRT-PCR) 
Patient and two different control fibroblasts from healthy mothers, PMC42-LA 
grown in 75 cm2 culture flasks were collected by trypsinisation (0.05%) and 
washed three times in PBS. M17 and SY5Y cells with different treatments 
(cell culture section 2.2) were collected by 0.025% trypsinisation followed by 
PBS washes. Retinoic acid induced differentiated M17 cells on transwell 
filters were harvested for mRNA analysis by treating with 1 ml of 5 mg/ml 
dispase (Gibco; Melbourne, Australia) dissolved in PBS for half an hour and 
collected. Cells overexpressing ZnT5 and ZnT6 and cells with knockdown 
siRNA ZnT5 and ZnT6 constructs were collected by trypsinisation (0.025%) 
and PBS washes. Control and patient lymphoblasts were collected by 
centrifugation. 
Total RNA was extracted from cells using a QIAGEN RNeasy Mini kit 
(QIAGEN; Melbourne, Australia), following manufacturer’s instructions. 
Extracted RNA was purified by using DNase 1 treatment following the 
manufacturer’s protocol of the DNA free kit (Ambion; Melbourne, Australia). 
The purified RNA concentrations were estimated on a nanospec (Nanodrop 
1000, Thermo Scientific) at wavelengths of 260/280 nm. Once quantified, 
RNA was converted to cDNA using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems; Melbourne, Australia) following the 
manufactures protocol. Amplification reactions were performed with 20 μl 
sample volumes containing 8 μl SYBR Green Master Mix (Applied 
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Biosystem; Melbourne, Australia), 0.3 μM of forward and reverse primers 
(Table 2.2) and 20 ng cDNA (RNA content prior to RT step).  
The PCR reaction was performed at 50ºC 2 min, 95ºC 10 min (1 cycle), 95ºC 
15 sec, 60ºC 1 min (40 cycles). Samples were analysed in triplicate using 
7500 Real Time PCR System (Applied Biosystems; Melbourne, Australia). 
An internal control of E-actin (Table 2.2) was used to normalise. 
RNA quantities and efficiency of reverse transcription. Fluorescence 
produced by incorporation of SYBR green dye into double stranded DNA was 
recorded after the elongation phase of each repetitive cycle. The specificity 
of each reaction was determined by analysis of the melting point dissociation 
curve generated at the end of each PCR. The threshold cycle value (CT), 
defined as the cycle number when fluorescence levels exceed the threshold 
value was calculated after each reaction. The CT value of E-actin was 
subtracted from the transporter CT value to produce 'CT for each sample. 
The relative RNA expression level of each sample was calculated using the 
equation 2-ΔΔCT, where ''CT is the difference between the control 'CT and 
the sample 'CT. 
Amplification was performed for hZnT1, hZnT2, hZnT3, hZnT4, hZnT5, 
hZnT6, hZnT7, hZnT8, hZnT9, hZnT10 for lymphoblast and fibroblast from 
patient and control cells. Breast tissue from resting breast was analysed 
using hZnT5 and hZnT6 primers. M17 and SY5Y neuronal cells with different 
treatments of DHA and Zn, vitamin E, differentiated cells as explained in 
(materials and method section cell culture 2.2).  
  
Table 2.2 Real-Time PCR Primers 
 
Primers to ZnT1were designed to GenBank sequence Accession No AF323590 
Primers to ZnT2 were designed to GenBank sequence Accession No NM_032513 
Primers to ZnT3 were designed to GenBank sequence Accession No U76010 
Primers to ZnT4 were designed to GenBank sequence Accession No AF025409 
Primers to ZnT5 were designed to GenBank sequence Accession No AF461760 
Primers to ZnT6 were designed to GenBank sequence Accession No XM_059432 
Primers to ZnT7 were designed to GenBank sequence Accession No AY094606 
Primers to ZnT8 were designed to GenBank sequence Accession No NM_173851 
Primers to ZnT9 were designed to GenBank sequence Accession No NM_006345 
Primers to ZnT10 were designed to GenBank sequence Accession No NM_018713 
Primers to E-actin were designed to GenBank sequence Accession No E00829 
Primers to GAPDH were designed to GenBank sequence Accession No NM_002046 
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Forward Primer 
 
Reverse Primer 
PCR 
product 
length in 
(bp) 
ZnT1-RealF1   
CTGGTGAACGCCATCTTCCT 
ZnT1-RealR1   
CAATCTCGTGCGGCTCGAT 
183 
ZnT2-RealF2   
TGTGATCCTGGTGTTGATGGA 
ZnT2-RealR2   
CAGGCTGTGCAGGGCTTCT 
103 
ZnT3-RealF1   
CACCCTCCGAGACGTTCTTC 
ZnT3-RealR1   
GGCACCGACAACAGCGTAT 
90 
ZnT4-RealF2   
AACCAGTCTGGTCACCGTCA 
ZnT4-RealR2  
CTATCCTGCCCATGGTTACG 
93 
ZnT5-RealF1   
CCAGCGCTCGATTAACAAAATA 
ZnT5-RealR1   
TGTGAACAGCTTTTAGGAGATCA 
134 
ZnT6-RealF2   
TCCTTTTTTGGCAAGTTGTTACG 
ZnT6-RealR2   
AAGCAGGAAGCCAGTACATATCAAG 
111 
ZnT7-RealF1   
TTGCCCCTGTCCATCAAAG 
ZnT7-RealF2   
AGACCTAAACCAGCCCGAGATC 
81 
ZnT8-RealF1   
GTGGCGGCCAACATTGTACTA 
ZnT8RealF2 
CACAAAAGCAGCTCTGACGCT 
102 
ZnT9-RealF1  
ACACCAGATCCTTCTCATCCGT  
ZnT9-RealF2 
CAAGATAGTCCTGCACCCATCA  
101 
ZnT10-RealF1 
CTTCCCGCTTATCAAGGAGACC 
ZnT10-RealF2  
GCTAATTCCAGGCACAGCAGAG 
106 
EAC-RealF   
GACAGGATGCAGAACGAGAT 
EAC-RealR    
TGATCCACATCTGCTGGAAGGT 
138 
 
GAPDH-RealF 
CCACCCATGGCAAATTCC 
GAPDH-RealR 
TGGGATTTCCATTGATGACAA 
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Overexpression and knocked-down constructs of ZnT5 and ZnT6 were 
analysed using hZnT5, hZnT6 primers (Table 2.2). 
2.6 PCR and sequencing for coding & promoter regions 
DNA was isolated from patient and control fibroblasts and lymphoblast cells 
using the Wizard® Genomic DNA Purification Kit (Promega) following the 
manufacturer’s instructions. DNA concentrations were checked on a 
nanospec (Nanodrop 1000, Thermo Scientific) at wavelengths of 260/280 
nm. The promoter regions of hZnT5 and hZnT6 genes (4000bp upstream 
from the start codon) were amplified using different primer sets (Table 2.3) 
from patient and control lymphoblast and fibroblast cells. hZnT2 intron-exon 
structure analysis was also performed using different set of primers 
(Table2.3).  
The coding regions of hZnT5, hZnT6 and hZnT2 were amplified by RT-PCR 
(Reverse transcriptase) for patient and control lymphoblast and fibroblast 
cells using cDNA. 5' and 3' untranslated regions (UTR) were analysed to find 
any changes between patient and control samples for hZnT5 and hZnT6 
genes (Table 2.4). Similarly hZnT2, hZnT5, hZnT6 open reading frames 
(ORF) were analysed by RT-PCR using cDNA from M17 cells with different 
Zn and DHA treatments (refer section cell culture 2.2). 
PCR amplification was performed using 55 pmol of forward and reverse 
primers. These were added to the PCR mixture consisting of 200 ng of 
DNA/200 ng of cDNA, 200 μM of each dNTP, PCR buffer, 1.5 mM MgCl2 and 
1U Taq DNA polymerase (Sigma-Aldrich, Melbourne, Australia).  
  
Table 2.3 Primers used for Genomic DNA PCR 
Primers to ZnT2 were designed to GenBank sequence Accession No NM_032513 
Primers to ZnT5 were designed to GenBank sequence Accession No AF461760 
Primers to ZnT6 were designed to GenBank sequence Accession No XM_059432 
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Forward Primer Reverse Primer 
PCR 
product 
length in 
(bp) 
ZnT5-P1F 
TCAGGCTCCTCTCATTCTCC 
ZnT5-P1R 
TGTTTCTTACAGCCCCGAAC 
1105 
ZnT5-P2F 
GGCAAGTCCATAAAGTGAAAGC 
ZnT5-P2R 
CTGAGGAGGAGAATGGCTTG 
1166 
ZnT5-P3F 
CAAGCCATTCTCCTCCTCAG 
ZnT5-P3R 
GACCAAAATTTGCCTCCTCA 
994 
ZnT5-P4F 
GAGACAGGGTTTTGCCATGT 
ZnT5-P4R 
CAAGCAGAACACTCGCCTTT 
931 
ZnT5-P5F 
TGGGAATACAGCCCAGTAGG 
ZnT5-P5R 
GACCAGCTTAATGCCAGAGC 
443 
ZnT5-P6F 
CCATACTGCCCAGACCCTTA 
ZnT5-P6R 
ATGGCGAAACCCTGTCTCTA 
787 
ZnT5-P7F 
AGCCACAAAAGCAGTCACCT 
ZnT5-P7R 
AAAATTTGCCTCCTCAGCAA 
434 
ZnT5-P9F 
TCCCCAAATTTCCCAGAGTA 
ZnT5-P9R 
GTGGGGAGCTTACAAAATGG 
670 
ZnT5-P10F 
CCATACTGCCCAGACCCTTA 
ZnT5-P10R 
GAGACCAGCCTGACCAACAT 
805 
ZnT5-P11F 
CCATCTGGACCCATCAGTCT 
ZnT5-P11R 
CCTGGCCCTGAATTCTTTCT 
718 
ZnT5-P13F 
TGACCACAAGGCAGACAAAG 
ZnT5-P13R 
AAGAATTCGAGGCAAGTCCA 
1123 
ZnT6-P1F 
AAGGGTGTCAGCAGAGATGG 
ZnT6-P1R 
GGGACTGTCATGATGGGATT 
882 
ZnT6-P2F 
CACCTTCTCACCGTGTCCTT 
ZnT6-P2R 
AGGCAGGAGAATTGCTTGAA 
1185 
ZnT6-P3F 
TCTCACCCAGGCTTCATCTC 
ZnT6-P3R 
TGTAGCACGTGTGTTTGTCAGA 
1263 
ZnT6-P4F 
TTAAGCATTTGGGATGAAGGA 
ZnT6-P4R 
GTGCTCGAGTTTTCCCAGAA 
984 
ZnT6-P5F 
GGAGGCCAAGGCAGGTAG 
ZnT6-P5R 
GAATTGCTTGAACCCAGGAG 
606 
ZnT6-P6F 
TTTCTTCCTGGCTTGCAGAT 
ZnT6-P6R 
GGTTTCACCATGTTGTGCAG 
662 
ZnT6-P7F ZnT6-P7R 255 
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TGGGCAGCTTAAATAACAGAAA GTGATTCAGCCTTTGGGAAG 
ZnT6-P8F 
TCAGCAACCCTAATCCAACC 
ZnT6-P8R 
TGTAGCACGTGTGTTTGTCA 
434 
ZnT6-P10F 
GGAGGCCAAGGCAGGTAG 
ZnT6-P10R 
ATGGCAAAACCCCGTCTC 
700 
ZnT6-P11F 
ACCCATCAGAAGAAATAAACCA 
ZnT6-P11R 
ATTTGAGGCCAGGCACAGT 
958 
ZnT2IE-1F 
CGTCCTCACTCAGCAACACC 
ZnT2IE-1R 
TCTTCGTTCCCTCACCTCAC 
657 
 
ZnT2IE-2F 
AGGACTCCCATTCCCCTATC 
ZnT2IE-2R 
AGGAGAATAACGTCACCCATGT 
583 
ZnT2IE-3F 
ATATTGGTGGCCCATTTCAC 
ZnT2IE-3R 
ACAGAGGCCATGGTTGACAT 
503 
ZnT2IE-4F 
ATATGAGGGGTGGGGTAAGG 
ZnT2IE-4R 
ACAGCTCCCAGTGTTCTTGG 
527 
ZnT2IE-5F 
GCCCTATCTCTCATGGCTGT 
ZnT2IE-5R 
CCACCTACCCTTCAGGTTGT 
533 
ZnT2IE-6F 
TTCTGAACTGTGGTCTGTCCTT 
ZnT2IE-6R 
GAACTGCCACACCTGAAAGC 
501 
ZnT2IE-7F 
TCAGTGTTAAGAGTGGAGAGGAA 
ZnT2IE-7R 
AACCCCAGCCTCAGTTTCTT 
530 
ZnT2IE-8F 
TACCTGGCAGAGGAATGGAA 
ZnT2IE-8R 
GAAAGGGAACATTTGGCTCA 
848 
ZnT2IE-9F 
TATGAATCTGAGCCCCTCCA 
ZnT2IE-9R 
CAAGTGACCAAACCCACCTC 
912 
 
  
Table 2.4 Primers used for RT-(Reverse transcriptase) PCR  
Primers to ZnT2 were designed to GenBank sequence Accession No NM_032513 
Primers to ZnT5 were designed to GenBank sequence Accession No AF461760 
Primers to ZnT6 were designed to GenBank sequence Accession No XM_059432
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Forward Primer 
 
Reverse Primer 
PCR 
product 
length in 
(bp) 
ZnT5-A   
GCAGCGGCGAGACATGAGGAG 
ZnT5-B   
CACTACCACTCCTCCAGACAG 
1113 
ZnT5-C   
TCTCTCATTATGCCTTTTGC 
ZnT5-D   
GCATCTTTAATCAGTGGAACA 
1127 
ZnT5-E   
CAGCATTGGTGTGATCGTATC 
ZnT5-F   
AAGATTCCTTGATCCAGTAGT 
629 
ZnT6-A   
AGAACGGCTTCCGGCGGG 
ZnT6-B   
GAGGCATTGGGATTACGTGA 
1124 
ZnT6-C  
AAGTCTTACTCCAGACAACA 
ZnT6-D    
AATGTGAACAAGACTACTAT 
759 
 
ZnT6-C1F 
TTGACTCCTTGGCTTCCAAT 
ZnT6-C1R 
AAAGGAGAGAAACTTTAACAAAAATC 
974 
ZnT2-C1F 
AGACACGGGAGCGCTTG 
ZnT2-C1R 
ATGATGTTCACAGCCACAGC 
788 
ZnT2-C2F 
GTGACGGGGGTACTGGTGTA 
ZnT2-C2R 
TGCCTGACAGTCCTTCATGT 
639 
ZnT2-C3F 
TCGCCATTGCTCAGAATACA 
ZnT2-C3R 
GGGAGGCTCAAATGAGAGTG 
630 
ZnT2-C4F 
GGACCCTCACACTCTCATTTG 
ZnT2-C4R 
GCCAACTGGCTCTTGTTCTC 
686 
ZnT2-C5F 
ACTGGTGTACCTGGCTGTGG 
ZnT2-C5R 
CCGAGTAGTCCTCGATCTGG 
605 
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The following PCR amplification conditions were applied: one cycle at 94 °C 
for 3 min, 35 cycles at 94 °C for 45 s, annealing temperature for 30 s, 72 °C 
for 60 s, with final extension at 72 °C for 10 min. PCR products were run on 
1.5% Agarose (Amresco; Ohio, USA) gels and bands were excised, purified 
and sent for sequencing to Monash Sequencing Centre, Melbourne. Results 
were aligned to the original sequence using Sequencer 4.2 software to 
identify any modifications. 
2.7 Transcription Factor Binding Site Analysis 
Genomic sequences were entered into MatInspector (Genomatix Software - 
http://www.genomatix.de/en/index.html) to determine transcription factor 
binding sites in the regions of interest. The resultant data was exported to 
excel. Transcription binding motifs relevant to lactation (STAT-5), metal 
homeostasis (MRE) Metal Responsive Element and other hormonal 
influenced transcription binding factors (ERE) Estrogen Responsive element, 
(PRE) Progesterone Responsive Element and (RXR) Retinoic X Receptor 
were identified manually by scanning the conserved binding motif sequences 
through the promoter region upto 4000bp upstream of start codon for all 
members of ZnT family. 
2.8 Western Blots 
Lymphoblasts and fibroblasts from patient and control cells, PMC42-LA cells 
and resting breast tissue were collected were analysed for protein 
expression. M17 cells treated with different Zn and DHA concentrations, cells 
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overexpressing ZnT5 and ZnT6 and with knockdowns containing siRNA 
ZnT5 and ZnT6 constructs were also collected for protein analysis. 
Cell pellets were resuspended in lysis buffer (1% w/v sodium dodecyl 
sulphate (Sigma-Aldrich; Sydney, Australia), 10 mM Tris-hydrochloric acid, 
pH of 6.8, containing one Mini EDTA-free protease inhibitor cocktail tablet 
(Roche Applied Science) per 10 ml. Cells were disrupted by passing through 
a 25-gauge needle 8-10 times and sonicated (40% power output, 30% duty 
cycle) on ice, three times for 15 sec with 30 sec break between each 
sonication, by using a Microsone Ultrasonic cell disrupter (Misonix 
Incorporated, NY, USA). Samples were then stored at -80ºC until needed for 
analysis. 
Quantification of protein concentration in cell lysates were performed using 
BCA protein assay kit (Pierce; Melbourne, Australia), following the 
manufacturer’s instructions. Protein samples were prepared with 6x loading 
dye (10% glycerol, 20% SDS, 1.5 M Tris-HCl pH 6.8, 1.8 M bromophenol 
blue, dH2O, 10% merceptophenol). Page RulerTM Prestained Protein ladder 
(Fermentas) was used as a protein molecular weight marker. Sixty 
micrograms of each extract was fractionated by 10% SDS-PAGE using Bio-
Rad Mini Protein Gel system for 1.5 hours at 125 V according to 
manufacturer’s instructions. Proteins were transferred to nitrocellulose 
membranes (Whatman; Dassal, Germany) at 10 V for 90 minutes using a 
Trans-Blot Transfer Cell (Bio-Rad) in 25 mM Tris, 200 mM glycine pH 8.3 
and 20% methanol. 
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Membranes were then stained with 0.1% Ponceau S (Sigma-Aldrich; 
Sydney, Australia). Ponceau S stain was removed with 0.1% NaOH (Sigma-
Aldrich; Sydney, Australia). Membrane was blocked for one hour with 1 % 
casein in TBS (0.05 M Tris and 0.15 M NaCl). Blots were incubated overnight 
at 4oC with monoclonal antibodies for ZnT5 (Kambe et al.; 2002 JBC 
277:19049) diluted at 1:500 and ZnT6 (Abnova mouse monoclonal 
#H00055676-M01) diluted at 1:250 in 1% casein (Sigma-Aldrich; Sydney, 
Australia). After washes with TBS proteins were detected using 1:4000 
dilution of HRP (horseradish peroxidase) conjugated sheep anti-mouse 
antibody (Millipore; Melbourne, Australia) for 1.5 hours at room temperature. 
After removal of excess secondary antibody, membranes were rinsed twice 
in TBS for 10 min and then twice more in TBS with 0.1% tween 20 (Sigma-
Aldrich; Sydney, Australia). Proteins were detected by enhanced 
chemiluminescence (Immobilon Western Chemiluminescent HRP Substrate; 
Millipore; Melbourne, Australia) according to manufacturer’s instructions. 
Images were captured using LAS-3000 FujiFilm Lumino-Image Analyzer (Fuji 
Photo Film; Tokyo, Japan). Blots were stripped for 5-10 min using Reblot 
Plus Strong (Millipore; Melbourne, Australia) solution and then reprobed with 
β-actin monoclonal antibody diluted 1/5000 followed by goat anti-mouse 
secondary antibody to determine the protein loading for lysates. 
Densitometry to quantify results was performed using Fuji Film Multi Gauge 
V3.0 computer software, and ratios for protein levels were calculated relative 
to β-actin. β-actin and Ponceau S stains were used as controls. 
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2.9 Immunofluorescence  
Fibroblasts from patients and controls and PMC42-LA cells were grown on 
10mm diameter glass cover slips. Breast tissue (BT) blocks (1cm3) were 
immersed in OCT (Tissue Tek; Sydney, Australia) and frozen in liquid 
nitrogen for 3 minutes followed by sectioning (8-10 μm thickness) on gelatin 
(5%) coated slides using Leica CM1800 cryostat at between -17 and -20ºC. 
M17 cells were grown overnight in tissue culture treated 8 well μ-slide Ibidi 
chambers (DKSH; Melbourne, Australia) followed by 0, 10, 20 μg/ml DHA 
with and without 5 μM of zinc for 48 hours. Stably transfected overexpressing 
ZnT5 and ZnT6 and knockdown cells containing siRNA ZnT5 and ZnT6 and 
respective controls having empty vectors were grown in tissue culture treated 
(8 well μ-slide) Ibidi chambers. 
When cells reached 50% confluency on coverslips, they were rinsed with 
PBS (after 48 hours for M17 treated chambers), and fixed in 4% 
paraformaldehyde (Sigma-Aldrich; Sydney, Australia) for 5 minutes, 10min 
for BT. After 2 washes with PBS (Amresco; Ohio, USA), they were 
permeabilized with 0.1% TX-100 (Sigma-Aldrich; Sydney, Australia) for 10 
minutes (Breast Tissue (BT) 5% for 5 min) followed by blocking in 1% BSA 
for 10 minutes (3% for 90 min). Cells were incubated overnight at 4oC with 
primary antibody diluted in 1% BSA in PBS (ZnT5 1/100, ZnT6 1/75). After 
three PBS washes, a secondary antibody Alexa Flour 488 anti-mouse 
(Chemicon; Melbourne, Australia) diluted at 1:2000 was added and then 
incubated for 2 hours at room temperature following three washes with PBS. 
Coverslips were mounted on glass slides, a rectangle coverslip was mounted 
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on BT slides, using ProLong Gold antifade reagent (Invitrogen; Melbourne, 
Australia). Confocal images were obtained using a Leica confocal 
microscope system TCS SP2 (Leica; Melbourne, Australia). 
Cultured M17 cells were grown on 10 mm diameter glass cover slips in 12 
well plates. Cells were treated with 10 μM ZnCl2 for one hour followed by 
three washing with PBS of 2 mins each. Half of the wells were again treated 
with 15 μg/ml of DHA for additional one hour at 37oC followed by three 2 
mins PBS washes. Cells grown on coverslips without additional ZnCl2 and 
DHA were used as a control. Immediate after different treatments all cells 
were incubated for 30 mins with 5 μM of Zinquin ((ethyl-[2-methyl-8-p-
toluenesulfonamido-6-quinolyloxy]acetate), generously supplied by Dr Peter 
Zalewski, Department of Medicine, University of Adelaide, Adelaide, 
Australia) at 37oC. 
Another set of cells treated with zinc and DHA were checked for the recovery 
of fluorescence where after DHA treatment, cells were washed with PBS and 
placed with fresh media for different times (3, 6, 9, 24 hours). After 3 PBS 
washes coverslips were mounted on a drop of Fluoroguard (BioRad, Sydney, 
Australia). Epifluorescence was viewed with an Olympus BX50 microscope 
with a PlanApo 60X 1.4 oil objective using UV light filter range 365 nm-
395nm. 
2.10 Alkaline phosphatase assay  
Fibroblast and lymphoblast from patients and controls, PMC42-LA, breast 
tissue, DHA and Zn treated M17 cells, overexpressing ZnT5 and ZnT6 or 
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with knockdowns containing siRNA ZnT5 and ZnT6 and respective controls 
were collected for TNAP (Tissue Non specific Alkaline Phosphatase) activity. 
Collected pellets were lysed using ALP lysis buffer (10 mM Tris-HCL, pH 7.5, 
0.5 mM MgCl2, 0.1% Triton-X 100). 20 μg of total cellular proteins were pre-
incubated in lysis buffer for 10 minutes at room temperature. A 100ul volume 
of substrate solution (2 mg/ml p-nitrophenyl phosphate in 1M diethanolamine 
buffer, ph 9.8, containing 0.5 mM MgCl2) (Sigma-Aldrich; Sydney, Australia) 
was added. After 10 minutes incubation at room temperature, p-nitrophenol 
released by TNAP, a soluble yellow substance, was measured at 405 nm 
absorbance. Shrimp ALP (Roche Applied Sciences, Germany) was used as 
a standard. 
2.11 ZnT5 and ZnT6 Pyrosequencing Assay  
Bisulfite Pyrosequencing for DNA methylation analysis 
Bisulfite conversion of DNA was performed using EZ DNA Methylation 
Gold™ kit (Zymo Research) following the manufacturers’ protocol. Briefly, 
2μg of genomic DNA was incubated with CT conversion reagent and 
incubated at the following temperatures; 98°C for 10 min, 64°C for 2.5hr and 
held at 4°C.  DNA was then transferred to a spin column, washed, 
desulphonated, purified and finally eluted in a 10μl volume. 
Quantitative Bisulfite Pyrosequencing was used to determine the percentage 
methylation at individual CpG sites within the ZnT5 and ZnT6 promoter 
regions (NT_022184.15; 11212499-11212863). Briefly, 0.2 μg of bisulfite 
treated DNA was added as a template in PCR reaction using 12.5 μl Hot Star 
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Taq mastermix (Qiagen), total volume 25 μl. Primer sequences and PCR 
conditions are shown in Table X Biotin-labelled PCR products were captured 
with streptavidin sepharose beads (GE Healthcare), and made single 
stranded using a Pyrosequencing Vacuum Prep Tool (Qiagen). Sequencing 
primers were annealed to the single stranded PCR product by heating to 
80°C, followed by slow cooling. Pyrosequencing was then carried out on a 
Pyromark MD system. Cytosine methylation was quantified using proprietary 
PyroQ CpG 1.0.6 software. All PCR and pyrosequencing reactions were 
carried out in duplicate. 
Assay validations were carried out to rule out any amplification bias of 
primers for methylated DNA and to assess assay reproducibility using 
methods described previously (White et al 2006). All primers were found to 
be unbiased and data reproducible. Zero and 100% methylated controls 
(Epitect control DNA, Qiagen, 59568) were routinely run alongside samples 
as internal controls. 
2.12 Physiological zinc uptake and efflux 
M17 cells containing overexpression constructs or siRNA for ZnT5 and ZnT6 
and control cells containing empty vectors were seeded with similar numbers 
of cells in 12 well plates (Nunc). At around 95-100% cell confluency, cell 
cultured media was replaced with 400 Pl fresh media containing 5 PM ZnCl2 
and 1 PCi/ml of 65Zn (Oak Ridge National Laboratory, Oak Ridge, TN). The 
plates were treated for 0, 5, 10, 20, 40 and 60 minutes in triplicates for 
uptake experiments. For each experiment the triplicates represent one time 
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point. Immediately 400 Pl of media was removed for the zero time point and 
cells were then washed with 5 mM EDTA to remove any surface bound zinc. 
Cells were collected in 600 Pl of PBS. Cells in PBS and EDTA wash were 
retained and the counts per minute of 65Zn were obtained (Perkin-Elmer 1480 
automatic gamma counter). Cells in PBS were lysed with 10% SDS and 
homogenised using 21 gauge needle and the total protein amounts were 
measured using Pierce BCA protein assay kit (Thermo scientific). This 
collection protocol was repeated for 5, 10, 20, 40 and 60 minutes time points. 
Picomoles of zinc per microgram of protein were calculated for both 
adsorbed and internalized zinc. 
For efflux experiments, cells at 85% confluency were incubated in 5 PM 
ZnCl2 and 1 PCi of 65Zn/ml for 24 hours. The 65Zn was removed and the cells 
were incubated in 5 PM ZnCl2 with no 65Zn for 0, 5, 10, 20, 40 and 60 
minutes. Cells in PBS, media and EDTA wash were retained for radioactive 
analysis followed by protein estimation as described above for the uptake 
experiments. 
M17 cells were grown in the absence or presence of DHA (20 μg/ml) for 18 
hours in culture medium containing radiolabelled 65Zn (1 PCi of 65Zn/ml) and 5 
PM ZnCl2. The culture medium was replaced with medium containing 5 PM 
ZnCl2 with no 65Zn and cellular zinc efflux was measured over a period of one 
hour including time points at 0, 2, 5, 10, 20 and 60 minutes. The specific 
activity of the zinc was determined and zinc efflux was expressed as pmol 
Zn/μg DNA. 
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2.13 Bioinformatic in-silico analysis 
All members of SLC30 family (total 10 members) coding region (ORF) and 
the 5’ and 3’ UTR’s sequences were collected from NCBI database with 
specific Accession numbers listed in Table 2.2. For phylogenetic analysis, the 
nucleotide sequences were aligned using Clustal-X (version 1.83) algorithm. 
A phylogenetic tree was created using the bootstrapped Neighbour Joining 
(N-J) algorithm of 100 replicates. Tree view program was used to visualise 
the tree. 
TMD (Transmembrane domains) were analysed by submitting amino acid 
sequences to “TMHMM” and “TOPCONS” online database for predicting total 
number of TMD’s. The presence of miRNA (micro RNA) was checked by 
using “miRBase” online database. Identity and similarity matrix was generated 
using MatGAT v2.0 (version 2). to find out similarity or exact identity between 
different members of ZnT family. 
To predict 3D structures, the sp3 structure prediction database was used, 
where amino acid sequences were submitted to online database and 
neighbours were generated for viewing as multiple structural alignment or 3D 
superimposition in PDB file formats and viewed using Cn3D 4.3.1software for 
structure analysis. The list of neighbours is sorted by Z-score (A measure of 
the statistical significance of the result relative to an alignment of random 
structures already reported in database). Match was considered significant if 
ZSCORE value was greater than 6.3. Similarities with a Z-score lower than 2 
were considered spurious (not considered genuine or true). 
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To analyse the promoter regions, sequences up to 4000bp upstream of the 
translation site were collected for analysis. A similarity/Identity matrix was 
used to find the homology between different members of SLC30 family for 
coding and promoter regions. Important Transcription Binding Factors (TBF) 
(described in section 2.7) were reported for all members and further analysed 
for micro syntany analysis by arranging them in order of their occurrence 
between all members. 
2.14 Statistical Analysis 
All experiments were repeated in triplicate, and values expressed as means ± 
SD. Two tailed t-Test was used to determine statistical variation between 
treatments/ patients and controls. p<0.05 was considered significant. 
Data distributions were examined by the Kolmogorov-Smirnov test and all 
data sets were normally distributed. Analysis of variance was used to 
examine methylation in patients vs. controls and type of sample (lymphocyte 
vs fibroblast), and the interaction between these fixed factors, at each 
individual CpG, and across the mean of the investigated CpGs in a given 
gene. A P value of <0.05 was considered statistically significant. 
  
  
 
 
CHAPTER 3 
Altered expression of zinc 
transporters SLC30A5 and 
SLC30A6 (ZnT5 and 6) 
underlie a mammary gland 
disorder of reduced zinc 
secretion into milk
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3.1 INTRODUCTION 
The most frequently occurring form of zinc deficiency is caused by nutritional 
insufficiency. In rare cases, however, zinc deficiency is found in breast-fed 
babies, who present with symptoms characteristic of nutritional zinc 
deficiency, including dermatitis, diarrhoea, alopecia, loss of appetite, 
impaired immune function and neuropsychiatric changes (Aggett et al., 1980;  
Prasad, 1985). This form of zinc deficiency is a consequence of reduced 
levels of zinc in the maternal milk and has been reported in pre-term babies 
(27 to 33 weeks gestation) (Aggett et al., 1980;  Zimmerman et al., 1982;  
Weymouth et al., 1982;  Connors et al., 1983;  Parker et al., 1982;  Heinen et 
al., 1995) and less commonly in full term babies (Stevens and Lubitz, 1998;  
Glover and Atherton, 1988;  Khoshoo et al., 1992;  Bye et al., 1985). 
Pedigree analysis indicates that the condition is inherited (Sharma et al., 
1988). Zinc levels in the maternal milk of the zinc-deficient breast fed babies 
were less than 40% that of normal milk at matched weeks of lactation 
(Weymouth et al., 1982;  Zimmerman et al., 1982). Maternal zinc deficiency 
was not responsible for the low zinc levels in breast milk (Weymouth et al. 
1982;  Zimmerman et al., 1982). 
Several reports have linked zinc deficiency caused by reduced zinc levels in 
the milk to defects in SLC30A2 (ZnT2).  In a family where two exclusively 
breast-fed infants developed zinc deficiency associated with low milk zinc 
concentration, a mis-sense mutation that substituted a conserved histidine, at 
amino acid 54, with arginine (H54R) was reported (Chowanadisai et al., 
2006).  In another two unrelated families, the production of zinc-deficient milk 
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was linked to a (G87R) mutation that resulted in a glycine to arginine 
substitution at a different locus from the previous study (Lasry et al., 2012). 
More recently, two novel missense mutations in the SLC30A2 (ZnT2) genes 
were reported in a Japanese mother, who secreted zinc-deficient breast milk 
where milk zinc levels were reduced by 90% of that of normal (Itsumura et 
al., 2013). 
An inherited disorder of mice with similar phenotype to the human condition 
of reduced secretion of zinc into milk has been described (Piletz et al., 1978). 
Newborn pups who were nursed on ‘lethal milk’, homozygous mutant dams 
(lm/lm), developed dermatitis, alopecia and showed stunted growth, leading 
to death within a week. In the mouse disorder, a defect in the secretion of 
zinc from the mammary gland was demonstrated (Ackland and Mercer, 1992;  
Lee et al., 1992). A nonsense mutation at arginine codon 297 in the ZnT4 
zinc transporter, resulting in premature protein termination, was reported to 
be responsible for the mouse disorder (Huang and Gitschier, 1997). A study 
of the human orthologue (hZnT4) of the murine ZnT4 gene in two women 
with zinc-deficient milk including sequence analysis of cDNA, real time RT-
PCR and Western blot analysis of cells showed no differences between 
patient and control cells, which demonstrated that unlike the mouse disorder, 
defects in hZnT4 were not responsible for the human disorder of reduced 
secretion of zinc into milk (Michalczyk et al., 2003). In these patients it is 
likely, therefore, that the maternal mammary gland defect in zinc secretion is 
different from the “lethal milk” mouse model and that other candidate hZnT 
transporters may underlie the mammary zinc transport defect. 
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The following clinical presentation of two cases of zinc deficiency has 
previously been reported (Michalczyk et al., 2003). Infant 1 was born 
premature at 36 weeks and was breast-fed for three months. A red, 
necrolytic rash developed at two months of age (Figure 3.1a, b).  Zinc 
deficiency was confirmed at three months post-partum by tests showing zinc 
blood levels of 4.5 μmoles/l; 0.29 μg/ml (reference range 10.3–18.1 μmoles/l; 
0.67 -1.18 μg/ml). The level of breast milk zinc from the mother of Infant 1 
(Mother 1) was 0.29 μg/ml, which was less than one quarter that of the 
normal zinc level (1.35 μg/ml) at the corresponding stage of lactation. 
Treatment of the infant with zinc (50 mg/day) resulted in a dramatic 
improvement in the rash within three days. Infant 2 was born premature at 37 
weeks gestation and developed dermatitis affecting the face and perioral 
skin, with scalp scale and similar symptoms as that of Infant 1. The maternal 
milk zinc level (Mother 1) at seven months was 0.2 μg/ml, which was 
considerably less than the normal zinc level (0.85 μg/ml). On commencing 
treatment with zinc (50 mg/day), the rash cleared in three days and hair 
started to grow fully. It is interesting to note that both mothers who produced 
zinc-deficient milk had no clinical symptoms of zinc deficiency themselves.  
A study of the human orthologue (SLC30A4) of the murine Slc30a4 gene in 
these two mothers with zinc-deficient milk, including sequence analysis of 
cDNA, real time PCR and Western blot analysis, showed no differences 
between patient and normal control cells (two lymphoblasts and two 
fibroblasts from healthy mother), which concluded that unlike the mouse 
disorder, defects in SLC30A4 were not responsible for the human disorder of 
reduced secretion of zinc into milk (Michalczyk et al., 2003). In these patients  
  
Figure 3.1 Photograph of patient (infant number 1) showing 
dermatitis on feet  
Zinc-deficient Infant 1 born at 37 weeks gestation, showing necrolytic rash at 
extremities with blistering and desquamation (a) and (b). 
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it is likely, therefore, that the maternal mammary gland defect in zinc 
secretion is different from the “lethal milk” mouse model and that other 
candidate SLC30A transporters may underlie the mammary zinc transport 
defect. In this study we sequenced ZnT2 to detect mutations associated with 
two unrelated mothers who produced zinc-deficient milk and investigated 
whether modifications in other ZnT transporters may underlie this mammary 
gland disorder. Analysis of cells from mothers of zinc deficient babies 
showed alterations in ZnT5 and ZnT6 mRNA and protein, and epigenetic 
changes to ZnT5, relative to unaffected mothers. 
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3.2 RESULTS 
3.2.1 mRNA expression levels of hZnT5 and hZnT6 are 
reduced in Mothers 1 and 2 
Expression levels of hZnT1, hZnT2, hZnT3, hZnT4, hZnT5, hZnT6, hZnT7, 
hznT8, hZnT9, hZnT10 mRNA were measured in control (lymphoblasts and 
fibroblasts from healthy mother), Mother 1 and Mother 2 cells using real-time 
RT-PCR, to detect changes in gene expression at transcription level. The 
control reactions lacking either primers and/or template cDNA were negative 
for all analysed samples. The dissociation curve analysis of all PCR products 
revealed the single peaks of expected Tm (data not shown), confirming the 
specificity of all designed primers.  
The transcript levels of both hZnT5 and hZnT6 were significantly lower in 
lymphoblasts from Mother 1 (hZnT5=0.26+/-0.12; hZnT6=0.22+/-0.12) 
compared to controls (hZnT5=1+/-0.11 and hZnT6=1+/-0.09) (p<0.05, t-test). 
In Mother 2, while the transcript levels of hZnT5 were significantly lower in 
lymphoblasts (hZnT5=0.35+/-0.08) compared to controls (hZnT5=1+/-0.22), 
there was no significant decrease in hZnT6 (0.81+/-0.1) compared to healthy 
controls (1+/-0.15) (p<0.05, t-test) (Figure 3.2a).  
In fibroblasts from Mother 1, hZnT5 and hZnT6 transcript levels 
(hZnT5=0.14+/-0.09; hZnT6=0.4+/-0.11) were lower than in the control 
(hZnT5=1+/-0.12 and hZnT6=1+/-0.13) (Figure 3.2b).  
  
 
Figure 3.2 Real-time RT-PCR analysis of hZnT mRNAs in cells 
from Mother 1 or Mother 2 and corresponding 
controls. 
SYBR-Green real-time RT-PCR analysis of hZnTs mRNA was performed 
using the cells from Mother 1 or Mother 2 and corresponding controls. (a) 
Comparison of the hZnT1, hZnT3, hZnT7, hZnT9 and hZnT10 relative mRNA 
expression levels between Mother 2 cultured fibroblasts and corresponding 
controls revealed no significant differences (p!0.05, t-test). The significant 
reduction (p<0.05, t-test) of hZnT5 and hZnT6 transcript levels was detected 
in Mother 2 cells in comparison to control. (b) No differences were observed 
in hZnT1, hZnT3, hZnT7, hZnT9 and hZnT10 mRNA in lymphoblasts from 
Mother 1 and Mother 2 versus controls (p!0.05, t-test) however significant 
down-regulation (p<0.05, t-test) of Mother 1 and Mother 2 cells were found 
as compared to controls for hZnT5 and hZnT6 transcripts. (c) In human 
resting breast tissue the hZnT5 and hZnT6 expression was detected. The 
difference of 48-fold was observed between hZnT5 and hZnT6 transcript 
levels (p<0.05, t-test). The bars represent the mean (±SD) of 3 independent 
experiments. Stars indicate statistically significant differences (p<0.05, t-test). 
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Mean value of two different lymphoblasts and fibroblasts from healthy 
mothers was taken/used to put error bars. No differences in the mRNA 
expression levels of hZnT1, hZnT3, hZnT4, hZnT7, hZnT9, hZnT10 of 
fibroblasts and lymphoblasts from Mother 1 and Mother 2 were found  
relative to controls (p>0.05, t-test) (Figure 3.2a, 3.2b). hZnT2 and hZnT8 
mRNA transcripts were not found in any patient nor in control cells.  
As the mammary gland was the source of the zinc deficient milk, human 
breast tissue was analysed for the presence of ZnT5 and ZnT6 transcripts. 
ZnT6 transcripts were 48 times more abundant than ZnT5 transcripts in 
normal mammary tissue (Figure 3.2c). 
3.2.2 Sequencing of hZnT2 
As this transporter has been linked with the zinc deficiency disorder, the ORF 
of hZnT2 was sequenced in lymphoblasts and fibroblasts from control and 
patient samples. No nucleotide differences were seen between control, 
Mother 1 and Mother 2. Exon-Intron splice variants were also analysed using 
nine different set of primers (Table-2.3 and 2.4) corresponding to alternative 
splice sites for hZnT2 gene. No changes were observed for this transporter.  
3.2.3 Sequence analysis of hZnT5 and hZnT6 cDNA from 
patient cells and controls 
As there was reduced expression of hZnT5 and hZnT6 mRNA in fibroblast 
and lymphoblast cells from Mother 1 and Mother 2 compared to control cells, 
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sequence analysis of cDNA was carried out to detect changes in the coding 
regions of these genes. In hZnT5 two single nucleotide modifications from 
the Genbank sequence (AF461760) at position 1692 (C Æ T) and 1800 (T Æ 
A) from the start codon were identified in some control and patient cells. 
These modifications did not alter the amino acid sequence of hZnT5.
cDNA sequencing indicated no differences in the coding region of the hZnT6 
gene between patients and corresponding controls (lymphoblasts and 
fibroblasts from healthy mothers) and in all lymphoblasts tested (both 
patients and controls). A full-length hZnT6 mRNA and a variant that was 
missing 43 nucleotides starting from position 216 (Figure 3.3a) were found in 
lymphoblasts. Similarly, in all fibroblasts (patients and controls) two versions 
of hZnT6 ORF were detected, one full length and another with 49 nucleotides 
missing from position 757 to 806 from start codon (Figure 3.3b).  
Sequence analysis was also performed at 5’ and 3’ untranslated (UTR) 
regions of hZnT5 and hZnT6 genes to find any changes present in the micro 
RNA (miR) binding regions. miR-1303 for ZnT6 and miR-1273 for ZnT5 
transporter were found at position +356 and +217 from start codon 
respectively, but no differences were found between patient vs control 
samples. 
3.2.4 Analysis of exon-intron structure of hZnT6 gene   
To investigate whether the different hZnT6 mRNA variants found in fibroblast 
and lymphoblast cells were due to alternate splicing, analysis of exon-intron 
structure of the gene was performed.  
  
Figure 3.3.1 Analysis of fragments of hZnT6 cDNA from 
lymphoblasts and fibroblasts from Mother 1, 
Mother 2 and corresponding controls to 
elucidate splice site variants. 
Fragment of hZnT6 cDNA from lymphoblast and fibroblast showing a deletion 
of 43 and 49 nucleotides (double dots) respectively in control, Mother 1and 
Mother 2 along with full length cDNA. (a, b). 
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The genomic sequence of hZnT6 was obtained using BLASTn search of 
human genome available from GenBank. The hZnT6 gene consists of 14 
exons positioned on chromosomes 2p22.3.  
The variant detected in lymphoblasts corresponds with absence of exon IV 
and the variant detected in fibroblasts corresponds with absence of exon IV 
(Figure 3.3c). Thus the variants detected appear to result from alternative 
splicing of the hZnT6 transcript. 
3.2.5 Promoter Analysis  
To establish whether reduced levels of hZnT5 or hZnT6 were due to changes 
in the promoter regions of these genes, sequence analysis was carried out 
on the DNA up to 4000 base pairs upstream from the start codons of hZnT5 
and hZnT6. These regions both contained the following transcriptional 
regulatory elements: MRE (Metal Responsive Element), STAT-5 (binding site 
for prolactin), TATA binding site, PRE (Progesterone Responsive Element), 
and GRE (Gonadotrophin Responsive Element). In addition the region in 
hZnT5 contained an Insulin Responsive Element (IRE). Point changes were 
observed at position -1155 (TÆ:), -1325 (G Æ C) from the start codon and -
545 (AÆG), -1735 (CÆT) in control and Mother 1 fibroblasts for hZnT5 and 
hZnT6 respectively (Figure 3.4b), but did not affect any of the above 
transcription factor binding sites.  
3.2.6 Western Blot analysis of hZnT5 and hZnT6 
Western blot analysis was used to detect the expression of hZnT5 and 
hZnT6 proteins in patient and control fibroblasts and lymphoblasts.  
  
Figure 3.3.2 Diagram to illustrate the different exon-intron 
structure of the hZnT6 gene.  
In lymphoblasts the full length mRNA coexisted with the alternatively spliced 
form (missing exon IV); In fibroblasts, an alternatively spliced form of hZnT6 
which did not show exon IX was present, together with full length version of 
mRNA. (c)  
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Figure 3.4  Diagramatic presentation of promoter region  of 
hZnT5 and hZnT6 genes 
(a) Diagramtic representation of important transcription factor binding sites 
present 4000 bp upstream of the translation start point. The location and 
order of the indicated transcription binding factors is only approximate as 
hZnT5 and hZnT6 have multiple binding sites for different transcription 
factors. The number of binding sites present in each sequence is indicated by 
the number in the coloured box in the diagram for each gene. Abbreviations 
used in the diagram: PRE (Progesterone Response Element), ERE 
(Estrogen Response Element), Stat-5 (binding site for prolectin), IRE (Insulin 
Response Element), MRE (Metal Response Element). (b) Point changes 
identified at different positions on hZnT5 and hZnT6 genes in affected 
mothers and controls. 
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A significant reduction in hZnT5 and hZnT6 proteins was observed for 
Mother 1 and Mother 2 lymphoblasts as compared to control lymphoblasts 
(mean value taken from two sepeate lymphoblasts and fibroblasts cells). 
No changes were observed in fibroblasts for hZnT6 protein expression but 
there was a significant reduction between Mother 2 and control for hZnT5. In 
lymphoblasts the major band detected with the ZnT5 antibody was of size 57 
kDa with a less intense band seen at 55 kDa, while in fibroblasts a single 
band of size 55 kDa was detected (Figure 3.5a). In lymphoblasts, no 
differences in ZnT5 band sizes were seen between control extracts and 
extracts from Mother 1 and Mother 2. Using the ZnT6 antibody, two bands of 
size 55 kDa and 57 kDa with equal intensity were found in lymphoblasts and 
one band of 55 kDa in fibroblasts. Similar band intensity was observed in 
control and in Mother 1 and Mother 2 extracts (Figure 3.5b). Lysates of the 
human breast carcinoma line PMC42 and human breast tissue were tested 
for the presence of hZnT5 and hZnT6 proteins. The hZnT5 antibody detected 
a weak band of size 57kDa in PMC42 cell extracts while a strong band of 55 
kDa was seen in breast tissue (Figure 3.5a). The ZnT6 antibody showed 
negligible amounts of hZnT6 in the PMC42 cells and a strong band at 55 kDa 
in the breast tissue (Figure 3.5b).  
3.2.7 Intracellular localization 
 Confocal microscopy of patient and control fibroblast cells to determine the 
intracellular localisation of hZnT5 and hZnT6 proteins showed a granular 
cytoplasmic distribution for both hZnT5 and hZnT6 that was similar in Mother 
2 (Figure 3.6a, 6e) and control fibroblasts (Figure 3.6b, 6f) respectively.  
  
Figure 3.5 Western blot analysis of proteins from two 
mothers with zinc deficient infants.  
Expression levels of hZnT5 and hZnT6 protein were analysed using 
appropriate antibodies. 
A band of the predicted size of 55 kDa was detected in all the fibroblasts and 
a major band of 57 kDa band along with minor band at 55 kDa was present 
for all the lymphoblasts for hZnT5. Both lymphoblasts and fibroblasts showed 
significant decrease in patient cells as compared to controls (a).  
A band was detected around 55 KDa for all fibroblast cells (patient and 
control) for hZnT6 gene. Lymphoblast showed two bands of equal intensity at 
55 and 57 kDa sizes. No significant differences were observed between 
control and patient fibroblasts but patient lymphoblasts showed significant 
decrease as compared to controls (b). 
PMC-42 showed band at ~57 kDa and BT breast tissue at ~55 kDa using 
both antibodies. An antibody to housekeeping human β-actin along with 
Ponceau S was used to indicate the relative levels of protein loaded on the 
gel from mothers 1 and 2 and corresponding controls Densitometry was 
performed to compare the results.
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Figure 3.6 Intracellular/Subcellular localization of hZnT5 and 
hZnT6 
Immunostaining of hZnT5 (upper row) and hZnT6 (lower row) in control 
fibroblast (a, e), Mother 2fibroblast (b, f), PMC-42 (c, g) and human breast 
tissue (d, h) E denotes luminal epithelial cells and L denotes lumen of the 
duct. Control and Mother 2 fibroblast cells grown on cover slips were fixed by 
4% paraformaldehyde and stained with hZnT5 and hZnT6 antibodies 
respectively followed by secondary antibody conjugated with Alexa 488. 
hZnT5 and hZnT6 localization was also tested in PMC-42 cells and human 
breast tissue cryo-sections following the same procedure. Images shows 
granular cytoplasmic and peri-nuclear localization of hZnT5 (a, b, c, d) and 
hZnT6 (e, f, g, h) in control fibroblast, Mother 2 fibroblast, PMC-42 and 
human breast tissue respectively. Scale bar = 10 μm. 
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Images of lymphoblasts suggested a similar distribution of hZnT5 and hZnT6 
between patient and control cells, although this was difficult to ascertain due 
to the small volume of cytoplasm in lymphoblasts (data not shown).  
A similar localization pattern was observed for PMC42 (Figure 3.6c, 6g) cells 
and breast tissue (Figure 3.6d, 6h) for hZnT5 and hZnT6 respectively. 
3.2.8 Alkaline phosphatase activity  
Significantly reduced alkaline phosphatase activity was found in patient 
lymphoblasts (Mother 1 and Mother 2) relative to control lymphoblasts 
(Figure 3.7). In fibroblasts, alkaline phosphatase levels were low and no 
significant differences were detected between Mother 1, Mother 2 and 
controls (two different fibroblasts from healthy mothers were analysed). 
Alkaline phosphatase activity was also detected in PMC42 cells and breast 
tissue and overall breast tissue showed maximum activity. 
3.2.9 DNA methylation 
3.2.9.1 hZnT5 methylation 
In lymphoblasts, CpG site 2 was found to be significantly less methylated in 
Mother 1 (4%) and Mother 2 (4%) compared with control samples (13%) 
(Figure 3.8a). In contrast the reverse was seen in fibroblasts where Mother 2 
methylation (52%) was greater than in the control sample (38%) (Figure 
3.8b), Methylation levels at all four sites were significantly higher in 
fibroblasts than lymphoblasts with the exception of CpG1 and CpG2 for the 
controls (Figure 3.8b). 
  
Figure 3.7 Alkaline phosphatase activity 
Total alkaline phosphatase activity was detected at 405nm wave length using 
p-nitrophenol as a substrate for patient and control lymphoblast’s, 
fibroblast’s, PMC-42 and breast tissue. Activity was measured in U/μg of total 
protein. Significant differences were found for patient and control 
lymphoblasts. Mother 1 showed maximum decrease in activity followed by 
Mother 2 as compared to control lymphoblasts. No differences were 
measured between Mother 2 and control fibroblasts. Breast tissue showed 
maximum ALP activity. The bars represent the mean (±SD) of 3 independent 
experiments. Stars indicate statistically significant differences (p<0.05, t-test). 
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Figure 3.8 Bislphide pyrosequencing for DNA methylation of 
hZnT5 and hZnT6 genes 
(a) Lymphoblasts showed statistical significant hypomethylation in Mother 1 and 
Mother 2 as compared to control at CpG site 2 for hZnT5 gene. All other sites CpG 1, 
3, and 4 showed no changes between patient and control samples. The bars 
represent the mean (±SD) of 3 independent experiments. Stars indicate statistically 
significant differences (p<0.05, t-test). 
(b) Fibroblasts showed statistical significant hypermethylation in Mother 2 fibroblast 
as compared to control at CpG site 2 for hZnT5 gene. All other sites CpG 1, 3, and 4 
showed no changes between patient and control samples. The bars represent the 
mean (±SD) of 3 independent experiments. Stars indicate statistically significant 
differences (p<0.05, t-test). 
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3.2.9.2 hZnT6 methylation 
Methylation within the ZnT6 gene was below the detectable levels in extracts 
from Mother 1, Mother 2 and control samples in lymphoblasts and fibroblasts.
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3.3 Discussion 
Low levels of zinc in the maternal milk combined with a response by the 
infants to zinc therapy indicated a defect in the maternal breast affecting 
secretion of zinc into milk. The observation that neither mother was suffering 
from zinc deficiency suggested that specific defects to zinc exporters in the 
mothers’ breast tissue were involved in this pathology. Zinc transporters are 
involved with the activity of tissue non-specific alkaline phosphatase (TNAP) 
(Suzuki et al., 2005a). Significant reduction in the alkaline phosphatase 
(ALP) activity of Mother I and Mother II lymphoblasts was detected relative to 
control lymphoblasts. In fibroblasts, ALP activity was very low, and this may 
have accounted for the lack of differences detected between the affected 
Mothers and the control. The reduced TNAP in lymphoblasts is consistent 
with a reduced function of zinc export in the Mother I and Mother II cells 
relative to controls.  
Missense mutations in ZnT2 have been reported to underlie cases of 
maternal defects of zinc secretion into milk (Chowanadisai et al., 2006; Lazry 
et al., 2012; Itsumura et al., 2013). All reported studies on ZnT2 in premature 
babies with zinc deficiency have been based on patient's DNA extracted from 
mother's blood cells for the identification of novel mutations or modified 
tissue cultures for the expression levels (Chowanadisai et al., 2006; Itsumura 
et al., 2013). No studies have previously reported hZnT2 expression in 
human lymphoblast or fibroblast cell lines. In the two cases reported in the 
current study, no detectable ZnT2 mRNA was found in either lymphoblasts or 
fibroblasts from the two mothers who produced zinc-deficient milk. To rule 
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out the possibility of ZnT2 being responsible for this disorder, sequence 
analysis of the ORF and exon-intron splice variants was performed on patient 
and control samples from the two different cell types, but no changes were 
found. This confirmed that ZnT2 mutations were not responsible for the 
production of zinc deficient milk in mothers of premature babies with zinc 
deficiency.  This raised the possibility that more than one molecular defect 
could be responsible for this condition. Multiple members of the solute carrier 
family 30 (SLC30 zinc transport) may participate in the export of zinc into 
milk and there may be some redundancy amongst zinc transporters. This 
possibility is supported by observations that in mothers with ZnT2 mutations, 
some zinc was still present in the milk (Itsumura et al., 2013: Lasry et al., 
2012).  
Analysis of transcript levels of all other identified members of the mammalian 
ZnT/SLC30A family was performed. Significantly reduced levels of hZnT5 
mRNA in fibroblasts and lymphoblasts from Mother 1 and Mother 2 
compared to controls were observed. A reduction of hZnT6 transcripts was 
found in lymphoblasts and fibroblasts from Mother 1 but not in Mother 2, 
relative to control cells. Thus it is feasible that defects in hZnT5 and/or 
possibly hZnT6 may underline the mammary defect of reduced zinc secretion 
into milk as both mRNA and proteins of these transporters were present in 
human mammary tissue obtained from the resting breast. Both ZnT5 and 
ZnT6 are located in the early secretory pathway (Kambe et al., 2002, 
Kirschek, 2003; Huang et al., 2002; Kambe et al., 2011) consistent with a 
role in transport of zinc into intracellular vesicles that are destined for 
secretion. ZnT5 mRNA is highly expressed in β-cells and the protein is 
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located in insulin-containing cells where it may participate in transport of zinc 
into secretory granules (Kambe et al., 2002; Suzuki et al., 2005a). Thus in 
mammary epithelial cells the ZnT5 transporter may have compatible role in 
sequestration of zinc into vesicles destined for secretion from mammary 
epithelial cells. 
Sequence analysis of hZnT5 from Mother 1, Mother 2 and control 
lymphoblast and fibroblasts indicated that some samples had two single 
nucleotide modifications compared with the GenBank sequence (AF461760) 
at positions 1692 and 1800 from the start codon. These were silent 
mutations, thus excluding defects in the ORF of hZnT5 as a causal factor in 
relation to defective secretion of zinc into milk or in explaining the reduced 
mRNA levels.  
In cells from Mother 1, Mother 2 and controls, we found alternative splice 
variants of ZnT6. In lymphoblasts, in addition to the full-length transcript, a 
variant that lacked exon IV was present. In fibroblasts, a variant that lacked 
exon IX was detected in addition to the full-length transcript.  Similar 
transcripts were found in extracts from both mothers and controls, indicating 
that the alternate splicing was not associated with the zinc deficient 
phenotype. Splice variants of ZnT5 differing in the 5’ and 3’ regions have 
previously been found in Caco-2 cells, where one form contained all 17 
exons, while the other lacked exons 1, 2, 4 and exons 15-17, (Jackson et al., 
2007; Thornton et al., 2011). We did not detect splice variants in either 
lymphoblasts or fibroblasts. 
Protein analysis indicated the presence of two isoforms for both hZnT5 and 
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hZnT6. Bands of 55 kD and 57 KDa were found in lymphoblasts. A 55 kDa 
band was the only band seen in fibroblasts. The 55 kDa protein was also the 
single dominant band in the mammary gland. The band sizes detected in 
both mothers and control were consistent with previously reported sizes of 55 
and 57 and 60 KDa found in a range of human cells and tissues (Kambe et 
al., 2002; Cragg, 2002: Cragg, 2008). Identified bands of 55 kDa for the ZnT6 
protein corresponded with predicted size of the splice variant found in 
lymphoblasts where exon IV was missing 43 nucleotides (Fig 3.5b). 
Although we found alternatively spliced mRNA in both lymphoblasts and 
fibroblasts, we detected two protein sizes only in lymphoblasts for the ZnT6 
transporter. This could be due to the low abundance of the protein product of 
the shorter transcripts in fibroblasts. Alternatively our antibody might not 
detect the variant found in fibroblasts. 
The protein levels of hZnT5 and hZnT6 in lymphoblasts and fibroblasts were 
measured to establish if they were reduced, consistent with the mRNA data, 
in lymphoblasts from affected mothers. Both hZnT5 and hZnT6 protein levels 
were reduced compared to the control. In fibroblasts however, the protein 
levels of hZnT5 and hZnT6 of cells from the affected mothers were no 
different from the control. The reasons for the differences in the fibroblast 
data between mRNA and protein are not clear. 
Both SLC30A6 mRNA and protein were more strongly expressed in normal 
breast tissue than in isolated lymphoblasts and fibroblasts. The high 
expression of the transporters in normal breast cannot necessarily be 
attributed to a greater expression in mammary epithelial cells as the breast 
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tissue also contains lipids, endothelial cells and smooth muscle fibres.  The 
breast cancer epithelial cell line PMC42 expressed approximately one tenth 
the amount of ZnT5 and ZnT6 protein of the mammary tissue and 
considerably less than lymphoblasts and fibroblasts. This may be related to 
the transformed state of these cells or their cancer origin. It is not known if 
ZnT5 and ZnT6 are altered in breast cancer tissue or cell lines, although 
recently expression of ZnT5 and ZnT6 has been found up-regulated in grade 
IV gliomas as compared to grade II gliomas (Lin et al., 2013). ZnT5 mRNA 
levels were also increased in prostate cancer (Franz et al., 2013).  
The mammary gland hZnT6 mRNA levels were 48 times greater than ZnT5. 
Assuming that ZnT5/ZnT6 operates as a heterodimer, this difference in 
transcript levels suggests that hZnT6 may have an additional function in 
mammary gland, possible accounting for the additional splice variants. 
ZnT5 and ZnT6 form heterodimers within the early secretory pathway and 
this oligomerization is required for their zinc transport function (Kambe, 
2012). The ZnT5/6 heterodimer transports zinc from the cytosol into vesicles 
in HeLa cells (Kambe et al., 2002). ZnT6 is not directly involved in zinc 
transport across the cell membrane as it does not have a zinc-binding site 
within the TMDs because of the lack of conserved hydrophilic residues but it 
may function as a modulator (Fukunaka et al., 2009). Based on the X-ray 
structure of YiiP, a ZnT homologue in E. coli, (Lu and Fu, 2009; Lu & Fu, 
2007) has four hydrophilic residues in TMDs II and V form the zinc-binding 
sites for ZnT6. Thus if one of either hZnT5 or hZnT6 protein is reduced it may 
impair the function of the dimer in transporting zinc.  
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Changes in hZnT5 and hZnT6 mRNA and protein levels in the mothers 
producing zinc-deficient milk indicate the possibility that these transporters 
may be implicated in the zinc deficiency disorder although no mutations were 
detected in the coding region. The suppression of gene expression could be 
due to mutations in the gene promoter regions where important transcription 
binding sites are present. Changes or mutations within these binding sites 
can interfere with transcriptional machinery and hence suppressing 
expression of the target gene.  
Both hZnT5 and hZnT6 possess a number of hormone responsive elements 
including MRE (Metal Responsive Element), STAT-5 (binding site for 
prolactin), TATA binding site, PRE (Progesterone Responsive Element) and 
GRE (Gonadotrophin Responsive Element). hZnT5 also includes an IRE 
(Insulin Responsive Element). The presence of these elements is consistent 
with these transporters having a hormone-responsive role in mammary 
function, in particular milk secretion, which is controlled by prolactin. To 
detect changes in important binding sites present in the promoter region of 
our genes of interest, promoter analysis was performed 4000bp upstream of 
the translation start site. However, no changes were observed within these 
binding sites. We then investigated miRNAs present in 3’ region of these 
transporters, as modifications at 3’ regions could alter the expression of 
genes. Again, no changes were observed. 
The immunolocalisation studies indicated that the distribution of both hZnT5 
and hZnT6 protein was similar in fibroblasts, lymphoblasts and breast tissue 
and were consistent with the vesicular described localisation of the two 
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proteins described previously (Huang et al., 2002; Suzuki et al., 2004; Suzuki 
et al., 2005).  
DNA methylation is an epigenetic modification that plays an important role in 
regulation of gene expression. This determines whether a genome region is 
transcriptionally active or repressed, and hence controls cell specific gene 
expression (Robertson KD. 2005; Bird A., 2002). Since CpG islands are 
present in the promoter region of hZnT5 and hZnT6 genes, their expression 
may potentially be regulated by promoter methylation status. DNA 
methylation is involved in the down-regulation of other members of the SLC 
family of transporters (Hong et al., 2005; Kikuchi et al., 2006; Zschocke et al., 
2007; Philibert et al., 2007; Gonen et al., 2008). DNA hypermethylation 
downregulates ZIP8 in cadmium resistant metallothionin null mice (Fujishiro 
et al., 2009). Methylation caused by factors including diet may exert 
influences during the neonatal development, seen for example with folate, 
where a deficiency during pregnancy in mice leads to reduced Zip4  
methylation in the offspring (McKay et al., 2011), where as folate is a methyl 
donor. Promoter methylation of the hZnT5 gene contributes to reduced 
expression of an associated reporter gene that leads to decreased zinc 
absorption from intestinal cells (Coneyworth et al., 2009). Increased DNA 
methylation of CpG islands in the promoter region of Zip6 was observed in 
splenocytes of aged mice relative to young mice and contributed to age-
related deficiency of cellular zinc. Similar hypermethylation was found for 
ZnT1 and ZnT5 zinc transporters (Wong et al., 2013). DNA hypomethylation 
was responsible for homocysteine-induced cyclin-A gene silencing and 
growth inhibition in endothelial cells (Jamaludin et al., 2007). 
 109 
 
 
We investigated the possibility that DNA methylation could account for the 
reduced levels of hZnT5 and hZnT6 transcripts found in cells from mothers 
producing zinc-deficient milk. Methylation patterns are tissue-specific and 
may differentially regulate gene expression in different cells (Thomson et al., 
2010; Schneider et al., 2010). In folate-methyl deficient rats, DNA 
hypomethylation was found in hepatic tissue while DNA hypermethylation 
was found in the brain (Pogribny et al., 2008) indicating differential tissue 
response with the same nutritional deficiency. Our analyses indicated 
differences in methylation levels between fibroblasts and lymphoblasts and 
between affected mothers and controls. In fibroblasts, the methylation of 
hZnT5 at one of 4 CpG sites measured was increased by 20% in Mother 2, 
and this may account for reduced hZnT5 mRNA detected in these cells.  In 
lymphoblasts in Mothers1 and 2 the methylation of this same CpG site was 
reduced by 65% compared to control lymphoblasts. A notable feature of the 
methylation results was the large variation between control samples.  In 
contrast to this the variation within Mother 1 and Mother 2 samples was 
smaller, but given the small numbers of samples it is not possible to 
determine if the patients and controls actually differed in variability at this 
position. Similar to the variations in nucleotide sequences within populations 
(genetic polymorphisms), variations in methylation termed epi-
polymorphisms have been identified (Abraham et al., 2012), and may be 
attributable to mechanisms including transposable elements (Waterland, and 
Jirtle, 2003).  
 110 
 
Hypermethylation at this variable CpG in fibroblasts could be responsible for 
reduced expression of the hZnT5 gene. In lymphoblasts, this CpG site was 
hypomethylated in affected mothers compared with controls, but expression 
levels were reduced at both the mRNA and protein levels. Although promoter 
DNA hypermethylation, rather than hypomethylation, is generally regarded as 
the suppressive epigenetic modification, this relationship is not always 
observed, particularly with respect to individual CpG sites. Another study 
revealed that several genes where both gain and loss of DNA methylation at 
specific CpG sites was associated with both increased or reduced expression 
(Ions et al., 2013),  although direct causality was not demonstrated. The 
difference in DNA methylation at this specific CpG site between affected 
mothers and controls could thus in theory contribute to the differences in 
gene expression observed in both lymphoblasts and fibroblasts, but is clearly 
not the only determinant.   The proximity of two transcription factor binding 
sites (CDF-1, DEAF) to this CpG site indicate that altered patterns of DNA in 
this region may have functional manifestations that arise through effects on 
the action of these transcription factors.  CDF-1 plays a role in progression 
through the cell cycle (Dohna et al., 2000) (Lucibello et al., 1995) (Zwicker et 
al., 1995). Thus ZnT5 transcription may be regulated in parallel with the cell 
cycle in manner affected by DNA methylation in this region. 
DEAF-1 binds to its own promoter and also suppresses the expression of 
PTA (peripheral tissue antigen) (Yip et al., 2009). It also has other functions 
in regulating epithelial cell gene expression and mammary gland 
morphogenesis (Barker et al., 2008). Further evidence supports that CHR is 
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a core element in transcriptional regulation by DREAM complexes (Muller et 
al., 2012).   
We detected no DNA methtylation in the (very selective) region of the hZnT6 
promoter we analysed, thus can only conclude that differences in gene 
expression were not associated with an increase in DNA methylation in this 
region to a detectable level.  We cannot exclude the possibility that DNA 
methylation in other regions of the hZnT6 promoter differed between the 
affected mothers and controls. 
ZnT5 and ZnT6 genes in mothers producing zinc deficient milk are 
summarized in Figure 3.9. 
  
Figure 3.9 ZnT5 and ZnT6 changes in mothers producing zinc 
deficient milk 
Summary of results for two mothers producing zinc deficient milk. Significant 
increase and decrease is represented via an upward and downwards arrow 
respectively. No changes or undiagnosed results are shown via horizontal 
line. 
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3.4 Conclusion 
In summary, two cases of zinc deficiency in neonates caused by a maternal 
defect in the transport of zinc into milk were investigated. Significant 
reduction in hZnT5 and hZnT6 mRNA and protein were observed suggesting 
a possible causal link to the zinc deficiency disorder. A significant functional 
difference between affected mothers and control lymphoblasts was 
confirmed by reduced alkaline phosphatase activity. There was an absence 
of any modifications altering, amino acids in coding regions, transcription 
binding sites in promoter region or 5’ and 3’ untranslated regions (UTR). 
Novel splice variants along with full-length expression were detected in 
hZnT6. Altered DNA methylation was observed in ZnT5 at epi-labile CpG 
sites in lymphoblasts and fibroblasts from mothers producing zinc-deficient 
milk compared with controls. This may account for reduced ZnT5 mRNA and 
protein in lymphoblasts. The reduced hZnT6 mRNA and protein in 
lymphoblasts may be secondary to reduced hZnT5 protein levels, given that 
hZnT5 and hZnT6 function as a heterodimer in regards to zinc transport.
  
 
 
CHAPTER 4 
Functional analysis to 
determine co-dependency of 
ZnT5 and ZnT6 in neuronal 
cells.  
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4.1 Introduction 
To elaborate the role of ZnT5 and ZnT6, further studies were carried out in 
neuronal cells as zinc has a vital role in the normal functioning of neurons. 
Out of a total of 10 members of the cdf family, each transporter works 
differently in different cells. For example ZnT3 stores zinc in synaptic 
vesicles; ZnT5, ZnT6 and ZnT7 stores zinc in the trans Golgi network. .Some 
members of cdf family are important in brain and their altered expressions 
have been linked to different disorders. ZnT6 levels are significantly 
increased in the brain of Alzheimer disease (AD) patients (Lybartseva et al., 
2010; Lovell et al., 2006). Similarly elevated expression of ZnT6 have been 
observed in hippocampus gyrus of the human brain with Alzheimer’s and 
mild cognitive impairment (Smith et al., 2006).  
ZnT5 and ZnT6 have been shown to work together to supply zinc to alkaline 
phosphatases, a Zinc dependent enzyme, in the early secretory pathway 
comprising the endoplasmic reticulum (ER) and Golgi apparatus (Suzuki et 
al., 2005a). ZnT6 mRNA is expressed abundantly in the brain, liver and small 
intestine but the protein has only been detected in brain and lung (Huang et 
al., 2002; Yu et al., 2007; Suphioglu et al., 2010). These changes in mRNA 
and protein levels suggest that ZnT6 expression is controlled at the 
translational level in a tissue specific manner (Kambe et al., 2004). 
ZnT5 is widely expressed in all mammalian tissues and ZnT5 null mice 
develop muscle weakness, lean body composition, poor growth in male null 
mice leading to death due to heart block at 15 weeks of age (Inoue et al., 
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2002), suggesting that ZnT5 plays a crucial role in cell survival. Regulation of 
ZnT5 expression occurs at the transcription and post transcription (mRNA 
stability) levels. ZnT5 protein expression is reduced in human ileal mucosa 
with high dietary zinc intake (Cragg et al., 2005). Similarly, exposure of Caco-
2 cells to high doses of zinc results in inhibition of ZnT5 transcription and 
translation (Jackson et al., 2007). The formation of ZnT5/ZnT6 heterodimer 
complexes using a gene disruption/re-expression system in chicken DT40 
cells indicates the possibility that ZnT5 functions in zinc ion transport across 
the cellular membrane with ZnT6 acting as a modulator to enhance zinc 
transport activity to the complex (Fukunaka et al., 2009). ZnT5 has been 
showed to work as both uptake and efflux pump (Valentine et al., 2007; 
Thornton et al., 2011).  
In the current study the main aim was to investigate the role of ZnT5 and 
ZnT6 in M17 cells. To investigate mututal dependency, real time q-PCR and 
western analysis were performed on cells harbouring knockdown and 
overexpressing constructs of ZnT5 and ZnT6. An alkaline phosphatase 
assay was performed to establish whether both are required for enzyme 
activity in human neuronal cells. Immuno analysis and 65Zn accumulation and 
efflux experiments were performed to establish the intracellular localization 
and to determine if ZnT5 and ZnT6 are required for cellular zinc 
accumulation or zinc efflux.  
 117 
 
4.2 Results 
 
4.2.1 Overexpression constructs 
To investigate the function of ZnT5 and ZnT6 in neuronal cells, over-
expression and knocked-down constructs were created and the expression 
levels of ZnT5 and ZnT6 mRNA were measured in control cells (containing 
empty vectors) and cells overexpressing ZnT5 and ZnT6 constructs using 
real-time PCR. Significant 48 and 50-fold increases in the mRNA expression 
levels of ZnT5 and ZnT6 were found (p<0.05) between control and 
overexpressed ZnT5 and ZnT6 genes respectively (Figure 4.1a, 4.2a). The 
control reactions lacking either primers and or template cDNA were negative. 
The dissociation curve analysis of all PCR products revealed single peaks of 
expected Tm (data not shown), confirming the specificity of all designed 
primers.  
Significantly higher ZnT5 and ZnT6 protein expression levels were observed 
in cells containing overexpression constructs of ZnT5 and ZnT6 genes as 
compared to wild type controls. A 55 kDa band was detected using the ZnT5 
antibody and the ZnT6 antibody produced a band approximately 57 kDa in 
size (Figure 4.1b, 4.2b top bands). Densitometry performed to measure 
differences in protein levels relative to β-actin, indicated significant increases 
of 262% and 324% observed in cells overexpressing ZnT5 and ZnT6 
respectively relative to control cells with empty vectors (p<0.05) (Figure 4.1b, 
4.2b).
  
Figure 4.1 Overexpression and knockdown constructs of 
ZnT5 
SYBR-Green real time RT-PCR analysis of cells overexpressing ZnT5 
showed significant increase (P<0.05, t-test) in ZnT5 mRNA compared to 
control containing empty vector (a). Western blot analysis showed one major 
band at 55 kDa and densitometry analysis after comparing with β-actin as a 
control, showed significant increase (P<0.05, t-test) in intensity of band 
strength for cells overexpressing ZnT5 compared to empty vector controls (b). 
Localization of ZnT5 in overexpressing construct showed strong perinuclear, 
cytoplasmic vesicular labelling (cii) as compared to less intense but similar 
labelling in control cells (ci).  
Real time PCR data showed significant decrease in ZnT5 knockdown cells as 
compared to control empty vectors (P<0.05, t-test) (d). Protein estimation by 
western blot analysis showed significant decrease of ZnT5 protein (P<0.05, t-
test), in knockdown cells as compared to controls (e). Immunolabelling of 
ZnT5 showed similar localization but reduced signal in ZnT5 knockdown cells 
(fi, fii). 
RNA expression level of each sample was calculated using the equation 2-
∆∆CT. All data presented are the results of 3 independent experiments. 
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Figure 4.2 Overexpression and knockdown constructs of 
ZnT6 
Syber green real time analysis of cells overexpressing ZnT6 showed 
significant increase in ZnT6 mRNA (P<0.05, t-test) compare to control 
containing empty vector (a). Western blot analysis showed one major band at 
~57 kDa and densitometry analysis after comparing with β-actin as a control, 
showed significant increase (P<0.05, t-test) in intensity of band strength for 
overexpressing ZnT6 as compared to control cells (empty vectors) (b). 
Localization of ZnT6 in overexpressing construct showed strong perinuclear, 
cytoplasmic vesicular labelling (cii) (indicating Trans Golgi consistent with 
previous studies) as compared to less intense cytoplasmic vesicular labelling 
in control cells (ci).  
Real time analysis at mRNA level showed significant decrease in ZnT6 
knockdown cells as compared to controls (P<0.05, t-test) (d). Protein 
expression by western blot analysis showed significant decrease (P<0.05, t-
test) in ZnT6 knockdown cells as compared to controls (e). Immuno 
localization of ZnT5 showed similar labelling but reduced signal in 
knockdowns of ZnT6 as compared to control cells (fi, fii). 
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Confocal images were obtained from cells containing overexpression 
constructs for ZnT5 and ZnT6 and with empty vector controls. In control cells 
the ZnT5 and ZnT6 protein was distributed evenly in cytoplasm with a 
vesicular pattern (Figure 4.1ci, 4.2ci). Cells with overexpressing constructs 
showed pronounced perinuclear label consistent with previous reported 
studies for both transporters (Figure 4.1cii, 4.2cii).  
4.2.2 Knockdown constructs 
To demonstrate that our knock-down constructs were functional, ZnT5 and 
ZnT6 mRNA expression levels were measured using real time PCR in control 
cells containing empty vectors and cells with ZnT5 and ZnT6 siRNA knock-
down constructs. Significant 0.7 and 0.5 fold decreases in mRNA expression 
levels were observed (p<0.05) in cells with knock-downs of ZnT5 and ZnT6 
constructs relative to the empty vector controls (Figure 4.1d, 4.2d). The 
control reactions with no primers or template cDNA from control (empty 
vectors) and knockdown constructs were negative.  
Consistent with previous western results, the ZnT5 and ZnT6 antibidies 
produced a 55 kDa and a ~57 kDa band size respectively (Figure 4.1e, 4.2e 
top bands). Densitometry was performed to detect differences in protein 
levels relative to E-actin. Significant decrease of 46% and 52% in band 
intensity were observed in cells containing knockdown of ZnT5 and ZnT6 
respectively, relative to cells with empty vectors (p<0.05) (Figure 4.1e, 4.2e). 
Immuno-localization of ZnT5 and ZnT6 proteins showed a cytoplasmic, 
vesicular localization in control cells (Figure 4.1fi, 4.2fi), and cells with ZnT5 
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and ZnT6 knockdowns did not show altered localization of the proteins in 
comparison to control. The only difference detected was reduced signal 
intensity (Figure 4.1fii, 4.2fii). 
4.2.3 ZnT5 and ZnT6 interactions 
The effect of altered expression of ZnT5 and ZnT6 was investigated to 
establish their inter-dependence. ZnT6 mRNA expression and protein levels 
were measured in cells containing overexpression and knock-down ZnT5 
constructs. Similarly ZnT5 mRNA and protein expression levels were 
observed in cells containing overexpression and knockdown constructs of 
ZnT6. When ZnT6 was overexpressed, no change was detected in 
expression of ZnT5 mRNA (using ZnT5 specific real time PCR primers) 
(Figure 4.3a) or in protein levels (ZnT5 antibody) (Figure 4.3b). Similarly no 
changes in mRNA levels (Figure 4.3d) or band intensity for western blot 
(Figure 4.3e) were observed in cells containing ZnT6 knock-down constructs, 
compared to controls (empty vectors) using ZnT5-specific primers and ZnT5-
antibody (p>0.05). ZnT6 overexpression and knockdown had no impact on 
the localization of ZnT5 protein (Figure 4.3ci, 4.3ciii; 4.3fi, 4.3fiii). 
In contrast, ZnT6 showed responses following ZnT5 overexpression and 
knockdown in M17 cells. Cells in which ZnT5 was overexpressed, showed a 
3-fold increase in ZnT6 at the mRNA level (Figure 4.4a) and a 105% 
increase at protein level (Figure 4.4b) (p<0.05). Similarly in cells with ZnT5 
knockdown constructs there was a 57% decrease in ZnT6 mRNA (Figure 
4.4d) and a 40% decrease at the protein level (Figure 4.4e) (p<0.05). No 
differences were observed in band sizes for ZnT5 and ZnT6 genes.  
  
Figure 4.3 Expression of ZnT5 in response to ZnT6 
overexpression and Knockdown 
Real time PCR analysis showed increased expression of ZnT5 in 
overexpressing cells with ZnT5 gene but no differences in expression levels 
between cells overexpressing ZnT6 and control were observed using ZnT5 
qRT-PCR primers (a) (p>0.05, t-test). Western blot analysis showed no 
differences in the band intensities (b) (p>0.05, t-test) between overexpressing 
ZnT6 and control cells using ZnT5 antibody. Overexpressing ZnT6 had no 
impact on the localization of ZnT5 (ci, ciii).  
mRNA expression levels measured by Real time PCR showed  no changes 
between ZnT6 knockdown compared with respective controls (p>0.05, t-test) 
using ZnT5 specific primers (d). Protein expression by western blot analysis 
showed no differences in band intensities between ZnT6 knockdown and 
control cells (e) (p>0.05, t-test). ZnT6 knockdown did not show any changes 
of ZnT5 localization compared to controls (fi, fiii). 
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Figure 4.4 Expression of ZnT6 in response to ZnT5 
overexpression and knockdown 
Real time PCR analysis showed significant increase in cells overexpressing 
ZnT5 and ZnT6 as compared to control cells using ZnT6 qRT primers at 
mRNA level(P<0.05, t-test) (a). Western blot analysis showed increase in the 
band intensities and showed significant increase in cells overexpressing ZnT5 
as compared to control cells (empty vectors) using ZnT6 antibody (b) 
(P<0.05, t-test). Overexpressing ZnT5 showed slight increase in the intensity 
of perinuclear localization of ZnT6 as compared to respective control (ci, ciii).  
A significant decrease was observed at mRNA level between ZnT5 
knockdown compared to controls using ZnT6 qRT primers (P<0.05, t-test) 
(d). Protein expression by western blot analysis showed significant decrease 
(P<0.05, t-test) in band intensities between ZnT5 knockdown and control 
cells using ZnT6 antibody (e). Slight decrease in labelling signal was 
observed between ZnT5 knockdown as compared to controls (fi, fiii), but 
localization pattern remained same. 
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Consistent with the real time and protein expression data, cells 
overexpressing ZnT5 showed an increase in the perinuclear labelling of ZnT6 
(Figure 4ci, 4ciii), and a decrease in ZnT6 signal intensity was observed for 
ZnT5 knock-down cells compared to their respective controls (Figure 4.4fi, 
4.4fiii). 
4.2.4 Alkaline phosphatase activity 
Alkaline phosphatase is a zinc-dependent enzyme that requires ZnT5 and 
ZnT6 for its activity (Suzuki et al., 2005a; Suzuki et al., 2005b). TNAP (tissue 
nonspecific alkaline phosphatase) activity was measured using total cellular 
protein from cells with ZnT5 and ZnT6 overexpressing and knock-down 
constructs with respective empty vector controls. When compared with 
controls, cells overexpressing ZnT5 and ZnT6 genes showed an increase 
from 0.2 U/μg of protein to 0.26 U/μg, an increase of 24% and 0.24 U/ μg an 
increase of 16% respectively in alkaline phosphatase activity (p<0.05) 
(Figure 4.5a). Similarly in cells harbouring a knock-down construct of ZnT5 a 
reduction in alkaline phosphatase activity from 0.15 U/μg of protein to 0.10 
U/μg (representing 31%) was found and in cells harbouring a ZnT6 knock-
down construct, 0.10 U/ μg (30%) reduction as compared to control cells was 
found (p<0.05) (Figure 4.5b). 
4.2.5 65 Zn accumulation 
To demonstrate the relative roles of ZnT5 and ZnT6 in zinc accumulation, 
overexpression and knock-down constructs were created, and zinc 
accumulation was measured up to one hour following the addition of 65Zn to 
  
Figure 4.5 Alkaline phosphatase activity 
TNAP of the total cellular protein was measured in cells containing 
overexpressing and knockdown constructs of ZnT5 and ZnT6 along with their 
controls (empty vectors). Activity was measured in U/μg of total protein. 
Overexpressing ZnT5 (O.E.5) and ZnT6 (O.E.6) showed significant increased 
activity as compared to controls (P<0.05) (a). Knockdown constructs of ZnT5 
(K.D.5) and ZnT6 (K.D.6) showed significant decrease in alkaline 
phosphatase activity compared to controls (P<0.05) (b). Each value is the 
mean ±S.D. of triplicate experiments. Stars indicate the statistically significant 
difference (P<0.05, t-test). 
 125 
 
 
 
 
 126 
 
cells. Cells overexpressing ZnT5 and ZnT6 showed no differences in 
accumulation of 65Zn, compared to controls at any given time point (p<0.05) 
(Figure 4.6b, 4.6d). Cells with knock-downs of ZnT5 and ZnT6 also showed 
no differences when compared to controls (P<0.05) (Figure 4.6a, 4.6c). 
Overall, all cells, irrespective of knockdown or overexpression status showed 
an increase in accumulation of zinc to 0.3 pmoles of Zn/μg protein at 60 
minutes. 
4.2.6 65 Zn Efflux 
Zinc efflux was measured at different time points from zero up to one hour in 
cells with overexpressed and knock-down constructs that had been treated 
with 65Zn for 24 hours, followed by replacement of 65Zn-containing medium 
with normal media. No statistical differences were observed between cells 
overexpressing ZnT5 and ZnT6 compared to their respective controls (Figure 
7b, 7d). Similarly no significant differences were observed between cells with 
knock-down constructs of ZnT5 and ZnT6 compared to empty vectors 
(p<0.05) (Figure 7a, 7c). 
  
Figure 4.6. 65Zinc accumulation 
Zinc accumulation was measured up to one hour starting from 0 minutes 
followed by 5, 10, 20 and 40 minutes in pmoles of Zn/μg protein. 
Overexpressing ZnT5 and ZnT6 cells showed no changes in accumulation of 
zinc, compared to controls at any given time point (p<0.05) (b, d).  ZnT5 and 
ZnT6 knockdown cells also showed no differences (p<0.05) (a, c). 
Knockdowns, overexpressions and controls, showed increase in 
accumulation of zinc starting from 0 pmoles of Zn/μg protein to 0.3 pmoles of 
Zn/μg by one hour. Each value is the mean ±S.D. of triplicate experiments. 
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Figure 4.7  65Zinc Efflux  
Zinc efflux was measured for overexpression and knockdown constructs of 
ZnT5 and ZnT6 and respective controls. After treatment 65Zn containing 
medium was replaced with normal media. No differences were observed 
between cells overexpressing ZnT5 and ZnT6 compared to their respective 
controls at any given time upto one hour (p<0.05) (b, d). Similarly there were 
no changes between knock-down ZnT5 and ZnT6 cells compared to empty 
vectors (p<0.05) (a, c). Each value is the mean ±S.D. of triplicate 
experiments. 
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4.3 Discussion 
In this study we have shown an interactive relationship between ZnT5 and 
ZnT6 at transcriptional and translational levels in human neuronal M17 cells.  
In M17 cells, expression of all members of the ZnT family has been 
previously reported, where ZnT6 showed highest expression level of mRNA 
relative to other family members (Suphiouglu et al., 2010). The results of my 
investigation on ZnT5 and ZnT6 interactions indicates a dependency of ZnT6 
on ZnT5, where an overexpression construct containing the ZnT5 gene 
induced a significantly higher expression of ZnT6 gene at both the 
transcriptional (3 fold increase) and translational levels (105% increase). 
Additionally M17 cells with knockdown constructs of ZnT5 produced down-
regulation of ZnT6 gene at transcriptional (57% decrease) and translational 
(40% decrease) levels. 
The magnitude of the differences between the mRNA levels and protein 
expression are quite similar for both genes. In contrast to the dependence of 
ZnT6 on ZnT5, ZnT5 expression was not dependent on ZnT6. It is possible 
that ZnT5 can function independently from ZnT6 as well as participating in 
ZnT5/ZnT6 heterodimer function. ZnT5 is found in the β-cells of pancreas 
and involved in delivery of zinc into insulin granules (Kambe et al., 2002). 
Similarly another study has found that ZnT5 is involved in processing and 
activation of PKC (protein kinase C) and in Zn-mediated regulation of mast 
cell-dependent allergic responses (Nishida et al., 2009). There is no evidence 
for the involvement of ZnT6 in these processes. 
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ZnT6 lacks the His-rich region in the cytoplasmic loop between IV and V 
transmembrane domain (TMD) that is a characteristic feature of ZnT 
members. It also lacks two His residues in the transmembrane domain II and 
V (instead has leucine 60 and phenylalanine 201) that are highly conserved 
among all members and plays important role in zinc transport function 
(Kambe et al., 2004), instead ZnT6 has many potential protein kinase C and 
CK2 phosphorylation and N-glycosylation sites (Huang et al., 2002). 
Fukunaka et al., (2009) demonstrated by changing leucine and phenylalanine 
to conserved hydrophilic histidine residues (ZnT6L66H-F201H), that ZnT6 is not 
involved in the zinc binding site of the ZnT5/ZnT6 heterodimers and is 
unlikely to function in zinc transport across the cellular membrane. Another 
study from Ohana et al., (2009) demonstrated by direct measurement of zinc 
transport that ZnT5 is an essential component for zinc transport, where-as 
ZnT6 is catalytically non-functional. ZnT6 is not directly involved in transport 
of zinc but may function as a component that helps to facilitate the activity (as 
have phosphorylation and glycosylation sites) of ZnT5 in ZnT5/ZnT6 
heterodimer complex and hence zinc transport activity (Huang et al., 2002).  
Oligomerization is essential for zinc transport activity. Most ZnT transporters 
are thought to form homo-dimers. ZnT5, ZnT6 and ZnT7 have been 
demonstrated to work together in early secretory pathway (ESP), where 
ZnT7 forms homo-oligomers and ZnT5 and ZnT6 form heterodimers. A 
number of transporters form heterodimers as an essential function for their 
biological activity. For example Cis4/Zrg17 (Saccharomyces cerevisiae) and 
Msc2p/Zrg17p (Schizosacchaomyces pombe) form heterodimers in yeast, 
are homologues of ZnT5/ZnT6 and play crucial role in the early secretory 
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pathway in transport of zinc in endoplasmic reticulum and Golgi membranes 
(Ellis et al., 2005; Fang et al., 2008). A recent study demonstrated the 
possibility of ZnT3 and ZnT10 forming a hetero-oligomer although whether 
that complex is functional is not yet known (Patrushev et al., 2012). Hetero-
oligomeric complex formation is not only important for biological activity but 
could also play role in subcellular translocation. For example transporters 
ABCG5 and ABCG8, members of the ATP binding cassette, remain in 
endoplasmic reticulum when expressed alone and do not migrate to the 
plasma membrane for excretion of sterol out of the cell (into bile) without 
heterodimer formation (Graf et al., 2003), even though it's not the case for 
ZnT5 and ZnT6.  
ALP’s contain tightly bound zinc that is essential for the enzyme activity 
(Suzuki et al., 2005a). The TNAP activity was higher in cells containing ZnT5 
and ZnT6 over-expression constructs compared to their respective controls. 
Significant reduced TNAP activity was detected in cells with knockdown 
constructs of ZnT5 and ZnT6 genes. Similar to our results, in a previous 
study ~45% and ~20% TNAP reduction has been reported in ZnT5 and ZnT6 
knock-down cells respectively in chicken derived DT40 cells (Suzuki et al., 
2005b), while  ‘overexpression’ of ZnT5 had no effect on TNAP activity. The 
lack of effect of overexpression on TNAP in DT40 cells could be explained on 
the basis of tissue specificity, as these transporters may function differently in 
different cells. Furthermore, there may be redundancy between Zn 
transporters that could mask the individual effects of transporters. The DT40 
cell line derived from chicken lymphocytes has a high homologous 
recombination activity, where genetic recombination revealed an 
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unexpectedly high frequency of targeted integration into the homologous 
gene loci of DT40 and expresses most of the ZnT members and hence has 
been extensively used in the molecular study on the expression and 
interaction of the whole range of zinc transporters (Suzuki et al., 2005a).  
Evidence supports the concept that metal transporters perform other roles in 
addition to metal transport. For example the CTR1, copper transporter in 
Xenopus laevis plays a critical role in membrane associated fibroblast growth 
factor (FGF) signalling complex where it transduces FGF signals 
independently of copper levels (Haremaki et al., 2007). ZnT5/ZnT6 
heterodimers provide zinc for TNAP enzymatic activity in early secretory 
pathway (Fukunaka et al., 2009), in a similar way that ATP7A interacts 
directly with extracellular superoxide dismutase to supply copper in the early 
secretory pathway (Quin et al., 2006). Fukunaka et al. (2011) suggested the 
possibility that ZnT5/ZnT6 heterodimers are not only involved in supplying 
zinc for enzymatic activity but also for the stabilization of TNAP. He explained 
that the formation of these complexes activates TNAP with a two-step 
mechanism by regulating TNAP stability in ER (Endoplasmic Reticulum), 
which is independent of zinc transport activity and by providing zinc to TNAP 
in early secretory pathway (ESP) in the Golgi apparatus, where apo ALP’s 
(non-active form) gets converted to holo ALP’s (active form) after getting zinc 
(Suzuki et al., 2005b). Stored zinc in the early secretory pathway may be 
transported from intracellular compartments to the cytosol for different 
physiological functions by ZIPs (Yamasaki et al., 2007) or other zinc 
transporting proteins like calcium channels where L-Type calcium Channel 
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(LTCC) α1D subunit located on endoplasmic reticulum membrane acts as a 
gatekeeper for zinc wave; (Yamasaki et al., 2012). 
Consistant with our study, a 55 kDa band size was detected for ZnT5 in 
different human derived cell lines, larynx carcinoma (Hep-2), cervix 
carcinoma (HeLa), placental choriocarcinoma (JAR) (Kambe et al., 2002). In 
mouse study band sizes of 51 and ~55 kDa were detected in brain and lung 
respectively for ZnT6 as compared to 57 kDa size in present study, such 
differences have been attributed to posttranslational modifications (Huang et 
al., 2002). 
Immuno-localization indicates that ZnT5 and ZnT6 proteins are located within 
the interior of the cell. Similar cytoplasmic vesicular and perinuclear 
localization was observed for ZnT5 and ZnT6 in Hep2 and HeLa cells (Suzuki 
T., 2005b). An increase in intensity of label was observed in cells with 
overexpression constructs of ZnT5 and ZnT6 genes compared to wild type 
cells. The signal was strongest near the nucleus and was similar in 
appearance to that previously report, where a Golgi marker GM130, 
overlapped with ZnT5 (Kambe et al., 2002; Nishida et al., 2009). Similarly a 
decreased signal was observed in cells with knock-down constructs, 
compared to wild type cells, for both genes. No differences in localization 
were detected in cells with ZnT5 overexpression and knock-down constructs 
for ZnT6 expression and vice versa. This observation is consistent with 
previous study where subcellular localization of ZnT5 and ZnT6 was the 
same when they were expressed alone or together (co-localization) (Suzuki 
et al., 2005b). The results indicate that even though these transporters show 
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some extent of dependency on each other, this interaction is not impacting 
their localization in the neuronal cells. 
We investigated a function for the zinc transporters ZnT5 and ZnT6 in M17 
neuronal cells for a role in the accumulation and efflux of zinc using 65Zn. 
Knock-down and overexpression constructs of ZnT5 and ZnT6 genes did not 
affect cellular zinc accumulation or efflux over a period of 1 hour (Figure 4.6, 
4.7). This result suggests that both transporters are not working at the 
plasma membrane. Previous studies support these findings showing that 
overexpression of ZnT5 and ZnT6 did not make the cells resistant to high 
concentrations of zinc indicated by a growth inhibition analysis in yeast 
(Kambe et al., 2002). Similarly in another study, knockouts of ZnT5 and ZnT6 
showed no significant changes in the total cellular zinc contents as compared 
to wild type cells (Suzuki et al., 2005). This observation is in contrast to that 
found for the copper transporters ATP7A and ATP7B where overexpression 
results in cell resistance to excess copper (Petris et al., 1996). 
No changes observed with 65Zn experiment between overexpression, 
knockdown and wild type constructs at any time point up to one hour 
suggests that these transporters are not likely to be working in the early zinc 
pathway. A theory classifies intracellular zinc signals into two categories 
EZS, early transcription independent zinc signalling and LZS, late 
transcription dependent zinc signalling (Hirano et al., 2008). EZS occurs in 
the zinc wave where zinc levels in cell change rapidly within several minutes 
with extracellular stimulation (Yamasaki et al., 2007). In LZS the extracellular 
stimulus can affect intracellular signalling pathways by changing the 
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intracellular zinc levels mediated by changing the expression of zinc 
transporters. This theory is consistent with our results observed discussed in 
chapter 5, where external stimulus (DHA) changed the zinc fluxes after 48 
hours. To relate these transporters to late transcription dependent zinc 
signalling, our radiolabeled studies need to be extended for at least few 
hours.  
We attempted to prepare double knockdowns of ZnT5 and ZnT6 to study the 
effect of removal of both proteins from the cells but our persistent attempts 
were unsuccessful. In particular cells harbouring ZnT5 knockdowns did not 
last more than three passages which indicates the importance of this 
transporter for cell survival. This suggests that ZnT5 and ZnT6 may function 
as a heterodimer in neuronal cells, similar to that found in other cells.  
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4.4 Conclusion  
In summary, we conclude that ZnT5 and ZnT6 may function as a heterodimer 
in neuronal cells, similar to that found in other cells. The ZnT5/ZnT6 
heterodimer most likely has a role in transporting zinc in the secretory 
pathway as the activity of ALP depends on both ZnT5 and ZnT6 expression. 
ZnT6 expression was altered in ZnT5 knock out and overexpression cells, 
suggesting some interdependency of ZnT6 on ZnT5. Both ZnT5 and ZnT6 
may also function independently. The possibility of ZnT6 performing 
additional functions in addition to form heterodimer with ZnT5, is suggested 
by the number of splice variants reported in neuronal cells in chapter 5. To 
our knowledge this is the first study on ZnT5/ZnT6 co-dependency to be 
carried out with human neuronal cells. 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
Effect of Zinc and DHA on 
hZnT5 and hZnT6 transporters 
in neuronal cells  
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5.1 INTRODUCTION 
 
The omega-3 polyunsaturated fatty acids (PUFA) are important components 
of the human diet as they cannot be synthesized by mammals (Sinclair et al., 
2002). The mammalian brain is rich in PUFA. DHA is the main PUFA in brain 
and makes up approximately 3% of the dry weight of the human brain 
(Svennerholm et al., 1968). It has been demonstrated in a rat study where 
the impaired brain functions due to DHA deficiency (rats fed on very low DHA 
diet) can be recovered when DHA levels return to normal (Moriguchi and 
Salem, 2003). In cultured rodent neuronal cells, DHA protects cells from 
apoptotic death induced by serum deprivation (Kim et al., 2000) with an anti 
apoptotic effect that was DHA-specific. DHA also helps in promoting 
differentiation of developing photoreceptors (Rotstein et al., 1997). 
Both DHA (docosahexaenoic acid) and zinc play crucial role in brain function. 
Alterations in DHA levels and zinc homeostasis are key features of 
degenerative brain disorders (Garcia and Kim, 1997; Cuajungco and Faget, 
2003). A link between zinc and PUFA metabolism is established, where the 
clinical symptoms of zinc deficiency and PUFA deficiency are similar. There 
is a link between DHA deficiency and altered zinc homeostasis in the brain of 
rats fed on a DHA-deficient diet, that resulted in high hippocampal zinc levels 
(Jayasooriya et al., 2005). Although these studies demonstrated a 
relationship between DHA metabolism and zinc homeostasis, the molecular 
mechanisms of this interaction have not been clearly understood. 
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Zinc homeostasis in the brain, including the uptake and efflux of zinc from 
cells, is regulated by membrane-bound zinc transporters. Such transporters 
belong to members of the solute carrier 39 (SLC39) also known as Zip’s and 
the solute carrier 30 (SLC30) or ZnT’s, respectively (Overbeck, 2008). 
Differential expression of zinc transporters has been reported in the brain. 
ZnT6 mRNA levels are higher in cortical regions of patients with Alzheimer 
disease (Beyer et al., 2012). Increased ZnT6 expression was demonstrated 
in the hippocampus gyrus of early and late Alzheimer disease subjects along 
with a trend towards a significant elevation in mild cognitive impairment, 
compared to age matched controls (Smith et al., 2006). An elevation of ZnT6 
in hippocampus gyrus and cerebellum was also observed in preclinical 
Alzheimer’s (Lyubartseva et al., 2010). Another study also found an 
association of ZnT6 with neurofibrillary tangles (Leung et al., 2008). Among 
all zinc efflux transporters, ZnT5 showed the strongest immunoreaction in A-
beta positive plaques of cerebral cortex from Alzheimer’s patient (zhang et 
al., 2008).  
In our previous study, we reported that zinc transporters were expressed in 
human neuronal M17 cells and ZnT6 transporter was highly expressed 
relative to other ZnT’s (Suphioglu et al., 2010). The reduced zinc uptake and 
low intracellular levels of zinc in the DHA-treated cells was associated with a 
reduction in the expression of ZnT3, a zinc transporter that regulates 
vesicular zinc storage in neuronal cells (Suphioglu et al., 2010). ZnT5 and 
ZnT6 have also been proven to form heterodimers and are known to function 
together in transportation of zinc (Fukunaka et al., 2011). In neuronal NT2 
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cells, zinc deficiency impaired the ability of retinoic acid (that acts similar to 
DHA), to induce differentiation (Gower winter et al., 2013).  
The aim of the current study was to explore the molecular basis of the link 
between the omega-3 fatty acid DHA and zinc metabolism through hZnT5 
and hZnT6 transporters. 
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5.2 RESULTS 
5.2.1 Pre-treatment of neuronal cells with DHA induced zinc 
efflux 
To test the effect of incorporated DHA on zinc efflux from cells, M17 cells 
were grown with (20 μg/ml) and without (0 μg/ml) DHA enriched medium for 
48 hours. Cells were then grown in 65Zn and further incubated for 18 hours, 
with or without DHA. The culture medium was then replaced with medium 
containing no 65Zn and cellular zinc efflux was measured over a period of one 
hour. M17 that had been pre-treated with DHA showed an increased level of 
zinc efflux, relative to untreated cells (Figure 5.1). Zinc efflux was measured 
in pico moles (pm) of zinc per μg of DNA. At time 0 mins, the zinc 
concentration in the culture media was less in DHA treated cells as 
compared to untreated cells (+DHA 28.1±0.2 pm Zn/μg DNA; -DHA 41.6±2.5 
pm Zn/μg DNA) (P<0.05) but at time intervals from 2 mins (+DHA 45±1.1 pm 
Zn/μg DNA; -DHA 35.1±0.3 pm Zn/μg DNA), 5 mins (+DHA 59.7±1.7 pm 
Zn/μg DNA; -DHA 53.1±0.6 pm Zn/μg DNA), 20mins (+DHA 94.3±0.1 pm 
Zn/μg DNA; -DHA 79.5±1.9 pm Zn/μg DNA) to 60 mins (+DHA 104.1±0.8 pm 
Zn/μg DNA; -DHA 77.7±0.9 pm Zn/μg DNA) mins the efflux of 65Zn was 
progressively greater in the cells treated with DHA as compared to untreated 
cells (P<0.05). At a time interval of 10 mins the changes in Zn efflux between 
+DHA and –DHA were not significant (+DHA 65.3±2.0 pm Zn/μg DNA; -DHA 
61.2±1.6 pm Zn/μg DNA) (P>0.05). 
  
Figure 5.1 65Zinc efflux studies 
M17 cells cultured in DHA-enriched medium (20 μg/ml) or control medium (0 
μg/ml) for 2 days were incubated for 18 hours in culture medium containing 
radiolabelled 65Zn, with or without DHA. The culture medium was replaced 
with medium containing no 65Zn and cellular 65Zn efflux was measured in 
pmol/μg DNA over a period of one hour. M17 cells that had been pre-treated 
with DHA (solid bars) showed an increased level of zinc efflux in media, 
relative to untreated cells (open bars) at different time points. The data are 
shown as means (n = 3, *p<0.05). 
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5.2.2 DHA treatment reduced intracellular pools of labile zinc 
Neuronal M17 cells were tested for the presence of labile zinc pools using 
Zinquin after treating with zinc and DHA as described in Materials and 
Methods section. Granular cytoplasmic labelling was observed for Zinquin in 
all cells tested (Figure 5.2A, 5.2B). Significant differences were found 
between control cells with no treatment (Figure 5.2Aa) where very weak 
granular cytoplasmic label was observed that was in contrast to a strong 
labelling visible in cells treated with10 PM zinc for 30 mins (Figure 5.2Ab) and 
cells treated with 10 PM zinc for 30 mins followed by 15 Pg/ml DHA for 30 
mins (Figure 5.2Ac) where almost no visible labelling was detected. Addition 
of DHA caused significant reduction in the granular cytoplasmic labelling 
(free zinc inside the cell) (Figure 5.2Ac). To confirm these results DHA 
containing media was removed and cells were again incubated with normal 
media for 3, 6, 9 and 24 hours. The strength of Zinquin staining was 
progressively increased with the incubation time (Figure 5.2B). At 24 hours 
incubation in normal media, the staining was almost regained to original 
strength of control cells (Figure 5.2Bg).  
5.2.3 DHA treatments enhanced neurite outgrowth 
Along with release of zinc from the cells after incubation with DHA, we 
observed another interesting aspect of DHA treatment, increase in the length 
of the neuronal cells extensions, a process called neurulation (Ikemoto et al., 
1997, Frances et al., 2004).  
  
Figure 5.2 Intracellular pools of labile zinc.  
Neuronal M17 cells grown on cover slips with and without 10 PM of zinc, and 
15 μg/ml DHA were incubated for 30 mins in 5 PM Zinquin. Labile zinc was 
detected with UV filter range 365 to 395nm using Olympus microscope. 
Maximum labile zinc was observed in cells treated with 10 PM zinc (Ab) 
followed by no treatment (Aa) and 10 PM zinc followed by 15 Pg/ml DHA 
(Ac). A gradual increase of labile zinc labelling was seen in recovered DHA 
treated cells at 3 hours (Bd), 6 hours (Be), 9 hours (Bf) and 24 hours (Bg) 
after replacing DHA enriched media with normal media. Scale bar represents 
10μm.
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With supplementation of DHA to M17 neuronal cells, not only neurite length 
increased but also the number of branches per neuron increased (Figure 
5.3b, 5.3d). Addition of zinc to the cells did not change the effect of DHA on 
neurite length (Figure 5.3c). 
5.2.4 hZnT5 and hZnT6 contains DHA regulatory elements in 
their promoter regions 
Greater efflux of zinc in DHA treated neuronal cells along with reduction in 
Zinquin labelling in these cells indicate that DHA might play a role in zinc 
fluxes. As zinc fluxes are mediated by zinc transporters, hZnT5 and hZnT6 
efflux transporters were analysed for the presence of RAREs (Retinoic Acid 
Responsive Elements) and MRE (Metal Responsive Element). RXR is a 
member of nuclear hormone receptors family that comprises ligand activated 
transcription factors. RXR binds to target genes at specific DNA sequence 
called RAREs to promote transcription, resulting increase in target genes 
expression (Blomhoff, 2006). DHA acts as an agonist to RA (Retinoic Acid) 
and has been demonstrated to work as an endogenous ligand for the 
activation of RXR (De Urquiza et al., 2000). The DHA binding motif, called 
RAREs, with core sequence hexad (Ra/gGKg/tTCA) that can be configured 
into variety of structured motifs (Glass, 1994) was identified in promoter 
region of both hZnT5 and hZnT6 genes at specified positions along with MRE 
(Metal Responsive Element) with core sequence (TGCRa/gCNC) starting 
from the start codon. Multiple copies of core sequence of MRE’s (2, 3) and 
RARE’s (3, 7) were found in 4000 bp upstream in the promoter region for 
hZnT5 and hZnT6 respectively at specified positions (Figure 5.4a, 5.4b).
  
Figure 5.3 Impact of DHA on morphology of M17 neuronal 
cells 
Neuronal M17 cells cultured with and without DHA showed increased neurite 
length along with more individual branches per neuron with DHA 
supplementation as compared to DHA free media (b,d). The addition of zinc 
had no influence on DHA induced neurite growth (a,c). 
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Figure 5.4 RAREs and MREs in the promoter region of hZnT5 
and hZnT6 
Diagrammatic representation of binding sites for important transcription 
binding factors for DHA and metals (zinc in this study), RAREs (Retinoic Acid 
Responsive Elements with conserved consensus sequence Ra/gGKg/tTCA) 
and MREs (Metal Responsive Elements with conserved consensus sequence 
TGCRa/gCNa/g/t/cC) at different positions in the promoter region (4000 bp) 
upstream of the translation start point for hZnT5 (a) and hZnT6 (b) genes. 
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5.2.5 hZnT5 and hZnT6 mRNA levels were influenced by DHA 
and zinc  
To investigate if treatment with DHA changed the transcriptional levels of 
ZnT5 and ZnT6, mRNA expression levels of both transporters were 
measured in control cells and cells exposed to different zinc and DHA 
treatments (as described in Materials and Methods section 2.5) using real-
time quantitative PCR. No differences in the mRNA expression levels of 
hZnT5 and hZnT6 were found between cells exposed to different DHA 
treatment without zinc (p>0.05, t-test) (Figure 5.5a, 5.5b). The addition of 5 
μM of zinc added to the culture medium together with different amounts of 
DHA, produced increase in expression for both hZnT5 and hZnT6 genes with 
increase in DHA concentrations. At 5 μg/ml and 10 μg/ml of DHA, increased 
trend in mRNA expression was observed but was not significant (p>0.05, t-
test). Significant increased expression was observed for hZnT5 and hZnT6 
genes at 15 μg/ml (1.4; 1 fold increase) (2.40±0.35; 1.89±0.17) and 20 μg/ml 
(1.7; 1.7 fold increase) (2.72±0.19; 2.57±0.38) (p<0.05, t-test) DHA levels 
respectively (Figure 5.5a, 5.5b). Similar results were also observed with 
another neuronal cell line SY5Y (data not shown). Retinoic Acid (RA) induced 
differentiated M17 cells were also analysed by real time PCR to check the 
effect of differentiation on mRNA expression levels for hZnT5 and hZnT6 
genes but similar results as for undifferentiated cells were observed (data not 
shown).
 
  
Figure 5.5 SYBR-Green Real-time RT-PCR analysis of hZnT5 
and hZnT6 mRNA from Zinc and DHA treated M17 
neuronal cells 
Comparison of the hZnT5 and hZnT6 mRNA expression levels between no 
zinc and different DHA treated cells revealed no significant differences 
(p!0.05, t-test). With addition of 5 μM of zinc to different DHA treatments 
significant increase was observed at 15 μg/ml and 20 μg/ml of DHA for hZnT5 
and hZnT6 genes (p<0.05, t-test). No significant increase or decrease in 
mRNA expression level was detected at 5 μg/ml and 10 μg/ml DHA treatment 
with 5 μM zinc (p>0.05, t-test) (a, b). 
The 'CT was calculated by subtracting the E-actin cycle threshold (CT) value 
(the cycle number in which the fluorescence emitted exceeds the threshold 
level) from that of the hZnT5 and hZnT6. Relative RNA expression levels of 
each sample was calculated using the equation 2-∆∆CT, where ∆∆CT is a 
difference between the treated (DHA treatments) ∆CT and control ∆CT. All 
data presented are the results of 3 independent experiments. The data are 
shown as means (n = 3, *p<0.05). 
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To check the influence of vitamin E on DHA treatments, cell pellets collected 
from different DHA and vitamin E treatments were analysed for hZnT5 and 
hZnT6 by quantitative real time PCR analysis.  
No significant mRNA differences were detected between –DHA ± vitamin E 
(1.03±0.03; 1.08±0.14) for ZnT5 (1.05±0.14; 1.17±0.11) for ZnT6 (p>0.05, t-
test) and +DHA ± vitamin E (0.97±0.09; 1.08±0.03) for ZnT5 (1.09±0.19; 
1.35±0.05) for ZnT6 (p>0.05, t-test) (Figure 5.6a, 5.6b). As vitamin E did not 
impact the results of DHA treatment, vitamin E was not added in subsequent 
experiments. 
The control reactions lacking either primers and or template cDNA were 
negative for all analysed samples. The dissociation curve analysis of all PCR 
products revealed the single peaks of expected Tm (data not shown), 
confirming the specificity of all designed primers.  
5.2.6 High doses of DHA in presence of zinc increased the 
protein expression of hZnT5 and hZnT6  
To determine if the described above changes in mRNA levels translated to 
different protein products, expression levels of hZnT5 and hZnT6 proteins 
were analysed in all DHA treated cells with and without zinc for 48 hours, 
using two different monoclonal antibodies (Materials and Methods section 
2.8). The hZnT5 antibody produced a major 55 kDa band in all lanes 
representing different treatments (Figure 5.7a). A major 57 kDa size band 
was detected for different treatments using hZnT6 antibody (Figure 5.7b). 
  
Figure 5.6 SYBR-Green Real-time RT-PCR analysis of hZnT5 
and hZnT6 mRNA from Vitamin E and DHA treated 
M17 neuronal cells 
Comparison of the hZnT5 and hZnT6 mRNA expression levels between no 
zinc and different DHA treated cells revealed no significant differences 
(p!0.05, t-test). With addition of 5 μM of zinc to different DHA treatments 
significant increase was observed at 15 μg/ml and 20 μg/ml of DHA for hZnT5 
and hZnT6 genes (p<0.05, t-test). No significant increase or decrease in 
mRNA expression level was detected at 5 μg/ml and 10 μg/ml DHA treatment 
with 5 μM zinc (p>0.05, t-test) (a, b). 
Vitamin E addition showed no significant changes to mRNA expression levels 
with or without addition of DHA (p>0.05, t-test) (a, b). 
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Figure 5.7 Western blot analysis of proteins from zinc and 
DHA treated M17 neuronal cells 
Expression levels of hZnT5 and hZnT6 protein were analyzed using hZnT5 
and hZnT6 antibodies. A predicted band size of 55 KDa and 57 KDa for 
hZnT5 and hZnT6 respectively were present for all different treatments of 
zinc and DHA (a, b top lane). The expression levels of a human β-actin along 
with ponceau S staining was used to indicate the relative levels of protein 
loaded on the gel (a, b middle lane). Densitometry analysis showed 
significant differences with (p<0.05, t-test) at 15 μg/ml and 20 μg/ml of DHA 
for hZnT5 and hZnT6 genes with consistent 5 μM of zinc in the culture 
medium (a, b bottom bar graph). Overall increase expression was observed 
with increase in the amount of DHA in presence of zinc for both genes but at 
5 μg/ml and 10 μg/ml the differences were not significant. Data is 
representative of three similar independent experiments. The data are shown 
as means (n = 3, *p<0.05) . 
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Consistent with real time results no significant changes were detected with 
different treatments of DHA without additional zinc added to the culture 
medium (p>0.05, t-test). Significant differences were observed at 10 μg/ml 
(50% increase; non-significant for hZnT6) (140±3.5), 15 μg/ml (85%; 80% 
increase) (185±7.07; 180±0.70) and 20 μg/ml (118%; 135% increase) 
(218±10.60; 235±7.77) of DHA for hZnT5 and hZnT6 respectively in 
presence of 5 μM of Zn (p<0.05, t-test). No changes were detected at 5 
μg/ml for hZnT5 and 5 μg/ml and 10 μg/ml DHA for hZnT6 in presence of 5 
μM Zn (p>0.05, t-test).  
Ponceau S stain was used to check relative levels of proteins transferred to 
the membrane. A housekeeping control protein, E-actin expression was also 
tested and used as a loading control.  
5.2.7 DHA does not affect localisation of hZnT5 and hZnT6 in 
M17 neuronal cells 
Confocal images were obtained following different zinc and DHA treatments 
of M17 cells using hZnT5 and hZnT6 antibodies to determine the intracellular 
localization of these transporters. The transporters were distributed evenly in 
cytoplasm showing a vesicular pattern possibly associated with zincosomes 
(Zaleweski et al., 1993) that store labile zinc inside the cell. DHA treatment 
had no effect on the localisation of the hZnT5 (Figure 5.8a,b,c,d,e,f) and 
hZnT6 (Figure 5.8g,h,i,j,k,l) zinc transporters as for all different treatments, 
granular distribution throughout the cytoplasm with some perinuclear 
localisation was observed.  
  
Figure 5.8 Immunofluoresence analysis of hZnT5 and hZnT6 
protein localisation in M17 neuronal cells 
Neuronal M17 cells treated with 0 μM Zn 0 μg/ml DHA (a,g), 0 μM Zn 10 
μg/ml DHA (b,h), 0 μM Zn 20 μg/ml DHA (c,i), 5 μM Zn 0 μg/ml DHA (d,j), 5 
μM Zn 10 μg/ml DHA (e,k), 5 μM Zn 20 μg/ml DHA (f,l) for 48 hours and 
grown in 8 well Ibidi chambers were stained with hZnT5 and hZnT6 
antibodies followed by fluorescent secondary antibody conjugated with Alexa 
488. Images shows granular cytoplasmic and peri nuclear localization of 
hZnT5 (a,b,c,d,e,f) and hZnT6 (g,h,I,j,k,l). Different DHA treatments in and 
absence of Zn did not change the protein localisation in cells for hZnt5 and 
hZnT6. Scale bar represent 20 μm. 
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5.2.8 DHA does not influence the alkaline phosphatase 
activity 
Alkaline phosphatase activity assay has been used as an indicator of 
enzymatically available intracellular zinc levels (Fukunaka et al, 2009). 
Collected pellets were lysed with lysis buffer and total alkaline phosphatase 
activity was detected at 405 nm wave length using p-nitrophenol as a 
substrate in M17 cells exposed to different DHA and zinc treatments for 2 
days. No significant differences were found between controls and any of the 
treatments (p>0.05, t-test) (Figure 5.9).  
5.2.9 hZnT5 and hZnT6 predicted variants in M17 neuronal 
cells by RT-PCR  
M17 neuronal cells with different DHA and zinc treatments were analysed for 
an effect of DHA on alternative splice variants of hZnT5 and hZnT6 genes. 
Different fragments covering the full ORF (Open Reading Frame) of hZnT5 
and hZnT6 genes showing major band representing full length fragment 
along with additional bands present were analysed irrespective of zinc and 
DHA treatments (Figure 5.10.1, 5.10.2). This confirmed that DHA was not 
influencing alternative splicing of ZnT5 and ZnT6. The bands shown in figure 
could be novel splice variants associated specifically to neuronal cells. 
Individual band sizes from different fragments were matched to intron-exon 
map of full length expressed transcript from published NCBI database. 
  
Figure 5.9 Alkaline phosphatase activity 
To measure activity cell lysates were incubated with p-nitrophenyl substrate 
following treatments with DHA and zinc for 48 hours. Total alkaline 
phosphatase activity was detected at 405 nm wave length. First five lanes 
with no zinc and increasing DHA levels from 0, 5, 10, 15 and 20 μg/ml and  
second five lanes with consistent 5μM zinc and increasing levels of DHA as 
before showed no significant differences (p>0.05, t-test) . All data presented 
are the results of 3 independent experiments. The data are shown as means 
(n = 3, *p<0.05).  
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Figure 5.10.1 Predicted variants for hZnT5 gene. 
To see the effect of DHA, the full length of hZnT5 gene using three different 
primer pairs was amplified by RT-PCR using cDNA from different treatments 
of DHA with and without zinc for 48 hours as explained in section 2.6.  
No differences were observed between cells with different treatments of DHA 
and zinc, but additional bands (possible variants) were observed in gels for 
hZnT5 gene along with full length gene. Individual band sizes from different 
fragments were matched to intron-exon map of full length expressed 
transcript from published NCBI data-base for hZnT5. After confirming the 
sizes with NCBI sequences, all additional bands in gels correspond to 
possible splice variants. 
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Figure 5.10.2 Predicted variants for hZnT6 gene 
The full length of hZnT6 gene was amplified using two different primer pairs 
by RT-PCR using cDNA from different treatments of DHA with and without 
zinc for 48 hours (section 2.6). 
No differences were observed between cells with different treatments of DHA 
and zinc, but additional bands (possible variants) were observed in agarose 
gels for hZnT6 gene along with full length expression. Individual band sizes 
from different fragments were matched to intron-exon map of full length 
expressed transcript from published NCBI data-base for hZnT6. After 
confirming the sizes with NCBI sequences, all additional bands in gels 
correspond to possible splice variants. 
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After comparing the sizes with NCBI sequences, all additional bands 
corresponding to possible splice variants were identified (Table 5.1). To 
further confirm that these additional bands are real splice variants, sequence 
analysis is required.  
  
Table 5.1 Splice variants generated by RT-PCR for hZnT5 and 
hZnT6 genes  
Table showing different predicted splice variants covering open reading 
frame (ORF) for hZnT5 and hZnT6 genes generated by reverse transcriptase 
PCR. Three and two separate fragments for ZnT5 and ZnT6 respectively 
were analysed using specific primers to cover the whole length of the genes. 
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hZnT5
Fragment 1 Fragment 2 Fragment 3
1113bp (Full length exons 1-9) 1127bp( Full length exon 9-13) 629bp( Full length exon 13-16)
990bp (Exon 2 missing) 998bp (Exon 12 missing) 501bp (Exon 15 missing)
749bp (Exon 2-5 missing) 841bp (exon 11, 12 missing)
hZnT6
Fragment 1 Fragment 2
1124bp (Full length exon 1-14) 759bp( Full length exon11-14)
1037bp (Exon 2 missing) 711bp (Exon 12 missing)
952bp (Exon 2,3 missing) 642bp (Exon 12, 13 missing)
909 (Exon2-4 missing)
726bp (Exon 2-7 missing)
362bp (Exon 2-10 missing)
340bp (Exon 2,9,12,14 missing)
259bp (Exon 2-13 missing)
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5.3 DISCUSSION 
The experiments described in the current chapter investigated the effect of 
DHA on the expression of the hZnT5 and hZnT6 transporters, previously 
reported to have a role in the mammalian brains (Lyubartseva et al., 2010; 
Smith et al., 2006; Zhang et al., 2008).  
M17 cells that had been treated for 48 hours with DHA and then incubated 
with 65Zn showed a 20% increase in zinc efflux in comparison to untreated 
cells. Previous experiments demonstrated the effect of DHA in cell culture, 
where DHA treatment of human neuronal M17 cells resulted in a decrease in 
the cellular uptake of 65Zn (Suphioglu et al., 2010). Consistent with this in 
vivo studies reported a link between DHA and brain zinc metabolism where 
mice raised on a DHA-deficient diet had higher hippocampal levels of free 
zinc than control animals and where the free zinc was sequestered in the 
brain tissue by up-regulation of ZnT3 transporter (Jayasooriya et al., 2005). 
A different technique was used to confirm the zinc movement in cultured M17 
cells where they were treated with the zinc fluorophore, Zinquin. Free zinc 
was predominantly detected in fluorescently labelled cytoplasmic granules, 
similar to that reported before "zincosomes" that are known to sequester free 
zinc (Zalewski et al, 1993). The level of fluorescence in the M17 cells was 
increased upon addition of 5μM extracellular zinc, indicating an increase in 
intracellular free zinc located in zincosomes. The addition of DHA to zinc 
treated cells resulted in a decrease of Zinquin fluorescence within first 30 
minutes and when the DHA was removed, the Zinquin fluorescence 
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increased over the next few hours and by 12 to 24 hours, it returned to levels 
seen in the absence of zinc. This is consistent with the 65Zn efflux results, an 
observation where DHA inhibits zinc uptake and promotes zinc efflux 
(Suphioglu et al., 2010). Removal of DHA resulted in restoration of the 
intracellular zinc which commenced within hours and was complete over 24 
hours. The cellular basis of the DHA effect is not clear but as it occurs over a 
relatively short time it may involve a direct effect on membrane dynamics 
rather than through an effect on gene expression. A direct effect of DHA on 
membrane structure/function is possible and this may regulate the function of 
transmembrane transporters including the ZnT’s but how specific this effect is 
not clear. It has been observed that hydroxyl derivative of DHA (2-
hydroxyldocosahexaenoic acid) OHDHA can change the brain membrane 
lipid composition by increasing the concentration of long chain PUFA in the 
brain of a transgenic mouse model of Alzheimer’s disease (Torres et al., 
2013). 
DHA may have long-term effects on cell membranes. An example of this is a 
study where the phosphatidylserine (PS) content was increased post 24 
hours DHA treatment and up to 48 hours and was found to modulate/facilitate 
signal transduction pathway in neuronal membranes (Kim et al., 2000). There 
are many examples of DHA-induced activation of molecules including DHA 
playing a role in signal transduction pathways by increasing the 
phosphatidylserine (PS) content in neuronal membranes which then can 
promote the activation of Raf-1 and PI-3 kinase pathways (Kim et al., 2000; 
Akbar and Kim 2002). Such evidence suggests that long term effect of DHA 
treatment could be mediated by the transporters. 
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DHA treatment induced neurite outgrowth and branch formation of M17 
neuronal cells that is consistent with previous reports. In vitro studies show 
DHA enhances the NGF-induced neurite growth in PC12 cells (Ikemoto et al., 
1997). DHA supplementation in cultured foetal mouse brain cells can 
stimulate the proliferation of neuronal cells (Bourre et at.,1983). Addition of 
DHA promotes the extension of neurite length and number of branches in rat 
hippocampal neuronal cells (Calderon and Kim 2004; Calderon and Kim 
2007). Raf-1 and PI-3 kinase pathways have been shown to be engaged in 
induction of neurite growth in H19-7 and PC12 hippocampal cell lines (Wood 
et al., 1993; Kuo et al., 1996; Kobayashi et al., 1997; Kita et al., 1998). 
Additionally following DHA deficiency, reduction of neurotrophic factor NGF in 
hippocampus reduced the neurite and dendrite development (Ikemoto et al., 
2000). The effect of the DHA may be to induce neurite outgrowth to maximise 
the cell surface area for uptake and efflux. 
Zinc treatment did not affect neurite outgrowth in our experiments on M17 
cells. However, Zip12 a putative zinc uptake transporter was needed for 
neurite growth in frog suggesting that zinc is required for neurite outgrowth in 
some systems (Chowandisai et al., 2012). The different transporters perform 
specific functions in different cell lines. ZnT3 stores zinc in the synaptic 
vesicles and ZnT5 and ZnT6 are known to provide zinc in trans-Golgi and 
endoplasmic reticulum for making it available for TNAP (Tissue Non-Specific 
Alkaline Phosphatase activity) which is then released into the cytoplasm, 
probably by ZIPs. Studies have been carried out in rodents where low dietary 
zinc intake in rats and mice impairs neurite outgrowth in the brain (Gao et al., 
2009; Dvergsten et al. 1984). CREB (Cyclic AMP Response Element-Binding 
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Protein) activity and neurite outgrowth are closely associated during neuronal 
differentiation. RA induces rapid CREB phosphorylation which is a critical 
step that controls CREB transcriptional activity and neurite outgrowth (Canon 
et al., 2004) 
The alterations of zinc fluxes may be mediated by members of the ZnT 
family, thus DHA may influence zinc transport via controlling zinc transporter 
expression. RARES are promoter sequences that are binding sites for RXR, 
a nuclear transcription factor/nuclear hormone receptor that can be activated 
by DHA (Lengqvist et al., 2004). RXR regulates many cellular processes 
including differentiation. RXR can bind to DNA as a homodimer, heterodimer 
with other nuclear receptors or as a monomer resulting in activation of 
different signalling pathways (Mangelsdorf and Evans, 1995) (Chen et al., 
1998). hZnT5 has three RAREs and hZnT6 has seven RAREs binding sites 
in the promoter region. Thus it is possible that DHA regulates ZnT5/ZnT6 
transcription and hence can influence zinc fluxes. 
The physiological effect of RXR action has been demonstrated where DHA 
was shown to be a natural endogenous ligand that binds directly to the LBD 
(Ligand Binding Domain) of RXR in mouse brain (De Urquiza et al., 2000). 
DHA has potential effects on RXR mediated gene transcription in vivo by 
playing an important role as an active signalling receptor complex (Lengqvist 
et al., 2004). RXR is also involved in nervous system development (Solomin 
et al., 1998; Mascrez et al., 1998). DHA is known to generate derivatives or 
metabolites during the cell culture that can activate RXR (Mukherjee et al., 
2004). 
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Toshiyuli (2011) proposed a theory, where intracellular signals can be 
affected by (EZS) transcription independent Early zinc Signalling and (LSZ) 
transcription dependent Late zinc Signalling. ESZ happens within several 
minutes upon extracellular stimulation and in LZS, intracellular zinc levels are 
altered several hours after extracellular stimulation, through changes in zinc 
transport expression. The external stimulus could be an RXR ligand eg DHA, 
that may induce the transcription of zinc transporters by activation of RXR in 
the LZS pathway, which occurs after few hours and is consistent with our 
results. In the presence of DHA that acts as a true RXR ligand, gene 
expression gets turned on by converting RXR apo-LBD (ligand binding 
domain) to the holo form thus activating the formation of co-activator 
complexes with histone acetyltranferase, to decompress/open chromatin that 
will initiate or trigger transcription and hence translation (Moras and 
Gronemeyer 1998) of ZnT5 and ZnT6 genes. Also this is supported by 
previous study where DHA induces histone acetylation (Sadli et al., 2012), 
and reduces hyperphosphorylation (Torres et al., 2013), but it still does not 
explain involvement of zinc in DHA dependent transcription. 
Zinc deficiency down-regulates the expression of RXR and impairs 
differentiation of human neuronal precursor cells (Gower-Winter et al., 2013).  
Reduced zinc availability impairs the ability of RXR to bind to response 
elements altering the transcription of target genes, which would reduce the 
ability of (RA) retinoic acid (agonist to DHA) to promote neuronal 
differentiation that is needed for the mouse development and adult 
neurogenesis (Morris and Levenson 2013). Zinc deficiency impairs the ability 
of retinoic acid to induce differentiation in the human neuronal cell line (NT2) 
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which confirms that zinc plays a vital role in cell differentiation in similar way 
as DHA (Gower-Winter et al., 2013). Furthermore zinc deficiency causes 
apoptosis in mouse brain (Gao et al., 2009). 
The zinc transporters ZnT5 and ZnT6 showed significant increased 
transcriptional and translational expression levels with high doses of DHA (15 
& 20μg/ml) in the presence of zinc. Our results suggest that zinc is required 
for the DHA effect and under physiological zinc (5μM) levels and high doses 
of DHA, DHA acts as a ligand and binds to RXR via LBD (Ligand Binding 
Domain) which further binds to DBD (DNA Binding Domain) which has a 
conserved consensus sequence complimentary to the RAREs present in the 
promoter region of hZnT5 and hZnT6 genes. Zinc being a metal binds to 
Metal Responsive Elements (MRE) and probably forms complexes with 
RAREs to initiates transcription and hence can affect the protein expression 
of these transporters.  
The 10 μM DHA increased hZnT5 expression but had no effect on hZnT6 
levels. Therefore the increased efflux in the presence of zinc could be a 
result of increased ZnT5 protein levels. ZnT5 and 6 are known to form 
heterodimers within the early secretory pathway and this oligomerization is 
required for their zinc transport function (Kambe T, 2012). The ZnT5/6 
heterodimer transports zinc from the cytosol into vesicles in HeLa cells 
(Kambe et al., 2002). ZnT6 is not directly involved in zinc transport across the 
cell membrane as it does not have a zinc-binding site within the TMDs due to 
the lack of conserved hydrophilic residues but it may function as a modulator 
(Fukunaka et al., 2009). Thus if one of either hZnT5 or hZnT6 protein is 
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reduced it may impair the function of the dimer in transporting zinc. 
α-Tocopherol (Vitamin E) is a lipid soluble antioxidant and has been found 
together with PUFA-enriched phospholipid domains of the cell membrane by 
co-localization studies (Atkinson et al., 2010). Vitamin E deficiency during 
embryogenesis depleted DHA and arachidonic acid, and increased hydroxy-
fatty acids derived from these PUFA, suggesting that vitamin E is necessary 
to protect these critical fatty acids (Lebold et al., 2013). To determine the 
effect of vitamin E on DHA treatments, cells were treated with and without 
DHA and vitamin E but no changes were observed with the addition of 
vitamin E.  
M17 cells showed no effect of DHA on ALP activity. This means that the 
increase in hZnT5 and hZnT6 caused by DHA does not affect the delivery of 
zinc to ALP and its subsequent function.  
DHA did not induce modifications in alternative splicing of hZnT5 and hZnT6 
nor did it alter the localisation of the proteins within cells. Both hZnT5 and 
hZnT6 proteins showed a granular cytoplasmic, perinuclear localization. 
Splice variants of ZnT5 affecting the 5’ and 3’ regions have previously been 
found in Caco-2 cells, where one form contained all 17 exons, while the other 
lacked exons 1, 2, 4 and exons 15-17, (Jackson et al., 2007; Thornton et al., 
2011). Even though no changes were observed in addition to DHA, RT–PCR 
of the coding regions did show additional splice variants along with full length 
expression indicating the possible additional roles of protein products of the 
splice variants for hZnT5 and hZnT6 transporters, in processes different than 
just pumping zinc in and out of the cell. 
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5.4 Conclusion 
Significant increase in efflux of zinc with addition of DHA indicates 
involvement of DHA in zinc transport across the plasma membrane. Higher 
mRNA and protein expression with higher doses of DHA in the presence of 
zinc suggests that DHA acts as a ligand for the activation of RXR which then 
could turn on gene expression by interaction with RAREs and MREs present 
within close proximity of transcription binding factor complexes in the 
promoter region of ZnT5 and ZnT6 genes. There appears to be a short-term 
effect of DHA visualised by Zinquin staining, but there may also be possible 
longer-term effects mediated by ZnT5 protein.  
 
  
  
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
In silico molecular 
characterization of ZnT family 
members
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6.1 Introduction 
Zinc transporters in mammals are classified into two metal transporter 
families, the ZIP (ZRT/IRT-like proteins) and Cation Diffusion Facilitator (CDF 
families) (Kambe et al., 2004; Liuzzi & Cousins, 2004). In bacteria, the ABC 
transporters and P-type ATPases have been shown to function as zinc 
transporters (Hantke K, 2001) but neither of them plays a physiological role in 
zinc transport in eukaryotes (Gaither et al., 2001).  
The Cation Diffusion Facilitator family was first established as a group that 
encoded proteins that confer metal resistance to cells (Nies and Silver, 
1995). The members of this large superfamily share similar topology across 
diverse range of organisms including bacteria, fungi, nematodes, insects, 
plants and mammals (Haney et al., 2005). The CDF family is also assigned 
as solute carrier 30 (SLC30A). More than 100 members of the SLC30 family 
are found in organisms at all phylogenetic levels. This family is divided into 
three subfamilies. Subfamily I consists a large proportion of prokaryotic 
members, whereas subfamily II and III contains eukaryotic and prokaryotic 
members in a similar proportion (Gaither and Eide, 2001). 
Ten different SLC30A (ZnT) members have been reported to date that 
belong to the Zn-CDF group of CDF superfamily (Mountanini et al., 2007). 
ZnT transporters are considered to mobilize zinc under physiological 
conditions across the biological membranes (Fukada & Kambe, 2011; 
Montanini et al., 2007). However recent reports have suggested that ZnT10 
plays an important role as a manganese (Mn) transporter as when defective, 
this gene causes Mn accumulation in liver and brain (Quadri et al., 2012; 
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Tuschl et al., 2012). Similarly ZnT4 can bind to other divalent cations such as 
copper, nickel and cobalt (Murgia et al., 1999). 
The x-ray structures of ZnT members have not yet been confirmed but 
sequence homology to the Yiip crystal structure in E.coli helped researchers 
to understand the function of these transporters (Lu and Fu, 2007). 
Fluorescent imaging showed mammalian ZnT-mediated zinc transport is 
catalysed by H+/Zn2+ exchange and identify the zinc binding site of ZnT 
proteins that are essential for zinc transport (Ohana et al., 2009). Similar 
studies in bacteria, yeast and plant ZnT homologues support this notion 
(Guffanti et al., 2002; Kawachi et al., 2008; MacDiarmid et al., 2002).  
The main aim of this study is to understand the relationship between different 
members of ZNT family on the basis of their structure and similarity not just 
by comparing with the coding region but by taking into the consideration of 
important regulatory factors present in the promoter region. An analysis was 
carried out on all members of the ZnT family using different softwares, for 
prediction of their structure and transmembrane domains after comparing 
sequence homology to YiiP. In the current study both coding and promoter 
regions were analysed to characterize individual members within different 
families. Other factors that played an important role in the overall regulation 
of these genes/transporters were also considered as the part of analysis that 
include transcription binding factors and microRNA’s. 
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6.2 RESULTS 
6.2.1 Characteristic features of ZnT family members 
A total of 10 different members of ZnT family have been characterised so far. 
All members are present on different chromosomes either on the minus or 
plus strand of the DNA. Most ZnT genes encode for one transcript but there 
are some that can have different variants, for example ZnT2 (SLC30A2) and 
ZnT5 (SLC30A5) have 2 variants and ZnT6 (SLC30A6) have 3 variants.  
A characteristic feature of this family is the presence of 6 transmembrane 
domains (TMD) with the exception of ZnT5 (SLC30A5) that has 15 and ZnT3 
(SLC30A3) with 4 TMD. All members of the family have different no of exons 
that give rise to total amino acid sequence (Table-6.1).  
Out of ten distinct ZnTs, ZnT9 has not been described in detail, hence exon–
intron structure analysis was performed in the current study. A schematic 
presentation of ZnT9 showed a total of 18 exons located on chromosome 4 
at the plus strand encoding 568 amino acids (Figure 6.1). The total length of 
the exons in base pairs (bp) is provided underneath the boxes. 
6.2.2 Transmembrane domain (TMD) analysis of ZnT members 
Transmembrane domains were analysed using TMHMM (Transmembrane 
Hidden Markov Model) online database. The characteristic feature of ZnT 
family members is the presence of 6 TMD with both C and N terminals facing 
the cytoplasmic side (Figure 6.2a).  
  
Table 6.1 Characteristic features of ZnT family members. 
10 members of ZnT family were analysed to show their position on 
chromosome, number.of exons, transmembrane domains (TMD), number of 
variants and total number of amino acids contributing to the full length 
protein. 
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Figure 6.1 Diagram to illustrate Intron-Exon structure of ZnT9 
A total of 18 exons of ZnT9 gene interspersed by introns were found on 
chromosome 4. The width of the exon boxes represents the length of 
individual exons. The exact length in base pairs (bp) of each exon is written 
underneath the box. 
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Figure 6.2 Analysis of transmembrane domains of ZnT 
members 
(ai) Six transmembrane domains of the ZnT members is shown in red, 
cytoplasmic loops and C and N terminals are shown in blue and green 
fragments represents extracellular loops. 
(aii) The exact location of start and finish of transmembrane domain, inside 
and outside loops for all ZnT members is compiled in table form. TMD2 and 
TMD6 are highlighted for ZnT3 as low probability prediction by using TMHMM 
software. Allocation of ZnT members in four different Groups on the basis of 
TMD analysis is shown by different colours shading. 
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Using TMHMM data base, most of the members comply with the 
characteristic feature of having six TMD with following exceptions: ZnT3 
having 4 TMD with high probability and 2 with low probability, ZnT9 with 5 
TMD and very unusual ZnT5 with 15 TMD (Figure 6.2.1b, 6.2.2c, 6.2.3d). To 
confirm the probability of unusual numbers of TMD’s, another software called 
TOPCONS was used for the prediction. Six TMD were predicted for ZnT3 
with two additional TMD number 2 and 6 that were predicted with low 
probability while the other four were predicted with high probability using 
TMHMM database (Figure 6.2.1bi, bii). The two low probability TMD are 
highlighted in the table (Figure 6.2aii). ZnT9 showed similar 5 TMD and ZnT5 
predicted 16 TMD’s using TOPCONS online database (data not shown). ZnT 
proteins usually have long C terminal tails with the longest found in ZnT6 
(214 amino acids) and the shortest found in ZnT7 (89 amino acids). The 
length and the amino acid sequences upstream of the first trans membrane 
domain, at N terminal side varies among different members. 
Comparison within all members of the ZnT family on the basis of total 
number of TMD’s and their individual location, reveals four different groups. 
Group II consist of, ZnT2, ZnT8, ZnT3 and ZnT4 that shows high similarity to 
each other. Similarly, Group I comprises ZnT1 and ZnT10. ZnT6 and ZnT7 
have been put in Group III where TMD’s position is very similar and the 
fourth category Group IV consists of transporters that did not match to the 
rest of the members and comprises ZnT5, ZnT9 and with additional splice 
variants of ZnT2 and ZnT5. The table of comparison highlights all different 
groups with different colours and position of trans membrane domains within 
N and C terminus (Figure 6.2aii). 
  
 
Figure 6.2.1 Analysis of transmembrane domains of ZnT3  
(bi) Graphical representation of TMHMM data showing 4 TMD for ZnT3 
transporter with C and N terminals inside the cell. 
 
(bii) Graphical representation of TOPCON data showing 6 TMD for ZnT3 
transporter with C and N terminals inside the cell. 
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Figure 6.2.2 Analysis of transmembrane domains of ZnT9  
(c) Graphical representation of ZnT9 transporter showing 5 TMD’s with C 
terminal facing outside the cell using TMHMM data. 
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Figure 6.2.3 Analysis of transmembrane domains of ZnT5  
 (di) Graphical representation of ZnT5 showing 15 TMD with C-terminal 
outside the cell and N-terminal being inside. 
 (dii) Schematic presentation of TMD structure of ZnT5, stating the starting 
point of each TMD from starting codon and total length underneath in base 
pairs. 
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6.2.3 Identity/Similarity Matrix Results 
Analysis of all members of ZnT family was performed using MatGAT 
software to test for similarity and identity in the coding and promoter region. 
The matrix of the coding region showed maximum similarity for ZnT2, ZnT3, 
ZnT4 and ZnT8. ZnT9 was least similar to any rest of the transporters among 
ZnT family (Figure 6.3a). When the promoter region was analysed, ZnT1, 
ZnT2 and ZnT3 were similar and ZnT7 was the least similar to the rest of the 
family members (Figure 6.3b). 
6.2.4 Phylogenetic analysis of SLC30 (ZnT) family members 
To investigate potential evolutionary relationships, human SLC30 proteins 
were aligned using clustal X and a phylogenetic tree was constructed using 
Neighbor-joining (N-J) algorithm. The robustness of the tree was confirmed 
by the relatively high bootstrapping values for each branch and by comparing 
it to the parsimony maximum likelihood PHYLIP 3.68 algorithm, which 
produced a similar branching structure (data not shown). After analysis 
different members were classified to different groups according to the 
sequence similarity between them. Group I comprises ZnT2, ZNT3, ZnT4 
and ZnT8, Group II has ZnT1 and ZnT10, Group III with ZnT5 and ZnT7 and 
Group IV ZnT6 and ZnT9 (Figure 6.4). 
6.2.5 Analysis of promoter region 
The promoter region of a gene is considered as non-coding, but still can 
regulate gene expression, as it consists of binding sites for transcription 
  
 
Figure 6.3 Identity/Similarity Matrix 
MatGAT v2.0 output matrix showing identity/similarity of ZnT family 
members. The upper matrix contains the identity of the data set and the 
lower is the similarity. (a) is showing identity and similarity data of coding 
region from 10 different transporters from ZnT family (b) is showing 
identity/similarity data of promoter region (4000bp from start codon) from 10 
different transporters of ZnT family.  
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Figure 6.4 Phylogenetic tree of the ZnT family members  
Amino acid sequences of human ZnT proteins were collected and aligned 
using Clustal X, and a phylogenetic tree was generated using the Neighbor-
joining (N-J) algorithm and visualized with the Tree View program. Branch 
labels indicate the robustness of the tree over 100 bootstrap replicates, while 
the scale bar indicates an evolutionary distance of 0.05 amino acid 
substitution per site. 
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factors. To analyse the important transcription binding factors (TBF) for all 
members of ZnT family, 4000bp upstream of translation start site were 
scanned manually. Metal Responsive Elements (MRE) and hormonal 
influenced transcription binding factors like Estrogen Responsive Elements 
(ERE), Gonadotrophin Responsive Elements (GRE), Insulin Responsive 
Sequence (IRS) and Retinoic X Receptor (RXR), Stat-5 were analysed in this 
study. TATA and CTC box are considered as the start of initial transcription 
complex, hence they were also analysed. Some of the TBF had multiple 
binding sites present in some of the transporters. Data on the presence of 
TBF sites in promoter region of ZnT family members along with their 
individual position from the start of translation start site (+1 ATG) is 
summarised in Table 6.2i. ERE and PRE transcription binding factor sites 
have long conserved sequences interspersed with random 3 nucleotides in 
between them. The position of the individual consensus sequence for half 
binding site is summarised in Table 6.2ii for all members of the ZnT family. 
6.2.6 Syntany analysis of transcription binding factors in 
promoter region of ZnT family members 
Syntany analysis was performed on important transcription binding factors 
sites (mentioned in previous section) present in the promoter region of all 
reported ZnT’s. A schematic diagram was created showing similarity among 
TBF present in different transporters (Figure 6.5). The TATA box was 
considered a standard centre point and other transcription factors were 
arranged around in the order of their occurrence in the promoter region.
  
Table 6.2 Important transcription binding factors among all 
ZnT members 
Table is showing important transcription binding factors of ZnT1 to ZnT10 
along with their conserved binding sequence and number of times they are 
present in the promoter region (4000bp) upstream from translation start side. 
Their individual positions are also specified in base pairs from the start point. 
TATA and CTC box that are considered to be the start of transcription along 
with Metal Responsive Elements (MRE), Stat-5 and other hormonal 
influenced transcription binding factors like Estrogen Responsive Elements 
(ERE), Gonadotrophin Responsive Elements (GRE), Insulin Responsive 
Sequence (IRS) and Retinoic X Receptor (RXR) have been summarised in 
(Table 2i). ERE and PRE have long conserved site with two core segments 
interspersed with three nucleotides between them. These half sites have 
been highlighted with different colours and their positions are specified 
underneath for all transporters with multiple existence in the promoter region 
(Table 2ii). 
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Figure 6.5 Microsyntany analysis of transcription binding 
factors present in promoter region of ZnT family 
members 
Schematic representation of important transcription binding factors present in 
the promoter region among all members of ZnT family. The TATA box is 
located in the centre of the diagram and the transcription factors are arranged 
in relation to their proximity in the promoter region. MRE along with other 
hormonal influenced transcription binding factors like ERE, GRE, IRS and 
Stat-5 are considered in this diagram. After alignment, ZnT’s have been 
classified in different subfamilies represented by different colours, according 
to similarity of TBF sites arrangement between different members. 
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In the case where more than one TATA box was present for different ZnT 
transporters, the closest to the translation site was considered for the 
analysis. MRE along with other hormonal influenced transcription binding 
factors like ERE, GRE, IRS and Stat-5 were considered in this analysis. After 
alignment, transporters were been sorted/allocated to different subfamilies 
according to their similarity in TBF sites occurrence in their promoters. 
ZnT2/3/4 and ZnT8 were grouped together in Group I. ZnT1/10 were placed 
in Group II, ZnT5/7 in Group III and ZnT6/9 in Group IV. 
6.2.7 Analysis of miRNA in the 3’ region of ZnT family 
members 
Micro RNA’s ‘miRNA’ binding sites, are present in the 3’ end of the 
untranslated regions of the gene and plays an important role in providing 
stability. All members of SLC30A family were analysed using online 
“miRBase” database and out of total 10 transporters ZnT3, ZnT5 and ZnT6 
showed presence of single miRNA binding sites in Homo sapiens. The 
position of miRNA sites in respective transporter was counted from the start 
of translation and is shown in Table 6.3. ZnT7 did not have any reported 
miRNA binding site in Homo sapiens but showed their presence in Mus 
musculais and Canis familaris. Similarly ZnT3 shows additional miRNA 
binding sites in Mus musculais and ZnT5 and ZnT6 in Pan troglodytes. 
Details on all reported miRNA are summarised in Table 6.3. 
  
 
Table 6.3 miRNA binding sites in 3’ region of ZnT family 
members 
Table showing reported miRNA sites present in different ZnT members along 
with detailed information about their position and location on plus or minus 
strand on the respective chromosomes. The bolded miRNAs in ZnT3, ZnT5 
and ZnT6 have been reported previously in Homo sapiens. Position shown in 
+number represent the prensence of miRNA from the start codon for 
respective transporter. Additional miRNA shown in table (non-bolded) have 
also been reported in other species like Mus musculais, Pan troglodytes and 
Canis familaris. 
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6.2.8 Predicted three dimensional structure of ZnT’s 
The three dimensional structures of ZnT transporters were predicted using 
Cn3D 4.3.1software, after submitting PDB files generated from sp3 structure 
prediction database. The list of neighbours were sorted by Z-score value (a 
measure of the statistical significance of the result relative to an alignment of 
random structures already reported in database). A match was considered 
significant if the ZSCORE value was greater than 6.3. Out of all ZnT 
members only four members came up with a significant ZSCORE, ZnT2 
(6.52), ZnT3 (17.19), ZnT6 (6.95) and ZnT8 (6.74). Out of these four 
transporters ZnT3, ZnT2 and ZnT8 showed homology with YiiP, ZnT 
homologue in E.coli. ZnT6 showed similarity with mosquito-larvicidal Cry4aa 
toxin from Bacillus thuringiensis (Boonserm et al., 2006). 
In the three dimensional predicted structures generated using Cn3D 
software, TMD’s were highlighted in yellow colour according to analysis using 
THMM software. ZnT2 (Figure 6.6.1a), ZnT6 (Figure 6.6.2d) and ZnT8 
(Figure 6.6.2c) showed six TMDs, which is a characteristic feature of this 
family but ZnT3 (Figure 6.6.1b) showed four TMDs with high probability 
(showed in yellow) and 2 with low probability (blue). As YiiP acts as a ZnT’s 
homologue in E.coli, ZnT2, ZnT3 and ZnT8 were considered for further 
analysis. Even though six TMDs were highlighted in predicted three 
dimensional structure of ZnT6, the topology would not be considered 
relevant, as it’s prediction is based on mosquito larvicidal Cry4aa toxin from 
Bacillus thuringiensis which, phylogenetically is different to ZnT’s. 
 
  
Figure 6.6.1 Predicted 3-dimensional structures of ZnT2 and 
ZnT3 
Diagram of three dimensional structure of ZnT2 (a) and ZnT3 (b) generated 
by Cn3D 4.3.1software with sequence homology to YiiP. TMDs are 
highlighted in yellow and numbered from T1-T6.  ZnT3 which has four TMD’s 
with high probability, shown in yellow are numbered and additional two TMD’s 
with low probability shown in blue (b). Identical residues are highlighted with 
red colour. 
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Figure 6.6.2 Predicted 3-dimensional structures of ZnT8 and 
ZnT6 
Diagram of three dimensional structure of ZnT8 (d) generated by Cn3D 
4.3.1software with sequence homology to YiiP and ZnT6 (c) to mosquito-
larvicidal Cry4aa toxin from Bacillus thuringiensis. TMDs are highlighted in 
yellow and numbered from T1-T6. Identical residues are highlighted with red 
colour. 
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As the ZSCORE value was maximum for ZnT3, it was analysed in detail. All 
of transporters are considered to form dimers with themselves (homo-dimers) 
similarly to YiiP or between other members (hetero-dimers) for example 
ZnT5/ZnT6.  
Considering the highest similarity of ZnT3 with YiiP, homodimer formation 
was analysed using YiiP sequence in 3-D structure (Figure 6.7). Chain A and 
chain B representing each subunit/protomer from YiiP and Chain A from 
ZnT3 transporter superimposed on YiiP on right side. The identical regions 
between YiiP and ZnT3 were highlighted with red colour and transmembrane 
domains were represented by pink colour and numbered 1 to 4 on right hand 
side when aligned with YiiP structure having six transmembrane helixes, 
represented by blue colour. α helices and β strands in C-terminal domain 
(CTD) are labelled as H1 and H2 and S1 to S3 respectively. Zinc ions are 
represented by grey spheres and labelled as Z1 to Z4 as there are four zinc 
binding sites for Yiip’s and ZnT’s. Out of four sites Z1 is the known conserved 
zinc binding site for ZnT’s (Lu and Fu 2007). 
  
 
Figure 6.7 Homology Model of ZnT3 homodimer 
The homology modelling was based on the crystal structure of YiiP and was 
generated by the Cn3D 4.3.1 program. ZnT3 viewed from membrane plane 
showing homo-dimers. Zinc ions are represented by grey spheres and are 
labelled as Z1 to Z4. Transmembrane domains of ZnT3 are represented by 
pink colour and numbered 1 to 6 on right hand side when aligned with YiiP 
structure by X-ray crystallography having six transmembrane helixes 
(represented by blue colour). Alpha helices and β strands in C-terminal 
domain (CTD) are labelled as H1 and H2 and S1 to S3 respectively. 
 193 
 
 
 
 194 
 
 
6.3 DISCUSSION 
ZnT members (SLC30A family) are named starting from ZnT1 to ZnT10 
based on their order of characterization (Palmiter and Huang, 2004). Out of 
all members, exon-intron structures have already been described, except for 
ZnT9 (Seve et al., 2004) 
ZnT9 consists of 18 exons present on chromosome 4 at the + strand with 5 
transmembrane domains and total length of 568 amino acids. ZnT9 was first 
described as a human HUEL protein (Sim and Chow, 1999). ZnT9 has 
stretches of homology to cation efflux domain pfam01545 and has been now 
renamed as GAC63 because it acts as a component of the p160 co-activator 
signal transduction pathway (Chen et al., 2005), and considered a misnomer 
(where classification was inappropriate) in relation to being a member of ZnT 
(Kambe, 2012). 
Phylogenetic analysis along with Similarity/identity matrix, characterises ZnT 
protein members into 4 groups according to their sequence homology to 
each other. ZnT2/3/4 and ZnT8 were put together in group I, ZnT10/1 in 
group II, ZnT5/7 in group III and ZnT6/9 in group IV. Similar results have 
been reported recently where different members have been characterized in 
subgroups or subfamilies (Kambe, 2012; Huang and Tepamorndech, 2013). 
The characterization indicates that during evolution they have been 
diversified to perform different functions in tissue specific manner. 
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The three dimensional structures of ZnT transporters have not yet 
determined but the characteristic feature of this family is the presence of 6 
TMD (transmembrane domains) with cytoplasmic C and N terminals. All 
members comply with this topology with the exception of ZnT9 and ZnT5 that 
are predicted to have an odd number of TMD, 5 and 15 respectively and the 
C terminal remains outside the cell. ZnT5 is the longest among all 
transporters of ZnT family with total of 765 amino acids. The carboxyl- 
terminal with 365 amino acid residues consists of 6 TMD as a characteristic 
feature of all members along with an exceptionally long amino terminal 
consisting of additional nine TMD fused to the conserved six TMD at the N-
terminal end of the protein (Kambe et al., 2002). The function of this 
additional region is not known. The predicted protein size for ZnT5 is 84 KDa 
but none of the reported studies showed that high size instead different 
reports showed a band size around 55 KDa, suggesting that not all of the 
exons may be present in the mature protein. ZnT3 showed 4 TMD with high 
probability with two additional TMD with low probability. As for ZnT3 it has 
been reported to have 6 TMD. Another software called “TOPCONS” was 
used in the current study to confirm the prediction and 6 TMD were predicted 
with same additional low probability TMD numbered two and six. ZnT9 
prediction of 5 TMD domains was the same using this additional prediction 
software. 
Most ZnT members have a histidine rich loop with an HX1-6H cluster (H is 
histidine and X is often serine and glycine) between TMD IV and V that is 
exposed to cytoplasm. This region is absent in ZnT6 and instead it has 
 196 
 
 
serine-rich region (Fukanda and Kambe, 2011; Kambe et al., 2004). Deletion 
and mutational analyses of this loop in ZnT transporters suggests that it 
plays a key role as a potential zinc binding site or might be involved in zinc 
delivery from cytoplasm to zinc binding site within TMDs (Kawachi et al., 
2008; Suzuki et al., 2005a). ZnT6 is not directly involved in transport of zinc 
(Discussed in chapter 4 and chapter 5). His-rich region of AtMTP1 (metal 
tolerance protein in Arabidopsis thaliana) acts as a buffering pocket to catch 
and stock zinc in the vacuole and acts as a sensor of the cytoplasmic free 
zinc ions (Kawachi et al., 2008). Similarly His-rich loop in ZnT5 is essential 
for the activation of TNAP (tissue non-specific alkaline phosphatase) (Suzuki 
et al., 2005b)  
Both N and C terminals play an important role in zinc transport across the 
cell membrane and ensure the structural stability of proteins. If there are 
alterations in either of the region, transporters do not function properly, as it 
was illustrated by deletion of C-terminal tail of ZnT1 and ZnT5 that produced 
a toxic phenotype, where cells could not survive as this region is important 
for the stability of the protein structure. Similarly at N-terminal deletion of the 
first TMD of ZnT1 resulted in zinc sensitivity and deletion of first two 
membrane spanning domains resulted in non-functional molecule (Fukunaka 
et al., 2009; Palmiter and Findley., 1995). Consistent with these findings the 
ZnT3 C-terminal region regulates intracellular zinc trafficking by forming a 
covalent di-tyrosine bond in response to oxidative stress (Salazar et al., 
2009). The C terminal region of ZnT5 plays an important role in formation of 
hetero-oligomer complex by identifying ZnT6 as a partner molecule 
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(Fukunaka et al., 2009). Interaction between ZnT1 and protein kinase Raf-1 
also demonstrated the importance of C-terminal region in protein-protein 
interactions where Raf-1 binds to the carboxyl-terminal of ZnT1 and its 
activity is dependent on Znt1 function (Jirakulaporn and Muslin, 2004).  
The function of some ZnT transporters can be related to the post 
transcriptional modifications that create different splice variants of ZnT 
transporters that might show different topology by lacking TMDs but still 
retain their zinc transport activity. For example ZnT2 has two different 
isoforms ZnT2-1 (long form) and ZnT2-2 (short form), and both forms are 
functional and transport zinc to the secretory granules (long form) and to the 
plasma membrane (short form) (Lopez and Kelleher, 2009). ZnT5 has two 
isoforms; one is present in the trans-Golgi and forms heterodimers with ZnT6 
to work as a zinc efflux; another splice variant, ZnT5B (hZTL1) is localized in 
the plasma membrane and function as zinc uptake from the extracellular 
environment, which is contradictory to function of all other members of ZnT 
family (Valentine et al., 2007: Crag et al., 2002). ZnT5B has unique 
characteristic features where it lacks 171 amino acids at N-terminal and 
cytosolic C-terminal tail and instead has a non-conserved extra TMD at C-
terminal. Fukunaka, (2009) suggested that changes in C-terminus of ZnT5 
transporter could make the topological changes in domains and can lead to 
different localisation pattern of resulting proteins  
Posttranslational modifications have been proposed for some transporters for 
example ZnT6 produced different size proteins in different tissues (Huang et 
al., 2002), but their exact functions are not known. ZnT2 is the only confirmed 
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example showing posttranslational modifications, where glycosylation 
resulted in 52 kDa band size instead of non-glycosylated 42 kDa (Kelleher 
and Lonnerdal, 2003). 
Oligomerization is crucial for the zinc transport activity of ZnT transporters. 
Most of the ZnT transporters form homo-dimers, apart from ZnT5 and ZnT6 
which form heterodimers. In homodimer formation each oligomer contains a 
zinc binding site within the TMDs. ZnT6 lacks that conserved hydrophilic 
residues in TMD and is not directly involved in zinc transport across the cell 
membrane but might function as modulator/facilitator (Fukunaka et al., 2009; 
Fukunaka et al., 2011). Another recent study also highlights the possibility of 
ZnT3 and ZnT10 forming an hetero-oligomer to prevent the increase in 
reactive oxygen species (ROS) levels by modulating the expression of 
catalse, although how these complexes may function is yet unknown 
(Patrushev et al., 2012). 
In analysing protein origin or phylogeny, the major emphasis is concentrated 
on the coding region as the Open Reading Frame (ORF). New research 
indicates the importance of the promoter region, where the surroundings of 
the ORF may have a great impact on the regulation of the coding region. The 
surrounding sequences of the ZnT transporters were analysed by looking for 
the important transcription binding factor sites present in the promoter region 
at the 5’ end and for micro RNAs present in the 3’ end that could play a vital 
role in the regulation of different genes. For example miR-373 induces 
tumour growth in pancreatic cancer, where zinc transporter ZIP4 activates 
the zinc-dependent transcription factor CREB and requires this transcription 
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factor to increase miR-373 expression through the regulation of its promoter 
(Zhang et al., 2013). Similarly miR-488 regulates zinc transporter ZIP8 during 
osteoarthritis (Song et al., 2013). All reported micro RNA’s in ZnT 
transporters have been listed in table 3 in different species along with Homo 
sapiens. Similarly TBF’s present in the 3’ promoter region play an important 
role in regulation of different genes. After arranging hormonally influenced 
transcription binding factor sites around the TATA box (start of transcription), 
a similar arrangement of their occurrence based on presence of TBF sites 
showed the same characterisation in different groups of ZnT transporters as 
for the coding region (Figure 6.5). 
The 5 and 3 prime regions of all known transporter 3D structures were 
analysed using online databases. Similarities with Yiip were seen and the 
TMD were highlighted according to the TMHMM analysis (Figure 6.2aii). The 
X-ray structure of Yiip has been determined (Lu and Fu, 2009; Lu and Fu 
2007). Yiip is a ZnT homologue in E.coli and exists as a Y-shaped structure 
that forms homo-dimers of two 33 kDa integral membrane proteins, have six 
TMD with cytoplasmic C and N terminals. 
The YiiP structure has provided a basic platform for researchers to 
understand the structural and functional properties of CDF family as most of 
the prediction is based on its X-ray structure. Each YiiP protomer/subunit 
contains four zinc binding sites. Site A is present within TMD and is 
considered as the primary zinc transport site and consist four conserved 
hydrophilic residues Asp45, Asp49 in TM2 and His153 and Asp157 in TM5. Site 
B resides at the interface between the membrane and cytoplasmic domain. 
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The other two are located in the cytoplasmic domain and considered as site 
C which has a metallochaperone like structures with an αββα fold (Lu and 
Fu, 2009; Lu and Fu 2007). Site C functions as a binuclear (two zinc binding 
sites) zinc-sensing site in the cytoplasmic domain to activate the export of 
zinc. Zinc binds at this site and induces a scissor like movement that affects 
the helices orientation in TMDs and zinc coordination gets modulated at site 
A (Kambe, 2012). In another alternative access mechanism for Zn2+/H+ 
antiport in YiiP explains that inward and outward facing conformation (Figure 
6.8) can bind to Zn2+ or H+. This movement of proton can provide the driving 
force to export zinc out of the cytoplasm. (Coudray et al., 2013). 
Based on the structure of the YiiP, 3-D models of ZnT3, ZnT5 and ZnT8 have 
been generated (Ohana et al., 2009; Salazar et al., 2009; Weijers, 2010). 
Sites A is highly conserved among ZnT members. Four hydrophilic residues 
in TMDs II and V that are involved in the formation of zinc binding site and 
correspond to site A in YiiP, are highly conserved. One aspartic acid is 
replaced with histidine in ZnT transporters and hence they have two histidine 
and two aspartic acid residues in their TMDs. Mutations in the histidine and 
aspartic acid conserved regions for ZnT5 abolish the zinc transport activity 
(Ohana et al., 2009) and confirms that these sites Asp599 and His451 are 
crucial for the zinc transport activity. 
  
 
Figure 6.8 Alternating access mechanism for Zn2+/H+ antiport 
by YiiP 
This mechanism involves inward-facing (A and B) and outward-facing (C and 
D) conformations where both inward and outward facing confirmations are 
able to bind Zn2+ or H+. The movement of protons provides a driving force to 
export Zn2+ out of the cytoplasm. The conformation in A corresponds to that 
observed in the helical tubes, whereas the conformation in C corresponds to 
the X-ray structure solved in the presence of Zn2+. 
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The zinc binding site in the cytoplasmic C-terminal portion that corresponds 
to site C in YiiP, has not yet been investigated, hence there is no 
confirmation on how ZnT transporters recognise the cytoplasmic zinc 
concentration.  
However, tyrosine mediated dimerization with putative conserved motif YXXE 
at Y357-372 for transporter ZnT3 was observed at C-terminal and it might 
play role in zinc transport function (Salazar et al., 2009). Our results for 
predicting 4 TMD with high probability and 2 TMD with low probability for 
ZnT3 when compared with previous reported 6 TMDs indicated that 
predicted 4 TMD’s (high probability) using TMHMM software are same to 
previous reported 6 TMD’s with the addition of TMD 2 and 6 with low 
probability and still contain all the conserved regions for potential zinc 
binding. The variation in results can be explained by the fact that these are 
all predictions.  
Homology models of ZnT8 with Yiip, predicted that both Arg325 and Trp325 
amino acids located in the α2-helix of the C-terminal domain are shielded by 
the planar surface of the three cytoplasmic β-strands and probably are 
unable to affect the sensing capacity of the C-terminal domain to transport 
zinc (Weijers, 2010). 
All the data presented indicates that ZnT transporters play crucial role in 
physiological and pathological events (Fukunaka & kambe, 2011; Kambe et 
al., 2008). Recent work has greatly helped us in understanding their 
architecture and functions, but the mechanisms involved in zinc mobilisation 
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and subsequent molecular events are still not fully understood. The main 
limitation is lack of X-ray structures for the ZnT transporters. The regulatory 
mechanisms involving post-translational modifications have still not been 
described for known ZnT’s as compared to ZIPs. For example protein kinase 
CK2 mediated phosphorylation was shown to regulate zinc transport by ZIP7 
transporter (Taylor et al., 2012).  
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6.4 Conclusion 
Overall after comparing promoter and coding region among different 
members: ZnT2, ZnT3, ZnT4 and ZnT8 show high sequence homology to 
one another, not only by comparing coding region but also similar pattern 
were observed for the important transcription binding factors present in the 
promoter region, which reinforces that these members can be put together in 
Group I. They have very similar structures (3D structure analysis) to deal with 
zinc and are under control of similar stimuli of hormones (TBF sites present 
in promoter region for different hormones). Belonging to the same group, 
hoewever, does not render these transporters to have similar physiological 
functions. They are expressed in cell and tissue-specific ways. A different 
transport mechanism has been described for ZnT3 in neurons, where the 
activity of ZnT3 is increased by direct interaction with a chloride channel 3 
(ClC-3), or vesicular glutamate transporter Vglut1 in neuroendocrine PC12 
cells (Salazar et al., 2005; Salazar et al., 2004). Similar specific mechanisms 
may also operate in other ZnT transporters in a cell or tissue specific 
manner. ZnT7 and ZnT5 are put together in Group III. ZnT1 and ZnT10 are 
considered in group II even though recent studies revealed the involvement 
of ZnT10 in transport of Mn and so this group may potentially be sub-divided 
further into separate group. ZnT6 and ZnT9 are put together in group IV with 
the consideration that these two are least similar to any rest of the members.
  
 
 
 
 
CHAPTER 7 
 
Summary  
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Zinc is an essential trace element that is required for all living organisms. In 
recent years the mechanisms underlying zinc transport have received more 
attention and molecular approaches have contributed new tools to better 
understand the role of membrane-bound zinc transport proteins. The main 
aim of my PhD project was to study the zinc transporters from SLC30A (ZnT) 
family. The data presented within this thesis contributes to the current 
understanding of mechanisms of zinc homeostasis in different human cell 
types. 
My first approach was to look for defects in the expression of zinc transporter 
proteins of the SLC30 family that could contribute to or underlie an inherited 
disorder of zinc deficiency that lead to the production of zinc-deficient milk. 
We concluded that two cases reported in chapter 3 with neonatal zinc 
deficiency are caused by a defect in the transport of zinc into milk with 
significant reduction in both ZnT5 and ZnT6 transporters. Defects in these 
two transporters have not previously been implicated in neonatal zinc 
deficiency. Two additional novel splice variants were identified in fibroblasts 
and lymphoblast cells. If more patients with this disorder were available, 
further studies could be carried out to determine if they possessed the 
methylation changes or mutations in ZnT2 gene, as have previously been 
reported for this disorder. A larger cohort should be investigated to truly 
demonstrate the observations arose from methylation studies at population 
level. To further confirm the methylation effect on zinc transport, methylation 
of these genes (ZnT5 and ZnT6) should be tested in culture using the 
enzymes for gene methylations.  
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To further investigate the role of ZnT5 and ZnT6, their dependency on each 
other was checked in neuronal cells as they are known to play a vital role in 
brain. We concluded for the first time that in neuronal cells ZnT6 expression 
(mRNA and protein) is dependent on ZnT5 gene. Overexpression and 
knockdown constructs of ZnT5 and ZnT6 genes did not show any changes in 
the accumulation or efflux of of zinc when compared to empty vectors 
suggesting that their main role is not to pump zinc in and out of the cell but 
probably to provide the zinc for zinc requiring enzymes for example alkaline 
phosphatase by storing them in the vesicles. To understand the zinc wave 
mechanism of transcription-dependent late zinc signalling mentioned by 
(Fukada et al., 2011), further analysis using 65Zn experiments with additional 
times up to 24 hours would provide more insights into ZnT5 and ZnT6-
mediated zinc transportation. There have been other zinc transporters that 
have been proven to have some role in neuronal cells. It would be interesting 
to know whether they have any relation with ZnT5 and ZnT6 or they work 
independently to these two transporters. 
After confirming the dependency of ZnT6 on ZnT5, the effect of DHA, a 
polyunsaturated fatty acid and zinc was investigated in neuronal cells to 
better understand their interactions. We found out that DHA reduces the 
intracellular labile zinc pools with increases neurite outgrowth. The 
expression levels of ZnT5 and ZnT6 proteins increases with higher DHA 
concentrations in the presence of zinc, hence establishing a causal relation 
between zinc and DHA metabolism. The DHA induced activation of ZnT5 and 
ZnT6 is probably through retinoic acid responsive elements (RARE’s) located 
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in the promoter region of these genes. Future studies could be carried out to 
confirm this notion by use of a luciferase assay for the promoter analysis.  
The final object of this project was to understand how ZnT5 and ZnT6 
transporters are related to rest of the ZnT family members. Our results 
obtained by using different variety of bioinformatics softwares confirmed that 
they are not similar to each other. ZnT5 showed close similarity with ZnT7 
and ZnT6 showed similarity with ZnT9, but these two groups are very diverse 
from other members and hence been put in two different subfamilies.  Along 
with phylogeny tree, to characterize all members in four subfamilies “syntany 
analysis” was performed on the basis of occurrence of important transcription 
binding sites present in the promoter region. For future studies similar 
syntany analysis of ZnT related gene loci (genes present upstream and 
downstream) can be analysed, as has previously been shown for Ikaros-
related genes (John et al., 2009). More detailed analysis of individual 
members of ZnT family could be performed by identification of specific zinc 
binding motifs and how they interact with zinc to transport this metal in and 
out of the cell. To further understand their evolutionary history, a comparison 
could be performed between ZnT’s and ZiP’s. 
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